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Abstract 
 
Calcineurin inhibitor (CNI)-induced hypertension is common after renal 
transplantation, rendering patients susceptible to cardiovascular and kidney 
disease, graft failure and death. CNI-induced hypertension occurs as a result 
of enhanced sodium retention by activation, via phosphorylation, of the renal 
thiazide-sensitive NaCl cotransporter, NCC (SLC12A3). CNI-treated renal 
transplant patients also have increased NCC abundance in isolated urinary 
exosomes. 
 
The studies described in this thesis were designed to investigate the effects 
of CNI treatment on mouse renal and intestinal sodium transport proteins, to 
determine whether alterations in proteins other than NCC may also 
contribute towards sodium retention. These changes were compared with 
those in an established mouse model of metabolic syndrome, comprising 
hypertension, insulin resistance, obesity and hypercholesterolemia which are 
also associated with CNI use. The abundance of NCC and phospho-NCC 
was also investigated in urinary exosomes from patients taking CNIs or with 
Gitelman syndrome. 
 
There was a higher abundance of NCC and pNCC in urinary exosomes from 
CNI-treated renal transplant patients compared with patients with Gitelman 
syndrome. Both CNI-treated and metabolic syndrome rodent models 
displayed a significant increase in pNCC. No differences were observed for 
intestinal transport proteins with CNI-treatment, however, a lower abundance 
of PiT1 and SGLT1 in the small intestine was observed with high-fat feeding. 
Renal NHE3 and ENaC were down-regulated in CNI-treated mice, a 
response that could be compensatory to the upregulation of pNCC in the 
DCT. 
 
These data provide evidence that CNIs influence a number of renal sodium 
transport proteins that may contribute towards the development of 
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hypertension following transplantation. These studies suggest an important 
role for calcineurin in the regulation of blood pressure and sodium transport 
in the kidney, and its possible involvement in the pathogenesis of 
hypertension and electrolyte disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	5				
Acknowledgements 
 
Firstly, I would like to express my gratitude to my supervisors, Doctor 
Stephen Walsh, Doctor Joanne Marks and Professor Robert Unwin for their 
support throughout my PhD. I am eternally grateful for all the invaluable 
guidance and knowledge you have provided me which has allowed me to 
mature as a scientist. 
 
I would also like to thank my fellow lab colleagues and everyone at the 
Centre for Nephrology for providing a motivating and friendly environment. 
 
Special thanks to Professor Joy Townsend, Mr John and Jean Woodcock, Mr 
Barry Sweetbaum and my close friend, Miss Chenchen Song, for their 
continuous support and encouragement throughout my entire educational life 
and for being there for me when I needed advice and direction.  
 
Lastly and most importantly, a huge thanks to my parents, Ms Cristina Castro 
and Mr Edward Jensen, and my sisters, Miss Jessica and Mariah Jensen. 
You’ve all been my biggest supporters from the very start and have always 
pushed me to go further in my career and I would not be where I am right 
now if it weren’t for all of you so thank you and I love you all. 
 
 
 
 
 
 
 
 
 
	6				
Table of Contents 
 
Abstract 3 
Acknowledgements 5 
Table of Contents 6 
List of Figures 11 
List of Tables 16 
Abbreviations 18 
Chapter I Introduction 20 
1.1 Hypertension 20 
1.2 Renal post-transplant hypertension 24 
1.2.1 Pre-transplant factors (pre-existing hypertension or diseased 
native kidneys) 25 
1.2.2 Donor-related factors (hypertensive donor – genetic influence) 25 
1.3 Calcineurin inhibitors (CNI) 26 
1.3.1 Post-transplant hypertension 26 
1.3.2 Calcineurin 27 
1.4 CNI-induced hypertension: Sodium retention 30 
1.4.1 Renal sodium transport 30 
1.4.1.1 Proximal convoluted tubule (PCT) 31 
1.4.1.2 Thick ascending limb (TAL) 36 
1.4.1.3 Distal convoluted tubule (DCT) 39 
1.4.1.4 Collecting duct (CD) 40 
1.4.2 Gastrointestinal sodium transport 44 
1.4.2.1 Proximal small intestine (PSI) 44 
1.4.2.2 Distal small intestine (DSI) 47 
1.4.2.3 Large intestine (LI) 48 
1.4.3 Regulation of the renal sodium chloride cotransporter: NCC 51 
1.4.3.1 Role of NCC in blood pressure regulation 51 
1.4.3.2 WNK-SPAK/OSR1-NCC phosphorylation cascade 52 
1.4.3.2.1 With-No-Lysine kinases 52 
1.4.3.2.2 SPAK/OSR1 54 
1.4.3.2.3 NCC 55 
1.4.3.2.4 NKCC cotransporters 56 
1.4.3.3 Regulators of the WNK-SPAK/OSR1-NCC phosphorylation 
cascade 58 
1.4.3.4 Pseudohypoaldosteronism II (PHAII) 59 
1.4.3.4.1 WNK1/WNK4 59 
1.4.3.4.2 KLHL3/CUL3 62 
1.4.3.4.3 SPAK/OSR1 63 
1.4.3.5 WNK-SPAK/OSR1 signalling cascade: Extrarenal roles 64 
1.4.4 Calcineurin inhibitors 67 
	7				
1.5 CNI-induced hypertension: Vascular tone 68 
1.6 CNI-induced hypertension: Sympathetic nervous system 72 
1.7 CNIs: Post-transplant Diabetes Mellitus (PTDM) 76 
1.8 Aims of this thesis 79 
Chapter II Materials and Methods 81 
2.1 Animal Studies 81 
2.1.1 Ethical Approval 81 
2.1.2 CNI Treatment 82 
2.1.3 Metabolic Syndrome 82 
2.1.4 Plasma and Urine Biochemistry 83 
2.1.5 Plasma and Urine Biochemistry: Sodium 83 
2.1.6 Plasma and Urine Biochemistry: Creatinine 84 
2.1.7 Plasma and Urine Biochemistry: Glucose 85 
2.1.8 Plasma and Urine Biochemistry: Phosphate 85 
2.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 86 
2.2.1 RNA Extraction 86 
2.2.2 cDNA Synthesis 87 
2.2.3 RT-PCR 87 
2.2.4 Agarose Gel Electrophoresis 87 
2.3 Antibodies 88 
2.4 Immunofluorescence 91 
2.4.1 Perfusion Fixation 91 
2.4.2 Paraffin-embedding 91 
2.4.3 Immunofluorescence Staining 91 
2.4.4 Confocal Microscopy 92 
2.5 Western Blot Analysis 96 
2.5.1 Tissue Lysis and Preparation 96 
2.5.2 Kidney Brush Border Membrane Vesicle (BBMV) Preparation 96 
2.5.3 Intestinal Brush Border Membrane Vesicle Preparation 97 
2.5.4 Protein Quantification 98 
2.5.5 Alkaline Phosphatase Assay 99 
2.5.6 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 100 
2.5.7 Gel Staining: Silver Nitrate 101 
2.6 Clinical Studies 102 
2.6.1 Ethical approval 102 
2.6.2 Human Plasma and Urine Biochemistry 102 
2.6.3 Urinary Exosome Isolation 102 
2.7 Statistical analysis 104 
Chapter III The effects of calcineurin inhibitors on renal and intestinal 
sodium transport 105 
3.1 Introduction 105 
3.1.1 Sodium retention via the WNK-SPAK/OSR1-NCC pathway in 
Pseudohypoaldosteronism II and CNI treatment 105 
	8				
3.1.2 WNK-SPAK/OSR1 regulation of renal and intestinal sodium 
transporters 106 
3.1.3 Aims of this study 108 
3.2 Materials and Methods 110 
3.2.1 Animals 110 
3.2.2 FK506 treatment and/or high-salt diet 110 
3.2.3 Plasma biochemistry 110 
3.2.4 Immunofluorescence analysis 111 
3.2.5 Protein preparations from kidney and intestinal mucosa tissues 
  111 
3.2.6 Western blot analysis 111 
3.2.7 Statistical analysis 112 
3.3 Results 113 
3.3.1 Physiological parameters 113 
3.3.2 NCC/pNCC expression following FK506-treatment 116 
3.3.3 Alterations in protein abundance of key sodium transporters in 
the kidney following FK506 treatment 121 
3.3.4 Alterations in protein abundance of key sodium transporters in 
the gastrointestinal tract following FK506 treatment 130 
3.4 Discussion 140 
3.4.1 Establishment of a CNI-induced model of sodium retention 140 
3.4.2 Analysis of FK506 treatment on renal and intestinal sodium 
transporters 142 
3.4.3 Gastrointestinal-renal signalling 147 
3.4.4 Conclusions 149 
Chapter IV Investigation of calcineurin inhibitors as a risk factor for 
Metabolic Syndrome 151 
4.1 Introduction 151 
4.1.1 Metabolic syndrome 151 
4.1.2 Obesity 152 
4.1.3 Hyperlipidemia/Hypercholesterolemia 153 
4.1.4 Hypertension 154 
4.1.5 Post-transplant diabetes mellitus 155 
4.1.6 Other clinical features 156 
4.1.7 Mouse models of diet-induced metabolic syndrome 159 
4.1.8 Aims of this study 160 
4.2 Materials and methods 162 
4.2.1 Animals 162 
4.2.2 Metabolic syndrome mouse model 162 
4.2.3 Plasma and urine biochemistry 163 
4.2.4 RT-PCR 163 
4.2.5 BBMV preparations from kidney and intestinal mucosal tissues 
  163 
4.2.6 Western blot analysis 164 
4.2.7 Statistical analysis 164 
4.3 Results 165 
	9				
4.3.1 Physiological parameters 165 
4.3.2 Influences of FK506 and/or diet-induced obesity on renal 
transport proteins 171 
4.3.3 Influences of FK506 and/or diet-induced obesity on proximal 
small intestinal transport proteins 181 
4.3.4 Influences of FK506 and/or diet-induced obesity on distal small 
intestinal transport proteins 186 
4.3.5 Influences of FK506 and/or diet-induced obesity on large 
intestinal transport proteins 190 
4.4 Discussion 193 
4.4.1 Establishment of a diet-induced model of metabolic syndrome 
  193 
4.4.2 FK506 treatment and high-fat feeding on renal and intestinal 
acid-base and phosphate transport proteins 195 
4.4.3 FK506 treatment and high-fat feeding on renal and intestinal 
sodium-glucose transport proteins 199 
4.4.4 FK506 treatment and high-fat feeding on renal and intestinal 
sodium transporters and channels 202 
4.4.5 Limitations and conclusions 206 
Chapter V Urinary exosome isolation and analysis of (p)NCC levels in 
calcineurin inhibitor-administered and Gitelman syndrome patients 208 
5.1 Introduction 208 
5.1.1 Urinary exosomes 208 
5.1.2 Urinary exosome biomarkers of renal disease 209 
5.1.3 Collection and storage of urine samples 212 
5.1.4 Urinary exosome isolation 213 
5.1.5 Normalisation 215 
5.1.6 Aims of this study 216 
5.2 Materials and methods 218 
5.2.1 Patients 218 
5.2.2 Human plasma and urine biochemistry 218 
5.2.3 Urinary exosome isolation 218 
5.2.4 Silver nitrate staining 218 
5.2.5 Western blot analysis 219 
5.2.6 Statistical analysis 219 
5.3 Results 220 
5.3.1 Urinary exosome isolation 220 
5.3.2 NCC/pNCC protein detection 228 
5.3.3 Patient biochemistry 229 
5.3.4 Analysis of urinary NCC/pNCC excretion in renal transplant 
patients  232 
5.3.5 Analysis of urinary NCC/pNCC excretion in Gitelman syndrome 
patients  234 
5.3.6 Further protein detection 238 
5.4 Discussion 240 
5.4.1 Urinary exosome isolation 240 
	10				
5.4.2 Urinary exosome analyses in patient urine 241 
5.4.3 Limitations 242 
5.4.4 Conclusions 246 
Chapter VI General Discussion 248 
6.1 Aims of thesis 248 
6.2 Sodium and blood pressure 251 
6.3 Sodium and the immune system 259 
6.4 Blood pressure regulation by the gastrointestinal tract 260 
6.5 The impact of SGLT-mediated sodium transport on cell swelling and 
blood pressure 266 
6.6 Conclusions and future perspectives 269 
Appendix I 272 
References 276 
	11				
List of Figures 	
Chapter I   
Figure.1.1. A schematic diagram of the calcineurin/NFAT-mediated 
pathway for T-cell activation 
 
29 
Figure.1.2. Renal sodium reabsorption 43 
Figure.1.3. Intestinal sodium absorption 50 
Figure.1.4. The WNK-SPAK/OSR1-NCC phosphorylation cascade and 
its contribution in PHAII pathogenesis 
 
66 
Figure.1.5. A mechanistic model for the pathogenesis of CNI-induced 
hypertension 
75 
   
Chapter II   
Figure.2.1. Sodium assay principle 84 
Figure.2.2. Creatinine assay principle 84 
Figure.2.3. Glucose assay principle 85 
Figure.2.4. Phosphate assay principle 86 
Figure.2.5. Bradford assay principle 99 
Figure.2.6. Alkaline phosphatase assay principle 100 
Figure.2.7. Enrichment factor calculation 100 
   
Chapter III   
Figure.3.1. Body weight 115 
Figure.3.2. Effects of FK506 on the NCC cotransporter  118 
	12				
Figure.3.3. Effects of FK506 on NCC phosphorylation and distribution 119 
Figure.3.4. Expression of the renal Na+/H+ exchanger, NHE3, after 
FK506 treatment 
123 
Figure.3.5. Expression of the renal type II Na+/Pi cotransporters after 
FK506 treatment 
 
124 
Figure.3.6. Expression of the renal Na+-glucose cotransporters after 
FK506 treatment 
 
126 
Figure.3.7. Expression of the renal glucose transporter, GLUT2, after 
FK506 treatment 
127 
Figure.3.8. Expression of the renal Na+-K+-2Cl- cotransporter, NKCC2, 
after FK506 treatment 
 
128 
Figure.3.9. Expression of the renal Na+ channel, ENaC, after FK506 
treatment 
129 
Figure.3.10. The effects of FK506 on NHE3 expression in the proximal 
small intestine (PSI) 
 
132 
Figure.3.11. The effects of FK506 on SGLT1 and GLUT2 expression in 
the PSI 
133 
Figure.3.12. The effects of FK506 on NaPi-IIb and PiT1 expression in 
the PSI 
 
134 
Figure.3.13. The effects of FK506 on NHE3 expression in the distal 
small intestine (DSI) 
 
135 
Figure.3.14. The effects of FK506 on SGLT1 expression in the DSI 136 
Figure.3.15. The effects of FK506 on NaPi-IIb and PiT1 expression in 
the DSI 
 
137 
Figure.3.16. The effects of FK506 on ENaC expression in the large 
intestine (LI) 
138 
  
 
 
 
	13				
Chapter IV   
Figure.4.1. Body weight, food and water consumption during FK506 
and/or high-fat diet treatment 
 
168 
Figure.4.2. Analysis of the renal Na+/H+ exchanger, NHE3, after FK506 
treatment and/or high-fat diet feeding 
 
173 
Figure.4.3. Analysis of the renal Na+/Pi cotransporters, NaPi-IIa and 
NaPi-IIc, after FK506 treatment and/or high-fat feeding 
 
174 
Figure.4.4. Analysis of the renal Na+/glucose cotransporters, SGLT2 
and SGLT1, after FK506 treatment and/or high-fat feeding 
 
175 
Figure.4.5. Analysis of the renal glucose transporter, GLUT2, after 
FK506 treatment and/or high-fat feeding 
 
176 
Figure.4.6. Analysis of the renal Na+-K+-2Cl- cotransporter, NKCC2, 
after FK506 treatment and/or high-fat feeding 
 
178 
Figure.4.7. Analysis of the renal Na+/Cl- cotransporter, NCC, after 
FK506 treatment and/or high-fat feeding 
 
179 
Figure.4.8. Analysis of the renal epithelial Na+ channel, ENaC, after 
FK506 treatment and/or high-fat feeding 
 
180 
Figure.4.9. Analysis of the Na+/H+ exchanger, NHE3, in the proximal 
small intestine (PSI) after FK506 treatment and/or high-fat 
feeding 
 
183 
Figure.4.10. Analysis of the Na+/Pi cotransporters, NaPi-IIb and PiT1, in 
the PSI after FK506 treatment and/or high-fat feeding 
 
184 
Figure.4.11. Analysis of the Na+/glucose cotransporter, SGLT1, and the 
glucose transporter, GLUT2, in the PSI after FK506 
treatment and/or high-fat diet feeding 
 
185 
Figure.4.12. Analysis of the Na+/H+ exchanger, NHE3, in the distal small 
intestine (DSI) after FK506 treatment and/or high-fat 
feeding 
 
187 
	14				
Figure.4.13. Analysis of the Na+/Pi cotransporters, NaPi-IIb and PiT1, in 
the DSI after FK506 treatment and/or high-fat feeding 
 
188 
Figure.4.14. Analysis of the Na+/glucose cotransporter, SGLT1, and the 
glucose transporter, GLUT2, in the DSI after FK506 
treatment and/or high-fat feeding 
 
189 
Figure.4.15. Analysis of the Na+/H+ exchanger, NHE3, in the large 
intestines (LI) after FK506 treatment and/or high-fat feeding 
 
191 
Figure.4.16. Analysis of the epithelial Na+ channel, ENaC, in the LI after 
FK506 treatment and/or high-fat feeding 
192 
   
Chapter V   
Figure.5.1. Urinary exosome isolation protocols 222 
Figure.5.2. A comparison between two modified urinary exosome 
isolation protocols 
 
223 
Figure.5.3. Confirmation of urinary exosome isolation 224 
Figure.5.4. Protein detection in urinary exosomes isolated from varying 
volumes of starting urine 
 
226 
Figure.5.5. Detection of exosomal markers from varying volumes of 
starting urine 
 
227 
Figure.5.6. Detection of NCC and pNCC cotransporters in isolated 
urinary exosomes 
 
228 
Figure.5.7. Analysis of NCC and pNCC protein excretion in CNI-
administered renal transplant patients 
 
233 
Figure.5.8. Analysis of NCC and pNCC protein excretion in Gitelman 
syndrome patients 
 
235 
Figure.5.9. Comparisons of NCC and pNCC excretion in CNI-
administered renal transplant patients and Gitelman 
syndrome patients  
 
237 
	15				
Figure.5.10. Protein detection of other renal transporters in isolated 
urinary exosomes 
239 
   
Chapter VI   
Figure.6.1. Proposed model of the effects of CNI treatment, high-salt 
and high-fat feeding on renal and intestinal transporters 
258 
Figure.6.2. Summary of the pathways regulated by dietary sodium and 
fat intake 
271 
 
	16				
List of Tables 
 
Chapter I   
Table.1.1. Summary of the prevalence, awareness, treatment and 
control of hypertension in the UK 
23 
   
Chapter II   
Table.2.1. Breakdown of the energy derivation from the standard 
maintenance and high-fat diets 
 
82 
Table.2.2. Qiagen primers utilised for RT-PCR 
 
89 
Table.2.3. Sigma primers utilised for RT-PCR 
 
90 
Table.2.4. Conditions used for RT-PCR 
 
90 
Table.2.5. Primary and secondary antibodies used for 
immunofluorescence 
 
93 
Table.2.6. Primary and secondary antibodies used for Western 
blotting 
 
94 
Table.2.7. Age- and gender-matched controls for renal transplant 
patients currently receiving CNI medication 
 
103 
Table.2.8. Age- and gender-matched controls for Gitelman 
syndrome patients 
104 
   
Chapter III   
Table.3.1. Plasma biochemistry 115 
   
Chapter IV   
Table.4.1. Plasma and urine biochemistry 170 
   
Chapter V   
Table.5.1. Plasma biochemistry 231 
	17				
   
Appendix I   
Table.A.1. Summary of the prevalence, awareness, treatment and 
control of hypertension in worldwide studies 
272 
 
 
	18				
Abbreviations 	
1,25 (OH)2D3 1,25 dihydroxyvitamin D3 
ALIX Apoptosis-linked gene-2-interacting protein X 
AMPK AMP-activated protein kinase 
ATP Adenosine triphosphate 
BBM(V) Brush border membrane (vesicle) 
BLM Basolateral membrane 
BMI Body mass index 
CD Collecting duct 
cDNA Complementary deoxyribonucleic acid 
CNI Calcineurin inhibitor 
CsA Cyclosporine A 
CUL3 Cullin-3 
CVD Cardiovascular disease 
DBP Diastolic blood pressure 
DCT Distal convoluted tubule 
DSI Distal small intestine 
DTT Dithiothreitol  
ENaC Epithelial Sodium channel 
FGF23 Fibroblast growth factor-23 
FK506 Tacrolimus 
FKBP12 FK506 binding protein-12 
GFR Glomerular filtration rate 
GLUT Facilitative glucose transporter 
GS Gitelman syndrome 
HDLs High-density lipoproteins 
HS High salt 
HF High fat 
KLHL3 Kelch-like-3 
LDLs Low-density lipoproteins 
LI Large intestines 
	19				
MAP Mean arterial pressure 
mRNA Messenger ribonucleic acid 
NaPi Sodium phosphate cotransporter 
(p)NCC (Phospho) Sodium chloride cotransporter 
NFAT Nuclear factor of activated T cells 
NHE3 Sodium hydrogen exchanger-3 
NKCC Sodium potassium chloride cotransporter 
OSR1 Oxidative stress-responsive kinase-1 
P(C)T Proximal (convoluted) tubule 
PHAII Pseudohypoaldosteronism Type II 
PNST Post-nuclear supernatant 
PSI Proximal small intestine 
PTDM Post-transplant Diabetes Mellitus 
PTH Parathyroid hormone 
RAAS Renin-angiotensin-aldosterone system 
RT-PCR Reverse transcription polymerase chain reaction 
SBP Systolic blood pressure 
SEM Standard error of the mean 
SGK1 Serum/glucocorticoid-regulated kinase-1 
SGLT Sodium-dependent glucose transporter 
SLC Solute carrier 
SNS Sympathetic nervous system 
SPAK STE20/SPS1-related proline/alanine-rich kinase 
TAL Thick ascending limb 
TGF Tubuloglomerular feedback 
THP Tamm-Horsfall protein 
TSG101 Tumour susceptibility gene-101 
WNK With-no-lysine [K] 
 
	20				
Chapter I 
Introduction 
 
1.1  Hypertension 
 
Hypertension, or high blood pressure, continues to remain an important 
public health challenge and one of the world’s leading risk factors for 
cardiovascular and chronic renal diseases. Hypertension is defined as blood 
pressures higher than normal blood pressure levels; systolic blood pressure 
(SBP) >120mmHg and diastolic blood pressure (DBP) >80mmHg, or the 
requirement for anti-hypertensive therapy. These can be further sub-
categorised into three hypertensive groups; pre-hypertensive (120 – 
139mmHg (SBP), 80 – 89mmHg (DBP)), stage I (140 – 159mmHg (SBP), 90 
– 99mmHg (DBP)) or stage II (>160mmHg (SBP), >100mmHg (DBP)) 
hypertension (Chobanian et al., 2003). The risk for cardiovascular disease 
(CVD) mortality doubles for each 20mmHg increase in SBP and for each 
10mmHg increase in DBP (Lewington et al., 2002). This is particularly critical 
in adults aged 40 – 69 years. 
 
Many observational studies, including those dating back as far as the 1970’s, 
have explored the direct relationship between increased blood pressure and 
the risks for cardiovascular and renal disease progression (Franklin et al., 
1997; Kannel et al., 1971; Klag et al., 1996; Lakka et al., 1999; Stokes et al., 
1989). One such study from the Framingham Heart Study has greatly 
contributed to our knowledge of hypertension and its association to CVD 
outcomes. With over half a century of work, their studies have shown 
associations with CVD through elevated SBP and pulse pressure, and 
hemodynamic changes, i.e., increased artery stiffness, with age (Franklin et 
al., 1997; Kannel et al., 1971). In relation to renal disease progression, in 
1996, Klag et al, conducted a follow-up study over 16 years specifically 
monitoring the development of end-stage renal disease in 332,544 men, and 
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found that 814 of these subjects either died of end-stage renal disease or 
were undergoing treatment (Klag et al., 1996). Vasan et al, in 2001, looked at 
the cardiovascular event rates in 6859 hypertension-free subjects over an 
11-year study and found 397 of these subjects had had a cardiovascular 
event that included death from CVD, myocardial infarction, stroke and 
congestive heart failure (Vasan et al., 2001).  
 
A systematic report on the global burden of hypertension by Kearney et al., 
showed, in 2000, nearly 1 billion adults (26% of the adult population) had 
hypertension and that this was predicted to increase to 1.56 billion (60% of 
the adult population) by the year 2025 (Kearney et al., 2005). Additionally, 
recent data from the Global Burden of Disease study demonstrated 
hypertension to be the biggest leading risk factor for global disease and 
mortality, accounting for 9.4 million deaths each year, particularly for adults 
aged 50 – 60 years and older than 70 years (Lim et al., 2012).  
 
Numerous worldwide studies have recorded information on hypertension 
prevalence, awareness, treatment and control, and have shown these rates 
to fluctuate over the recorded ~20-year period (as summarised in Table.1.1 
and Appendix.I.Table.A.1). For example, in the UK, over the past 15 years 
the prevalence of hypertension has significantly decreased among the 
population and both hypertension awareness and treatment has continued to 
rise (Table.1.1). However, control rates remain low with >68% of the 
population with uncontrolled hypertension and ~50% of the patients still not 
seeking treatment. While some studies have placed a bias on gender and 
location, i.e. lower prevalence of hypertension observed in women than men 
and a higher prevalence observed in urban areas than rural areas, other 
studies lean towards multifactorial factors; an interplay of genetic and 
environmental influences. Unfortunately, the point still stands that a large 
number of hypertensive subjects remain undetected, and prevention and 
control measures for hypertension continue to remain inadequate. Overall, 
the data collected from these studies underscores the urgent need to re-
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emphasise hypertension awareness programs targeting the public in order to 
prevent a CVD epidemic. 
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Table 1.1. Summary of the prevalence, awareness, treatment and control of hypertension in the UK. Hypertension prevalence rates were 
recorded according to the international definition of hypertension. Control rates show the proportion of control among treated hypertensive 
patients.  
Year of Data 
Collection 
Age 
Range Gender 
Sample 
Size 
Prevalence 
(%) 
Awareness 
(%) 
Treatment 
(%) 
Control 
(%) Reference 
1991 - 1992 35 - 64 
Male 812 45 30 13 31 (Antikainen et al., 
2006)  Female 797 32 36 17 39 
1995 35 - 64 
Male 678 44 34 20 40 (Antikainen et al., 
2006)  Female 727 31 51 28 42 
1998 >16 
Male 5222 41.5 40.3 25.7 31.1 (Primatesta et al., 
2001)  Female 6307 33.3 52.2 38 28.2 
2003 >16 
Male 4279 33.1 59.7 43.1 47.8 (Primatesta and 
Poulter, 2006)  Female 4555 30.1 63.9 52.4 43.9 
2006 20 - 79 
Male 3555 32.9 60.6 45.1 23.9 
(Joffres et al., 2013)  
Female 3826 27.3 70.7 58.2 31.1 
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1.2 Renal post-transplant hypertension 
 
Hypertension is very common following transplantation, affecting 80 – 85% of 
patients. The onset of post-transplant hypertension has been shown to occur 
between the first few months and the first year post-transplantation and, if left 
untreated and uncontrolled, its prevalence continues to increase over time 
(Campistol et al., 2004; Coles et al., 1972; Curtis et al., 1985a; Kasiske, 
1987; Kasiske et al., 2004). Most importantly, post-transplant hypertension 
has been shown to be highly associated with long-term graft survival, CVD 
development and recipient mortality (Campistol et al., 2004; Fernandez-
Fresnedo et al., 2001; Kasiske et al., 2004; Opelz et al., 1998). One of the 
most well cited studies by Opelz et al, in the Collaborative Transplant Study, 
was the first to analyse the negative outcomes of graft and patient survival in 
relation to blood pressure and observed a strikingly significant association 
between poor graft and patient survival and increased levels of systolic and 
diastolic blood pressure following transplantation (Opelz et al., 1998). 
Concluding that post-transplant blood pressure is a significant predictor of 
long-term graft outcome, a later supporting study demonstrated that patients 
with controlled SBP had significantly improved graft survival (Opelz et al., 
2005), thereby highlighting the importance of monitoring and controlling 
blood pressure after transplantation to confer beneficial graft survival and 
function.  
 
Extensive observational (both in clinical and laboratory settings) and 
statistical modelling analyses have identified numerous factors that may 
contribute to the development and persistence of post-transplant 
hypertension. These contributing factors include transplant-related factors 
(delayed graft function), age, gender, race, increased body weight, declining 
graft function, number of acute rejection episodes and, in particular, pre-
transplant and donor-related factors (Campistol et al., 2004; Cosio et al., 
1995; Kasiske, 1987). 
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1.2.1 Pre-transplant factors (pre-existing hypertension or diseased 
native kidneys) 
 
Patients with poorly controlled high blood pressure before transplantation 
were shown to require additional and/or higher doses of anti-hypertensive 
medication after transplantation and displayed significantly poor graft survival 
(Cosio et al., 1997; Ponticelli et al., 1993).  The presence of diseased native 
kidneys has also shown to have an effect on the function of the transplanted 
kidney, and that removal of these native kidneys can lower blood pressure, 
thereby prolonging graft function (Curtis et al., 1985b; Kasiske, 1987). 
 
1.2.2 Donor-related factors (hypertensive donor – genetic influence) 
 
Animal cross-transplantation studies of genetic hypertension have been 
previously performed to understand the mechanisms attributing to post-
transplant hypertension. Previous studies have utilised renal transplant 
experiments on normotensive rat recipients of hypertensive donors from the 
Milan hypertensive strain (Bianchi et al., 1974), the Dahl salt-sensitive 
hypertensive strain (Dahl and Heine, 1975; Dahl et al., 1974) and the stroke-
prone spontaneously hypertensive strain (Kopf et al., 1993; Rettig et al., 
1990b, 1990a, 1989). Normotensive recipients of a hypertensive kidney 
developed hypertension while recipients of a normotensive kidney displayed 
lower blood pressure levels similar to that of the donors, implying that the 
genetic background of the donor kidney determines the blood pressure of the 
recipients. This ‘genetic transmission’ has also been observed in follow-up 
human renal transplant studies, whereby, over an 8-year period, patients with 
no family history of hypertension that were engrafted with a kidney from a 
donor with a hypertensive family history showed elevated blood pressure and 
the requirement for anti-hypertensive therapy (Guidi et al., 1996). In a follow-
up study of the same patients, recipients from a normotensive family with a 
hypertensive kidney showed not only an increase in blood pressure but also 
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a greater degree of acute rejections (Guidi et al., 1998), supporting that not 
only can a ‘genetically hypertensive’ kidney cause hypertension in a 
normotensive recipient, it can also increase the susceptibility of the recipient 
to acute and chronic consequences. 
 
It is evident that many factors contribute to post-transplant hypertension in 
these patients. However, one particularly important and widely known 
contributing factor is the immunosuppressive therapy received by these 
patients in the form of calcineurin inhibitors, which will be the main focus of 
this thesis. 
 
1.3 Calcineurin inhibitors (CNI) 
1.3.1 Post-transplant hypertension 
 
Calcineurin inhibitors (CNIs), Cyclosporine A (CsA, or ciclosporin) and 
Tacrolimus (FK506), are the most widely used CNIs and are routinely 
administered to post-transplant recipients to prevent organ transplant 
rejection. The discovery of the immunosuppressive effects of CsA, in the 
1970s (Borel, 1976; Borel et al., 1994), provided a major breakthrough in 
medicine and became the principal immunosuppressive drug for organ 
transplantation. FK506 was later discovered and approved (Kino et al., 
1987a) as the main immunosuppressive drug alternative to CsA owing to its 
greater inhibitory potency (Kino et al., 1987b) and its association with a 
higher rate of patient/graft survival and lower rate of allograft rejection 
(Grimm et al., 2006; Krämer et al., 2005; Webster et al., 2005). This was 
demonstrated in a number of studies, whereby the incidence of acute 
rejection in FK506-treated patients were between 17.1 – 19.6% compared to 
35.7 – 37.3% in CsA-treated patients, showing almost a two-fold decrease in 
rejection rates and prompting this transition (Kim et al., 2004; Krämer et al., 
2005; Margreiter, 2002). 
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However, despite its clear benefits in improving graft survival and preventing 
organ rejection, CNIs are major risk factors for post-transplant hypertension. 
CsA, as it was discovered first, has been extensively demonstrated as an 
inducer of post-transplant hypertension in numerous follow up studies of 
renal transplant patients. For example, a study by Ponticelli et al, followed 
212 CsA-treated renal transplant patients for 5 years, and showed the 
prevalence of hypertension was 81.6% at 1 year and 81.2% at 5 years post-
transplantation (Ponticelli et al., 1993). This was similarly observed by 
Campistol et al, who showed more than 80% and 95% of renal transplant 
patients were hypertensive at 3 and 5 years post-transplantation, 
respectively (Campistol et al., 2004). In addition to these findings, patients 
are often diagnosed with elevated serum potassium levels (hyperkalemia) 
(Adu et al., 1983; Laine and Holmberg, 1995), reduced glomerular filtration 
rate (GFR) and increased vascular resistance (Kiberd, 1989), the reversal of 
which is achieved when CNIs are replaced with alternative 
immunosuppressants (Curtis et al., 1986). 
 
The mechanisms by which CNIs induce hypertension are still not fully 
elucidated and although the administration of CNIs in these transplant 
patients is required, the consequential hypertensive side effects will continue 
to hamper long-term graft and patient survival and increase the rate of 
mortality. It is therefore essential to understand the molecular pathogenesis 
of CNI-induced hypertension to enable better control of hypertension 
following transplantation. 
 
1.3.2 Calcineurin 
 
CNIs act by inhibiting the calcium (Ca2+)-dependent calmodulin-activated 
serine/threonine phosphatase, calcineurin (Clipstone and Crabtree, 1992; Liu 
et al., 1991, 1992). Calcineurin acts as a major regulator of many biological 
pathways such as cell proliferation, B-cell function, cardiac development and, 
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most importantly, T-cell proliferation via interleukin-2 (IL-2) expression 
(Clipstone and Crabtree, 1992; Heit et al., 2006; Molkentin et al., 1998; 
Ranger et al., 1998).   
 
Upon activation of the T-cell signalling cascade, intracellular release and 
binding of calcium to the regulatory B subunit of calcineurin (CnB) and 
calmodulin activates the phosphatase activity of calcineurin (Fig.1.1) 
(Stemmer and Klee, 1994). This associates with and dephosphorylates the 
conserved phosphoserines in the amino terminus of the cytoplasmic inactive 
subunits of the transcription factor, nuclear factor of activated T cells (NFAT) 
(Beals et al., 1997). This dephosphorylation promotes the translocation of 
NFAT into the nucleus, where persistent elevations of intracellular calcium 
concentration and calcineurin activity are required to maintain its nuclear 
localisation. From here, NFAT binds to DNA promoter regions to activate IL-2 
transcription, and the transcription of early cytokine genes, promoting T-cell 
proliferation (Flanagan et al., 1991; Shaw et al., 1988; Timmerman et al., 
1996).   
 
However, in order to prevent organ rejection, CNIs suppress T-cell 
proliferation (Fig.1.1). Its mode of action has been defined by numerous 
studies. CsA and FK506 exert their inhibitory effects through binding to the 
immunophilins, cyclophilin and FK506-binding protein-12 (FKBP12), 
respectively (Handschumacher et al., 1984; Harding et al., 1989; Liu et al., 
1991). These complexes then competitively bind to calcineurin, hindering 
substrate approach to the active site, and thereby disrupting calcineurin-
mediated NFAT dephosphorylation. This permits its re-phosphorylation and 
reappearance in the cytoplasm and prevents IL-2 transcription/T-cell 
proliferation (Emmel et al., 1989; Flanagan et al., 1991; Griffith et al., 1995; 
Kissinger et al.; Loh et al., 1996; Shaw et al., 1995).  
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Figure 1.1. A schematic diagram of the calcineurin/NFAT-mediated pathway 
for T-cell activation. Calcineurin becomes activated in response to an increase in 
intracellular Ca2+, dephosphorylates NFAT proteins which then facilitates its 
translocation into the nucleus. Here, the NFAT proteins bind to the regulatory 
sequences for target genes, such as IL-2, and activates gene expression. With the 
addition of CNIs, CsA and FK506, in complex with cyclophilin and FKBP12, 
respectively, bind to calcineurin which inhibits NFAT dephosphorylation, nuclear 
translocation and T-cell proliferation. 
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There are three proposed mechanisms contributing to CNI-induced 
hypertension; 1) increased renal sodium retention (which is the main focus of 
this thesis), 2) increased vasoconstriction and, 3) activation of the 
sympathetic nervous system. The next sub-sections aim to provide an 
overview into some of the sodium-dependent transporters present in the 
kidneys and gastrointestinal tract that were focused on in this research 
project. 
 
1.4 CNI-induced hypertension: Sodium retention 
1.4.1 Renal sodium transport 
 
The kidneys are crucial organs in the regulation of sodium (Na+) homeostasis 
and blood pressure. Mutations in renal Na+-related transport have been 
associated with both hypertension and hypotension. The capability to 
regulate Na+ excretion and reabsorption is accomplished through controlled 
expression of cotransporters, exchangers and ion channels within each 
segment of the nephron. This tightly controlled movement of ions across the 
cell into or out of the blood thereby allows the kidneys to adapt to dietary salt 
intake and regulate Na+ transport (and thus, blood pressure) accordingly.  
 
The proximal segment of the nephron, the proximal convoluted tubule (PCT), 
is involved in the majority of Na+ reabsorption processes while the distal 
segments, the distal convoluted tubule (DCT) and collecting duct (CD), are 
involved in the fine tuning of Na+ transport. The reabsorption processes in the 
proximal segment are regulated by the glomerular filtration rate (GFR) and 
tubuloglomerular feedback (TGF) mechanisms. Many hormones are also 
known to act on the tubule and affect electrolyte reabsorption. The GFR is 
the rate at which blood is filtered through the glomerulus and this is 
controlled by the TGF mechanism that stimulates compensatory effects on 
glomerular vascular resistance and reabsorption processes upon changes in 
filtrate salt content (Schnermann et al., 1970). As part of this feedback, Na+ 
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content is sensed by the macula densa, a region of specialised cells 
localised to the lining of the DCT and is in close proximity to the glomerulus 
(Fig.1.2a). These groups of cells monitor tubular sodium chloride (NaCl) 
concentration and adjust filtration accordingly through the GFR/TGF 
mechanism. For example, a decrease in GFR results in the decrease of NaCl 
delivery to the macula densa (as Na+ reabsorption would have occurred in 
the PCT) which stimulates, not only the vasodilation of the afferent arteriole 
at the glomerulus to increase GFR, but also stimulates renin release and 
activation of the renin-angiotensin-aldosterone (RAA) system that will 
increase blood volume, blood pressure and GFR.  
 
Electrolyte transport in the nephron can occur either by the paracellular 
(through the intercellular space between cells) or transcellular (through the 
cell) routes. Throughout the nephron, transcellular Na+-coupled transport is 
the general mechanism for Na+ reabsorption and movement across the 
apical membrane occurs down a chemical concentration and/or 
electrochemical gradient established by the basolateral Na+-K+-ATPase 
pump. The energy provided from this Na+-K+-ATPase pump is derived from 
adenosine triphosphate (ATP) hydrolysis resulting in the electrogenic 
transport of 3Na+ out and 2K+ into the cell (Skou, 1957, 1962). This creates a 
negative charge inside the cell, due to the low concentration of Na+, providing 
energy for solute transport. This pump therefore provides the main driving 
force along the whole nephron to facilitate Na+ and solute movement across 
the apical and basolateral membrane (BLM) (Fig.1.2b-e). In the following 
sections, Na+ reabsorption at each segment of the nephron will be described. 
 
1.4.1.1 Proximal convoluted tubule (PCT) 
 
A majority of reabsorption occurs within the PCT with around 65-75% of ions 
including sodium (Na+), potassium (K+), chloride (Cl-), phosphate (Pi or PO43-
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), calcium (Ca2+), and bicarbonate (HCO3-), and 100% of organic solutes 
such as glucose and amino acids, being reabsorbed.  
 
At the brush border membrane (BBM) of the PCT, the sodium-hydrogen 
antiporter 3, NHE3 (SLC9A3), is considered to be the main form of Na+-
coupled transport (Murer et al., 1976). Cloning, sequencing and expression 
analysis showed NHE3 to be specifically expressed in the kidney and small 
intestine (Tse et al., 1992). Studies in mice lacking NHE3 function were 
found to be mildly acidotic due to impaired HCO3- reabsorption (Schultheis et 
al., 1998a), indicating that NHE3, as well as playing a role in Na+ 
homeostasis, is a regulator of acid-base balance. NHE3 acts by exporting H+ 
in exchange for Na+ import (Fig.1.2b). The exported H+ can combine with 
filtered luminal HCO3- aided by carbonic anhydrase (CA) to generate carbon 
dioxide (CO2) which can freely diffuse into the cell.  Within the cell, CO2 is 
rehydrated to form carbonic acid, which dissociates, allowing the H+ to be 
exported back into the lumen for another cycle. The intracellularly generated 
HCO3- leaves the cell via the Na+-coupled basolaterally localised NBCe1A (or 
NBC1, SLC4A4) transporter at a 3 HCO3-: 1 Na+ stoichiometry (Boron and 
Boulpaep, 1983a, 1983b; Romero et al., 1997; Schmitt et al., 1999a; 
Yoshitomi et al., 1985).   
 
Sodium transport is also coupled to glucose reabsorption by two distinct Na+-
dependent glucose cotransporters; SGLT2 and SGLT1 (SLC5A2 and 
SLC5A1, respectively) (Fig.1.2b) (Hediger et al., 1987; Hummel et al., 2011; 
Kanai et al., 1994; You et al., 1995). SGLT2 is a low-affinity/high-capacity 
Na+-dependent glucose cotransporter predominantly expressed at the BBM 
in the S1 and S2 segments of the PCT (Kanai et al., 1994; Turner and 
Moran, 1982; You et al., 1995). Previous genetic and biochemical analysis 
revealed this transporter as the main regulator of glucose transport, 
reabsorbing Na+ and glucose at a 1:1 stoichiometry (Kanai et al., 1994; 
Turner and Moran, 1982). In addition, SGLT2 was found to work in 
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conjunction with SGLT1, a high-affinity/low-capacity Na+-dependent glucose 
cotransporter expressed in the later S3 segment of the proximal tubule (PT), 
which transports Na+ and glucose at a 2:1 stoichiometry (Lee et al., 1994; 
Turner and Moran, 1982). The concept of the sequential positioning and 
affinity/capacity properties of SGLT2 and SGLT1 transporters at the early 
and late segments of the PT, respectively, provides optimal reabsorption to 
ensure little glucose is lost in the urine. The major role for SGLT2 in glucose 
reabsorption has been shown in studies whereby mice deficient for SGLT2 
displayed significantly lower fractional glucose reabsorption in the early 
segments of the PCT and limited reabsorption in the downstream segments, 
which was most likely mediated by SGLT1 (Vallon et al., 2011). Additionally, 
SGLT2-deficient mice and individuals with SGLT2 mutations, display 
persistent glycosuria due to the impairment of glucose reabsorption (Calado 
et al., 2004; Heuvel et al., 2002; Magen et al., 2005; Santer et al., 2003; 
Vallon et al., 2011). In further studies, SGLT2 and SGLT1 have been 
proposed to mediate 97% and 3% of glucose transport in the kidney, 
respectively, however, under SGLT2-deficient or inhibited conditions, renal 
glucose reabsorption is still maintained at ~36 - 44% (Rieg et al., 2014; 
Vallon et al., 2011). In studies with SGLT2 inhibitor-treated mice, SGLT1-
mediated renal glucose transport was found to increase up to ~40%, 
suggesting compensation by SGLT1 when SGLT2 is absent (Rieg et al., 
2014). This was also supported in comparisons between wild type and 
SGLT1-deficient mice treated with an SGLT2-inhibitor, which revealed a 
difference in fractional glucose reabsorption of ~45% (Rieg et al., 2014). 
Furthermore, a double knockout of SGLT2 and SGLT1 completely eliminated 
renal glucose reabsorption and displayed a significantly enhanced glycosuric 
effect, compared to SGLT2 knockout alone (Powell et al., 2013; Rieg et al., 
2014). These studies demonstrate that, under euglycemic conditions, SGLT2 
contributes to the bulk reabsorption of glucose in the PCT, whereas SGLT1 
reabsorbs any residual glucose. In addition, under conditions of SGLT2 loss, 
compensatory SGLT1-mediated uptake is increased by up to ~40%. 
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Following Na+-coupled glucose transport, glucose leaves the cell through the 
basolateral Na+-independent GLUT glucose transporters (Fig.1.2b) (Chin et 
al., 1993).  
 
Phosphate (Pi) reabsorption in the kidneys is Na+-dependent and is also 
tightly regulated in the PT as it is the major site of extracellular phosphate 
homeostasis. Phosphate reabsorption is driven primarily by the Na+-K+-
ATPase pump and regulated by three classes of Na+/Pi cotransporters; type 
I, type II and type III, of which, based on ribonuclease protection assays, 
accounts for 15, 84 and 0.5% of total Na+/Pi cotransporter mRNAs, 
respectively, (Tenenhouse et al., 1998). The type II Na+/Pi cotransporters 
include two renal isoforms; NaPi-IIa (Npt2a, SLC34A1) and NaPi-IIc (Npt2c, 
SLC34A3) (Fig.1.2b). NaPi-IIa is thought to be the major regulator of Pi 
reabsorption. This conclusion was derived from previous cloning, 
immunohistochemical and expression analyses which revealed apical 
localisation of NaPi-IIa exclusively throughout the BBM of the PCT, with its 
highest levels in the early S1 segments (Collins and Ghishan, 1994; Custer 
et al., 1994; Magagnin et al., 1993). In addition, NaPi-IIa knockout mice 
display a significant reduction of Pi transport by ~70%, supporting that Pi 
transport is largely mediated by NaPi-IIa (Beck et al., 1998; Tenenhouse et 
al., 2003). Pi transport by NaPi-IIa is electrogenic, transporting Na+ and Pi at 
a 3:1 stoichiometry (Forster et al., 1999), and its expression is regulated by 
many factors such as parathyroid hormone (PTH), fibroblast growth factor-23 
(FGF23) and dietary phosphate (Kempson et al., 1995; Levi et al., 1994).  
 
Pi cotransport by NaPi-IIc is electroneutral, transporting Na+ and Pi at a 2:1 
stoichiometry (Segawa et al., 2002). Like NaPi-IIa, NaPi-IIc is expressed in 
the kidney but localised only to the S1 segment of the PCT BBM (Segawa et 
al., 2002). Its expression was found to be highest in weaning rodents which 
diminished with age, suggesting NaPi-IIc to be important for Pi reabsorption 
during growth (Segawa et al., 2002). Furthermore, NaPi-
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were found to be regulated by dietary Pi intake and shown to increase 
following NaPi-IIa gene ablation which may account for the remaining 30% of 
Pi transport in the PCT (Ohkido et al., 2003; Segawa et al., 2002; 
Tenenhouse et al., 2003). Although NaPi-IIc does not appear to be a major 
regulator of renal Pi reabsorption in adult mice, studies in humans have 
revealed otherwise. Genetic screening studies in humans have identified 
mutations in NaPi-IIc in patients with the Pi-wasting disorder, hereditary 
hypophosphatemic rickets with hypercalcuria (HHRH) (Bergwitz et al., 2006; 
Lorenz-Depiereux et al., 2006), leading to the proposal that NaPi-IIc may 
play a more significant role in Pi homeostasis in humans compared to mice.  
 
Less is known about the type I and III Na+/Pi cotransporter family in 
regulating Na+/Pi cotransport except that their contribution is very little 
compared to the type II family.  The type III Na+/Pi cotransporters, PiT1 (Glvr-
1 (Gibbon ape leukemia virus), SLC20A1) and PiT-2 (Ram-1 (amphotropic 
murine retrovirus), SLC20A2) were originally identified as ubiquitously 
expressed cell surface retroviral receptors (Johann et al., 1992; Miller et al., 
1994; O’Hara et al., 1990). These proteins were later identified as high-
affinity Na+-dependent phosphate cotransporters (Kavanaugh et al., 1994; 
Olah et al., 1994), and mRNA expression and supporting 
immunohistochemical studies primarily localised PiT2 to the apical BBM of 
the PCT but with a lower abundance compared to NaPi-II cotransporters 
(Kavanaugh et al., 1994; Tenenhouse et al., 1998; Villa-Bellosta et al., 2009). 
Previous RNAse hybrid depletion analysis in Xenopus laevis oocyte 
expression models have shown no effect on Pi transport following 
degradation of NaPi-I and NaPi-III mRNAs whereas degradation of NaPi-IIa 
mRNA completely inhibited Pi uptake (Miyamoto et al., 1997). Furthermore, 
in NaPi-IIa-deficient mice, although expression for NaPi-I and NaPi-III 
cotransporters increased, this was not sufficient enough to compensate for 
the loss of NaPi-IIa function, confirming a minor contribution for NaPi-I and 
NaPi-III to overall renal Pi reabsorption and further highlighting NaPi-IIa as 
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the major regulator (Hoag et al., 1999). Further research is required to 
elucidate the functional role of the type III Na+/Pi cotransporters. 
 
1.4.1.2 Thick ascending limb (TAL) 
 
The TAL reabsorbs up to 25% of filtered NaCl and plays a crucial role in the 
formation of concentrated or dilute urine. This is accomplished by the 
generation and maintenance of the countercurrent multiplication mechanism 
which utilises the segment’s impermeability to water to reabsorb NaCl. The 
major NaCl transport pathway is mediated by the electroneutral Na+-K+-2Cl- 
cotransporter, NKCC2 (or BSC1 (bumetanide-sensitive cotransporter 1), 
SLC12A1) (Fig.1.2c) (Greger, 1981b; Greger and Schlatter, 1981a).  
 
NKCC2 is the kidney-specific isoform of this family and is expressed at the 
apical membrane of the TAL where it facilitates the symport of Na+, K+ and 
Cl- at a stoichiometry of 1:1:2 (Ecelbarger et al., 1996; Greger and Schlatter, 
1981a; Greger et al., 1983; Payne and Forbush, 1994). Immunoelectron 
microscopy and immunocytochemistry have also shown the localisation of 
this transporter in the macula densa cells, which proposes a role in TGF 
(Nielsen et al., 1998; Obermüller et al., 1996). NKCC2 was originally cloned 
and sequenced from rat and mouse kidney and later in corresponding cDNAs 
from other species such as human and rabbit (Gamba et al., 1994; Igarashi 
et al., 1995; Payne and Forbush, 1994; Simon et al., 1996a). Mouse NKCC2 
was found to share 93.5% and 97.6 % amino acid identity to the rabbit and 
rat sequence, respectively (Igarashi et al., 1995). Sequence analysis also 
revealed NKCC2 to share 60% homology to the secretory NKCC isoform, 
NKCC1 (or BSC2, SLC12A2) (Payne and Forbush, 1994). NKCC1 is mainly 
involved in the regulation of Cl- secretion. NKCC1 was identified by screening 
and cDNA isolation from shark rectal gland and mouse inner medullary 
collecting duct (mIMCD-3) cell line libraries (Delpire et al., 1994; Xu et al., 
1994).  Later isolation of the human NKCC1 homologue revealed 91% and 
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74% homology to mouse and shark NKCC1, respectively (Payne et al., 
1995). Unlike NKCC2, NKCC1 is localised to the BLM of secretory epithelial 
cells and is ubiquitously expressed in a wide variety of tissues, such as the 
brain, thymus, lung, heart, skeletal muscle, colon and testis (Delpire et al., 
1994; Payne et al., 1995; Xu et al., 1994).   
  
As NKCC2 provides the major pathway for the uptake and maintenance of 
NaCl content in the Loop of Henle, its regulation must be tightly controlled. 
Several hormones regulate NaCl reabsorption in this segment, the most 
widely-studied stimulatory hormone is vasopressin. Vasopressin and other 
stimulatory hormones act by increasing intracellular cyclic adenosine 
monophosphate (cAMP), which, in turn, enhances NKCC2 activity (Giménez 
and Forbush, 2003; Hall and Varney, 1980; Hebert et al., 1981a, 1981b, 
1981c; Kim et al., 1999; Sasaki and Imai, 1980). The mechanism by which 
cAMP stimulates NKCC2 activity remains complex, however, most studies 
suggest the involvement of phosphorylation and trafficking of NKCC2 to the 
apical membrane.  Both NKCC2 and NKCC1 amino acid sequence analyses 
in rat, mice, rabbit and humans have identified potential phosphorylation 
sites. Three phosphoacceptor sites located in the N-terminal domain of shark 
NKCC1, Thr184, Thr189 and Thr202, have been previously identified and 
further site-directed mutagenesis experiments have demonstrated the 
Thr189 residue, in particular, to be critical for activity (Darman and Forbush, 
2002). This region of the N-terminus containing the three regulatory 
threonines is highly conserved between NKCC1 and NKCC2 (equivalent to 
Thr96, Thr101 and Thr114 in the mouse and rat NKCC2 sequence, and 
Thr100, Thr105 and Thr118 in the human NKCC2 sequence, respectively) 
suggesting that the phosphoregulatory mechanisms are conserved among 
the isoforms (Darman and Forbush, 2002).   
 
The generation and use of an antibody that specifically recognises residues 
Thr212 and Thr217 of the human NKCC1 cotransporter (corresponding shark 
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NKCC1 Thr184 and Thr189 residues, respectively), in mice following 
vasopressin infusion showed phosphorylation at equivalent residues Thr96 
and Thr101 of mouse NKCC2 and a significant increase in NKCC2 
immunostaining at the apical membrane, suggesting stimulated trafficking of 
NKCC2 to the apical membrane from an intracellular compartment  (Flemmer 
et al., 2002; Giménez and Forbush, 2003). Further mutagenic analysis of the 
three N-terminal threonines in oocytes expression models, using the rabbit 
NKCC2 sequence, demonstrated that the corresponding threonines Thr99, 
Thr104 and Thr114 (Thr96, Thr101 and Thr114 in rat/mouse NKCC2, 
respectively) are required for NKCC2 activation in response to hypertonic 
conditions, but none of these residues were found to be individually critical, 
unlike the Thr189 residue in NKCC1 (Giménez and Forbush, 2005). 
Additional threonine and serine residues have been found to be 
phosphorylated under other conditions. For example, intracellular chloride 
depletion or hypotonic low-chloride stimuli in oocyte expression models 
promote NKCC2 phosphorylation at human NKCC2 residues Ser91, Thr95, 
Thr100, Thr105, and Ser130 (Ponce-Coria et al., 2008; Richardson et al., 
2011). In addition, site-directed mutagenesis in oocyte expression models at 
two asparagine sites, Asn442 and Asn452, also showed a significant 
reduction in NKCC2 activity, suggesting that NKCC2 activity is mediated by 
glycosylation (Paredes et al., 2006).  
 
The driving force for NKCC2-dependent NaCl reabsorption is provided by the 
basolateral Na+-K+-ATPase pump, the apical K+ channel and a basolateral 
Cl- channel. These enable Cl- movement across the cell, recycling of K+ 
across the apical membrane and the generation of a positive lumen potential 
to drive paracellular Na+ transport and complete net transcellular NaCl 
transport in the TAL. This segment also reabsorbs any residual HCO3- via the 
NHE3 antiporter (Capasso et al., 1991). Potassium concentrations at this 
segment is regulated by both NKCC2 and the renal outer medullary K+ 
channel, ROMK (or Kir1.1, KCNJ1) (Bleich et al., 1990; Ho et al., 1993), 
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which drives the paracellular reabsorption of Na+, K+, Mg2+ and Ca2+. 
Chloride is reabsorbed through the basolateral chloride voltage-gated 
channel Kb, ClCNKB (CLCNKB) (Kieferle et al., 1994). This segment is the 
target of loop diuretics such as bumetanide and furosemide and its 
importance in ion transport balance has been highlighted in genetic analyses 
of the renal disease, Bartter syndrome. Bartter syndrome is an autosomal 
recessive tubular disease characterised by hypokalemia (low serum 
potassium levels), metabolic alkalosis (increase in serum pH) and 
hypochloremia (low serum chloride levels) with normal blood pressure and is 
caused by mutations in either NKCC2 (Simon et al., 1996a), ROMK (Derst et 
al., 1997; Simon et al., 1996b) or the ClCNKB chloride channel (Simon et al., 
1997).  
 
1.4.1.3 Distal convoluted tubule (DCT) 
 
The distal segments of the nephron are important regulators of blood 
pressure and play a critical role in the fine-tuning of NaCl transport. The DCT 
reabsorbs around 5–10% of filtered NaCl via the thiazide-sensitive sodium-
chloride cotransporter, NCC (TSC, SLC12A3), which transports NaCl at a 1:1 
stoichiometry (Fig.1.2d) (Ellison et al., 1987; Gamba et al., 1993; Plotkin et 
al., 1996).  NCC was the first member of the Na+-K+-Cl- cotransporter family 
to be identified and characterised at a molecular level. Its corresponding 
cDNA was originally isolated from epithelial cells in the urinary bladder of the 
winter founder (Gamba et al., 1993), and using a fragment of this isolated 
cDNA, its mammalian homologue and the NKCC2 cotransporter was later 
isolated from a rat renal cortex and outer medulla cDNA library, respectively 
(Gamba et al., 1994). Northern blot and in situ hybridisation analysis of NCC 
transcripts showed the expression of this cotransporter is restricted to the 
short-convoluted tubule segments in the cortex of the mammalian kidney, 
alongside, immunoblotting, immunoelectron microscopy and 
immunofluorescence experiments confirmed its precise localisation to the 
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apical membrane and subapical vesicular structures of the DCT cells 
(Gamba et al., 1994; Loffing et al., 2001; Plotkin et al., 1996). As NCC plays 
a major role in NaCl reabsorption at this segment, like NKCC2, its regulation 
must be tightly controlled. This involves a series of complex phosphorylation 
cascades which, in turn, result in the trafficking of the phosphorylated 
cotransporter from the cytosol to the apical membrane of the DCT. Mouse 
models of NCC inactivating mutations have demonstrated diminished 
expression of the cotransporter at the apical membrane and detainment in 
the cytosol (Yang et al., 2013). NCC is a target of thiazide diuretics such as 
chlorothiazide, hydrochlorothiazide and bendroflumethiazide, and is 
commonly administered to treat hypertension, thereby demonstrating this 
transporter as an important regulator of blood pressure.  Loss-of-function 
mutations in this transporter cause Gitelman syndrome, an autosomal 
recessive salt wasting disorder characterised by hypotension, hypokalemia, 
metabolic alkalosis, hypocalciuria (low urinary calcium excretion) and 
hypomagnesemia (low serum magnesium level) (Simon et al., 1996c). 
Furthermore, gain-of-function mutations in the known regulators of NCC, that 
result in an increase in NCC activity, have been shown to cause 
Pseudohypoaldosteronism Type II (PHAII) (also known as Gordon syndrome 
or familial hyperkalemic hypertension (FHHt)), an autosomal dominant 
disease characterised by hypertension, hyperkalemia and metabolic acidosis 
(refer to Section 1.4.3.4) (Boyden et al., 2012; Louis-Dit-Picard et al., 2012; 
Wilson et al., 2001).   
 
1.4.1.4 Collecting duct (CD) 
 
This last segment of the nephron reabsorbs 3–5% of filtered NaCl and plays 
a major role in acid-base regulation. This segment is composed of three cell 
types (Fig.1.2e); the principal cells (reabsorbs Na+ and secretes K+) and the 
acid-base regulatory a-intercalated (secretes H+) and b-intercalated 
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(secretes HCO3-) cells. As in the TAL, K+ concentration is regulated by 
ROMK in the principal cells. Sodium is reabsorbed through the aldosterone-
sensitive epithelial Na+ channel, ENaC. ENac is composed of three 
homologous a-, b- and g-subunits (SCNN1A, SCNN1B and SCNN1G, 
respectively) and is localised to the apical membrane of the principal cells 
(Canessa et al., 1994; Schmitt et al., 1999b).  Loss-of-function mutations in 
either subunits of this channel have been shown to mimic the autosomal 
recessive disease, Pseudohypoaldosteronism Type 1 (PHAI), characterised 
by salt-wasting, hyperkalemia, metabolic acidosis and unresponsiveness to 
mineralocorticoid hormones (Chang et al., 1996; Gründer et al., 1997; 
Pradervand et al., 1999a). Gain-of-function mutations in either the b- or g-
subunits cause the autosomal dominant disease, Liddle syndrome, 
characterised by salt-sensitive hypertension, hypokalemia and metabolic 
alkalosis (Firsov et al., 1996; Shimkets et al., 1994; Snyder et al., 1995). 
These gain-of-function mutations have been previously introduced into mice 
to generate models of Liddle syndrome (Pradervand et al., 1999b). The 
activity of this channel has been shown to be salt-sensitive and regulated by 
aldosterone (Loffing et al., 2000; Pacha et al., 1993). Studies in isolated 
tubules of rats fed Na+-depleted (0.0003%) diets, where serum aldosterone 
levels were high, demonstrated a significantly higher mean number of open 
channels compared to Na+-repleted diets (normal chow with saline drinking 
water), where serum aldosterone levels were low (Pacha et al., 1993). In 
addition, immunohistochemical analysis in kidneys of mice fed a high (3%) 
Na+ diet was unable to detect the a-subunit at the apical membrane, while 
the b- and g-subunits were detected in the cytoplasm (Loffing et al., 2000). In 
contrast, analysis in mice fed a low (0.05%) Na+ diet showed all three ENaC 
subunits localised to the apical membrane (Loffing et al., 2000). This 
suggests the regulation of ENaC, in response to dietary Na+ intake, is 
associated with changes in serum aldosterone levels which regulate ENaC 
abundance via the translocation from the cytoplasm and insertion of all three 
subunits into the apical membrane.  
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Also within this segment, lies the Cl-/HCO3- exchanger, pendrin (SLC26A4). 
RT-PCR, immunoblot and immunofluorescence analysis have localised 
pendrin to the BBM of the b-intercalated cells of the cortical collecting duct 
(CCD) (Royaux et al., 2001; Soleimani et al., 2001). Expression studies have 
shown that pendrin plays a critical role in HCO3- secretion in the kidney 
(Royaux et al., 2001; Soleimani et al., 2001). Although pendrin does not 
transport Na+ directly, its role has been implicated in controlling net NaCl 
reabsorption as overexpression of pendrin in mice exhibited increased Cl- 
reabsorption and chloride-sensitive hypertension (Jacques et al., 2013). 
Pendrin has also been previously suggested to a facilitate Na+ transport by 
functioning alongside NDCBE (SLC4A8), a Na+-dependent Cl-/HCO3- 
exchanger that transports Na+ and HCO3- at a stoichiometry of 1:2 (Fig.1.2e) 
(Grichtchenko et al., 2001; Leviel et al., 2010). However, this interaction 
remains to be confirmed. 
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Figure 1.2. Renal sodium reabsorption. A) In the nephron, incoming plasma Na+ content is sensed by the macula densa cells (yellow), which 
is in close proximity to the glomerulus and adjusts filtration and reabsorption processes throughout the nephron accordingly, from the PT 
(green), to the TAL (orange), DCT (purple) and the CD (blue). Sodium reabsorption in the nephron is closely regulated by a number of Na+-
coupled transporters and channels at the B) PT, C) TAL, D) DCT and E) CD. The driving force for Na+ transport is provided by the 
electrochemical gradient generated by the basolateral Na+-K+-ATPase and movement of other electrolytes such as K+ and Cl-. 
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1.4.2 Gastrointestinal sodium transport 
 
The gastrointestinal tract is the site of enzymatic digestion and nutrient and 
electrolyte absorption. The intestine is divided into three main segments; the 
proximal small intestine (consisting of the duodenum and jejunum), the distal 
small intestine (ileum), and the large intestine (colon).  Sodium absorption at 
these segments occurs by diffusion, cotransport with amino acids, glucose, 
HCO3-, Pi and Cl-, and H+ exchange across the BBM, which will be described 
in the following sections.   
 
1.4.2.1 Proximal small intestine (PSI) 
 
The proximal small intestine is where a majority (~80%) of Na+ absorption 
occurs, this is due to its large surface area, absorptive capacity and high 
expression of Na+-dependent transport proteins, particularly in the jejunum. 
Like in the kidney, Na+ absorption is driven by the ionic gradient maintained 
by the Na+-K+-ATPase pump throughout the gastrointestinal tract (Fig.1.3). 
 
Sodium transport in this section is coupled to glucose transport via the apical 
SGLT1 transporter. As mentioned previously, SGLT1 is a high affinity/low-
capacity Na+/glucose cotransporter which transports Na+ and glucose at a 
2:1 stoichiometry. Molecular characterisation and tissue distribution analyses 
revealed SGLT1 to be predominantly expressed and localised to the BBM of 
the small intestine and expressed at low concentration in the kidney, in 
contrast to its kidney-specific isoform, SGLT2 (Lee et al., 1994; Yoshikawa et 
al., 2011). Sequence analysis showed rat SGLT1 was 86% identical to rabbit 
and 87% identical to pig and human SGLT1 (Lee et al., 1994), implying the 
molecular characteristics of SGLT1 are similar across species. Functional 
characteristics were also previously determined through cloning, sequencing 
and expression studies of SGLT1 from rabbit small intestinal BBM which 
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exhibited a significant increase in Na+-dependent glucose uptake in cRNA-
injected oocytes, whilst water-injected controls did not (Hediger et al., 1987; 
Ikeda et al., 1989). Furthermore, SGLT1-knockout mice display glucose-
galactose malabsorption, indicating that SGLT1 predominantly mediates 
intestinal glucose absorption (Gorboulev et al., 2012). SGLT1 facilitates 
glucose uptake working alongside its basolateral counterpart, GLUT2, to 
ensure efficient Na+/glucose absorption (Fig.1.3a). GLUT2 was first isolated 
and cloned from rat liver (Thorens et al., 1988). Northern blot and 
immunofluorescence experiments established its expression and localisation 
to the small intestine, liver, kidney and b-pancreatic islet cells (Thorens et al., 
1988). Both SGLT1 and GLUT2 are expressed throughout the small intestine 
with higher levels at the proximal segment (Yoshikawa et al., 2011). Although 
GLUT2 has been identified at the BLM of enterocytes, reports have also 
demonstrated increased GLUT2 protein levels at the BBM in response to 
increased luminal glucose concentrations (Affleck et al., 2003; Kellett and 
Helliwell, 2000). These studies thereby proposed a new model for glucose 
absorption at the small intestine, which involves the rapid translocation and 
insertion of GLUT2 into the BBM in response to fluctuations in luminal 
glucose concentrations.  
 
Sodium absorption in the small intestine is also mediated by the NHE3 
exchanger (Fig.1.3a) (Murer et al., 1976). As mentioned previously, cloning, 
sequencing and expression experiments showed this exchanger was 
expressed in the kidney and throughout the gastrointestinal tract, except in 
the duodenum (Bookstein et al., 1994; Tse et al., 1992). Western blot and 
immunohistochemical analysis in human and rabbit tissues later supported 
NHE3 expression and localisation to the BBM of the villus epithelial cells in 
the jejunum, ileum and colon (Hoogerwerf et al., 1996).    
 
Not much is known about intestinal Pi transport in comparison to renal Pi 
absorption. Early studies in rats reported that the proximal small intestine 
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was responsible for the bulk Pi absorption and the later identified type II 
Na+/Pi cotransporter, NaPi-IIb (Npt2b, SLC34A2), was proposed as the main 
regulator of intestinal Pi transport (Fig.1.3a) (Hilfiker et al., 1998; Walling, 
1977). Kinetic and expression studies in oocyte models have revealed NaPi-
IIb as a high-affinity, electrogenic transporter, localised to the enterocyte 
BBM where it mediates the transport of Na+ and Pi at a stoichiometry of 3:1 
(Hilfiker et al., 1998). NaPi-IIb has shown to be upregulated by a number of 
factors such as 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), low-dietary 
phosphate and estrogen (Giral et al., 2009; Hattenhauer et al., 1999; Marks 
et al., 2006; Radanovic et al., 2005; Walling, 1977; Xu et al., 2003). Its role in 
Pi absorption has been confirmed in mouse studies whereby NaPi-IIb 
knockout mice fed on a low Pi diet, followed by an acute Pi load, showed 
~50% reduction in overall Pi absorption in comparison to wild type controls, 
with the remaining 50% of Pi absorption most likely occurring paracellularly 
(Sabbagh et al., 2009). In this study, NaPi-IIb was shown to account for 
>90% of total Pi absorption in isolated ileum segments, supporting this 
transporter as the predominant mediator of intestinal Pi absorption (Sabbagh 
et al., 2009). However, the exact contribution of NaPi-IIb to intestinal Pi 
absorption in different species remains controversial as the expression profile 
throughout the gastrointestinal tract appears to differ. One of the most 
significant findings was that NaPi-IIb protein was expressed in the ileum of 
mice (Radanovic et al., 2005; Stauber et al., 2005), a segment of the small 
intestine that was not originally considered a site of Pi reabsorption. In vivo 
studies utilising the intestinal loop technique in mouse small intestine 
confirmed the maximal rate of Pi absorption occurs in the ileum (Marks et al., 
2006). In contrast, in vivo uptake and in vitro studies, using BBM vesicles 
(BBMV), showed maximal Pi absorption and NaPi-IIb mRNA and protein 
expression at the duodenum and jejunum of rat small intestine, a pattern that 
was similarly observed in humans (Giral et al., 2009; Marks et al., 2006; 
Walling, 1977; Walton and Gray, 1979). Therfore, it is clear that Pi absorption 
differs among species, highlighting the difficulty to draw any conclusions with 
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regards to its role and significance to overall Pi absorption along the small 
intestine. However, the current belief is that, in response to low dietary Pi 
conditions, NaPi-IIb mediates Na+-dependent Pi transport in the rat jejunum 
and mouse ileum, but that an unknown Na+-independent transporter may 
contribute to overall Pi absorption in the small intestine when luminal Pi 
concentrations are high. 
 
A role for the type III Na+/Pi transporters, PiT1, in intestinal Pi transport has 
also been an area of interest and uncertainty. PiT1 transports Na+ and 
H2PO4- at a stoichiometry of 2:1. PiT1 mRNA has shown to be present in 
both rat and mouse small intestines (Giral et al., 2009; Tenenhouse et al., 
1998). Analysis of PiT1 protein confirmed its presence and localisation to the 
BBM of enterocytes in rat duodenum and jejunum. However, interestingly, 
PiT1 protein could not be detected in the ileum, despite its high mRNA 
expression (Giral et al., 2009). Furthermore, PiT1 mRNA and protein levels 
do not appear to be regulated by dietary phosphate (Giral et al., 2009), thus 
emphasising how little is known about the precise role of PiT1 in the small 
intestine. Nevertheless, owing to the absence of residual Na+-dependent Pi 
absorption in NaPi-IIb knockout mouse studies (Sabbagh et al., 2009), it is 
unlikely that PiT1 largely contributes to Pi homeostasis.  
 
The NKCC1 transporter has also been identified in the BLM throughout the 
small intestine; however, its main role in this organ has shown to lie towards 
the regulation of Cl- secretion rather than Na+ absorption (Grubb et al., 2000; 
Payne et al., 1995; Xu et al., 1994). 
 
1.4.2.2 Distal small intestine (DSI) 
 
The distal small intestine has a lower absorptive capacity compared to 
jejunum so only a small proportion of electrolyte absorption occurs 
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(Fig.1.3b). This segment is responsible for the ‘fine-tuning’ of electrolyte 
transport and for the absorption of vitamins and bile salts.  
 
Transcripts for the SGLT1 and GLUT2 transporters have been detected in 
this segment in order to facilitate Na+/glucose uptake, but at lower levels in 
comparison to the proximal segment (Lee et al., 1994; Yoshikawa et al., 
2011). However, chronic streptozotocin-induced rats demonstrate a 
significant upregulation in SGLT1 and SGLT1-mediated glucose transport, 
and an increase in villus length in this segment, indicating an adaptable 
response under conditions of high glucose load and diabetic conditions 
(Debnam et al., 1995). NHE3 has also been identified in this segment 
(Bookstein et al., 1994; Hoogerwerf et al., 1996; Tse et al., 1992).  
 
As previously mentioned, this segment is also suggested to be the main site 
of Na+-dependent Pi transport in mice and is largely mediated by the apical 
NaPi-IIb transporter (Hilfiker et al., 1998; Marks et al., 2006; Radanovic et al., 
2005; Sabbagh et al., 2009; Stauber et al., 2005).  PiT1 mRNA has also 
been detected in this segment at high levels, however, its protein expression 
negligible (Giral et al., 2009) and so is not believed to contribute to Pi 
absorption. 
 
1.4.2.3 Large intestine (LI) 
 
Most nutrients would have been absorbed before reaching the large intestine 
and so its role involves absorption of the remaining water and electrolytes 
and secretion of HCO3- before the complete excretion of waste products 
(Fig.1.3c).  
 
The Na+ channel, ENaC, and the Na+/H+ exchanger, NHE3, mediate Na+ 
transport in this segment. ENaC has been detected at high levels in the large 
intestine (Canessa et al., 1994), to facilitate electrogenic Na+ absorption 
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along an electrochemical gradient where it then leaves the cell via the Na+-
K+-ATPase pump. NHE3 has also been identified at high levels in this 
segment (Bookstein et al., 1994; Tse et al., 1992). It should be noted that, 
although mice lacking the NHE3 exchanger displayed impaired HCO3- 
reabsorption in the kidney, these mice also exhibited enlarged epithelial 
thickness in the large intestine and decreased pH of excreted colonic 
contents, indicative of a severe absorptive defect in the intestine which was 
most likely compensated for by increasing the surface absorptive area 
(Schultheis et al., 1998a). In addition, serum aldosterone levels were 
significantly increased in these mice which, in turn, led to enhanced ENaC 
activity and altered Na+ homeostasis, further demonstrating the importance 
of both NHE3 and ENaC in acid-base and Na+ balance in the kidney and 
gastrointestinal tract.  
			
50				
 
 
 
 
Figure 1.3. Intestinal sodium absorption. Sodium absorption across the BBM and BLM of A) PSI, B) DSI, and C) LI segments is mostly 
coupled to Pi transport via the NaPi-IIb and PiT1 transporters, glucose transport via the SGLT1 transporter, and H+ exchange via the NHE3 
exchanger. Like the kidney, sodium absorption is driven by the electrochemical gradient provided by the basolateral Na+-K+-ATPase pump. 
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1.4.3 Regulation of the renal sodium chloride cotransporter: NCC 
1.4.3.1  Role of NCC in blood pressure regulation 
 
Sodium transport in both the kidney and gastrointestinal tract is tightly 
regulated by numerous transporters and channels fuelled by electrochemical 
gradients. Defects in these transporters can have drastic consequential 
effects on blood pressure and plasma/urine electrolyte levels, and can lead 
to various renal tubular disorders.  
 
NCC has been particularly identified as an important regulator of blood 
pressure. As mentioned, NCC is expressed at the apical membrane of the 
DCT and is the main regulator of NaCl transport in this segment. This protein 
is the target of thiazide diuretics, which are key agents for hypertension 
treatment. NCC has been shown to play a crucial role in regulating 
extracellular fluid and blood pressure as inactivating mutations in this 
transporter cause the salt-wasting renal disease, Gitelman syndrome (Simon 
et al., 1996c). NCC-deficient mice display significantly reduced mean arterial 
blood pressure and an imbalance in electrolyte handling including 
hypomagnesemia and hypocalciuria (Schultheis et al., 1998b), clinical 
phenotypes of which resemble Gitelman syndrome. In addition, homozygous 
NCC mutation at T58M in mice (equivalent to human T60M, a common 
mutation in patients with Gitelman syndrome), also exhibited the typical 
characteristics of Gitelman syndrome; hypotension, hyperaldosteronism, 
hypokalemia, hypomagnesemia and hypocalciuria, as well as a blunted 
response to thiazide diuretics, all as a consequence of reduced 
phosphorylation and apical expression of NCC (Yang et al., 2013). The 
clinical symptoms of Gitelman syndrome are the ‘mirror-image’ of those 
observed in patients with PHAII.  These imply that the regulation of NCC in 
the kidney is important, not only for the homeostatic regulation of Na+, Cl- 
and K+, but also in the pathogenesis of PHAII.  
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1.4.3.2 WNK-SPAK/OSR1-NCC phosphorylation cascade 
 
The cellular mechanisms behind the regulation of NCC activity is of particular 
interest to this research project and is composed of a complex cascade of 
serine/threonine kinases and ubiquitin ligases. As depicted in Fig.1.4a, NCC 
function is regulated by sequential inhibitory and stimulatory interactions 
which in turn results in the trafficking of NCC to the apical membrane where it 
facilitates NaCl reabsorption. This regulatory pathway has been well 
established in many in vitro and in vivo murine and oocyte expression 
models. This cascade initiates with the activation of the With-No-Lysine [K] 
kinases, WNK1 and WNK4, which then phosphorylates and activates two 
closely related STE20-like serine/threonine kinases, SPAK (STE20/SPS1-
related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive 
kinase-1) (Anselmo et al., 2006; Moriguchi et al., 2005; Richardson et al., 
2008; Vitari et al., 2005). Following activation, SPAK and OSR1 kinases then 
phosphorylate the cytoplasmically inactive NCC cotransporter permitting its 
translocation to the apical membrane and allowing NaCl reabsorption 
(Richardson et al., 2008). 
 
1.4.3.2.1 With-No-Lysine kinases 
 
WNK kinases are a subfamily of serine/threonine kinases that act as 
‘molecular switches’ and are implicated in the regulation of electrolyte and 
blood pressure homeostasis. WNK kinases are so-named owing to their 
unusually unique localisation of the catalytic lysine residue, Lys233, in 
subdomain I, which is crucial for ATP binding, rather than in subdomain II 
where it is localised in other serine/threonine kinases (Min et al., 2004; 
Verissimo and Jordan, 2001; Xu et al., 2000). Subsequent database 
searches and sequence alignment revealed the existence of 4 homologous 
WNK kinases (WNK1 – 4) in mammals, all of which lacked this conserved 
lysine residue (Verissimo and Jordan, 2001).  
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WNK1 was the first identified member of the WNK family cloned and 
characterised from a rat brain cDNA library in search for novel members of 
the mitogen-activated protein kinase family (Xu et al., 2000). Sequence 
analysis found this kinase to be 85% identical to human WNK1 thereby 
allowing the regulatory effects of WNK1 to be mapped to humans (Verissimo 
and Jordan, 2001). All four WNK kinases exhibit a similar domain structure 
consisting of a small N-terminal domain followed by a highly conserved 
kinase domain, an autoinhibitory domain (which inhibits kinase activity via 2 
crucial phenylalanine residues, Phe524 and Phe526), and a long C-terminal 
coiled coil domain (Lenertz et al., 2005; Xu et al., 2002). The catalytic 
domains of WNK2, WNK3, and WNK4 were reported to be 95% homologous 
to WNK1 (Verissimo and Jordan, 2001). Although the four WNK4 kinases are 
highly similar, each differ in both chromosomal and tissue location. 
Expression analysis showed WNK1 as the most ubiquitous WNK kinase 
expressed in most tissues, the strongest being in the kidney, heart, muscle 
and testis (Choate et al., 2003; Verissimo and Jordan, 2001; Wilson et al., 
2001; Xu et al., 2000). WNK2 is predominantly expressed in the heart, brain 
and colon, WNK3 expression is mostly in the brain and intracellular junctions 
in all nephron segments, and WNK4 is expressed in the colon, skin and in 
the intracellular junctions of the DCT (Rinehart et al., 2005; Verissimo and 
Jordan, 2001; Wilson et al., 2001). WNK1 is rapidly activated by 
hyperosmotic stress or low Cl- depletion (Lenertz et al., 2005; Moriguchi et 
al., 2005; Richardson et al., 2008; Zagórska et al., 2007). Activation occurs 
through the autophosphorylation of a conserved key serine residue, Ser382, 
which is located within its activation loop (Xu et al., 2002; Zagórska et al., 
2007). This residue was found to be required for WNK1 activity as mutation 
of this residue to alanine ablated WNK1 activation, while mutation to glutamic 
acid enhanced WNK1 activity (Xu et al., 2002; Zagórska et al., 2007). As this 
residue is conserved among all the WNK isoforms, it suggests that the other 
isoforms are activated in a similar manner.  
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1.4.3.2.2 SPAK/OSR1 
As mentioned, SPAK and OSR1 protein kinases are substrates of WNK1 and 
WNK4 phosphorylation (Anselmo et al., 2006; Moriguchi et al., 2005; Vitari et 
al., 2005). SPAK, previously known as PASK, was first isolated from rat brain 
tissue and was identified as a member of the STE20/SPS1 protein kinase 
family with high sequence identity to the human SPAK sequence (Johnston 
et al., 2000; Ushiro et al., 1998). OSR1 was identified through large-scale 
sequencing and cloning studies, and was found to share 39% amino acid 
sequence identity to the human SOK1 (Ste20/oxidant stress response 
kinase-1) sequence (Tamari et al., 1999). Both SPAK and OSR1 are 
ubiquitously expressed and share a similar conserved structure with an N-
terminal catalytic domain, which is similar to other members of the STE20 
protein kinase subfamily, a serine motif (S-motif) and the conserved C-
terminal (CCT) domain (Johnston et al., 2000; Tamari et al., 1999; Ushiro et 
al., 1998; Vitari et al., 2006). A major difference between the two kinases is 
the presence of a unique N-terminal extension that mainly comprises of 
alanine and proline repeats in SPAK (Johnston et al., 2000; Ushiro et al., 
1998).   
 
The specific interactions of WNK1 and WNK4 with these protein kinases 
emerged from co-immunoprecipitation experiments and yeast two-hybrid 
screenings designed to identify binding partners of WNK1 and WNK4 
(Anselmo et al., 2006; Moriguchi et al., 2005; Vitari et al., 2005). Subsequent 
confirmation of SPAK and OSR1 as substrates for WNK1 was demonstrated 
through induced activation of endogenous SPAK/OSR1 in cells under WNK1 
stimulating conditions (Anselmo et al., 2006; Moriguchi et al., 2005; Zagórska 
et al., 2007). These studies also revealed the association between SPAK and 
OSR1 with WNK kinases was mediated by their CCT domains and though 
interactions with specific RFx[V/I] motifs (x represents any amino acid) 
present in both WNK1 and WNK4 (Delpire and Gagnon, 2007; Moriguchi et 
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al., 2005; Vitari et al., 2005, 2006). SPAK and OSR1 activation by WNK 
isoforms was accompanied by phosphorylation at two conserved sites, a 
threonine residue within the T loop catalytic domain, Thr233 (SPAK) and 
Thr185 (OSR1), and a serine residue located within the S-motif C-terminal 
non-catalytic domain, Ser373 (SPAK) and Ser325 (OSR1) (Vitari et al., 
2005). Phosphorylation of these threonine residues in the T-loop is important 
for SPAK/OSR1 activation as confirmed through inhibited activation upon 
mutation to alanine and enhanced activity upon mutation to glutamic acid, 
whereas the role for S-motif phosphorylation is still not yet known (Vitari et 
al., 2005). In addition, siRNA WNK1 depletion showed markedly impaired 
SPAK/OSR1 phosphorylation at the T-loop and S-motif by >50% and thus 
impaired SPAK/OSR1 kinase activity (Zagórska et al., 2007).   
 
1.4.3.2.3 NCC 
Phosphorylation of SPAK and OSR1 kinases, in turn, results in the 
phosphorylation and activation of NCC, linking the signalling cascade that 
connects the WNK kinases and the NCC cotransporter. The CCT domains of 
SPAK and OSR1 were previously shown to associate with NCC via a 
docking interaction through the RFx[V/I] motif at the N-terminal tail 
(Richardson et al., 2008). Following this interaction, SPAK and OSR1 
phosphorylate NCC at conserved residues within the N-terminal regulatory 
region; Thr46, Thr55, and Thr60 (human NCC), stimulating NaCl 
reabsorption (Moriguchi et al., 2005; Richardson et al., 2008). This 
phosphorylation mechanism was initially demonstrated in oocyte expression 
models, whereby a phosphorylation-defective NCC mutant, which was 
present on the apical surface of the membrane, showed a significant 
decrease in transport activity, highlighting the importance of the 
phosphorylation reaction for NCC function (Pacheco-Alvarez et al., 2006). In 
vivo analysis of NCC phosphorylation in the kidney has also shown that 
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phosphorylated NCC (pNCC) is localised exclusively to the apical 
membranes of the DCT (Pedersen et al., 2010; Yang et al., 2013), 
suggesting that the phosphorylation of NCC regulates its expression and 
function at the plasma membrane. The phosphorylated residue, Thr60 (Thr58 
in mice), was found to be essential for NCC activation and maintenance at 
the membrane, as mutation to alanine prevented NCC activation under 
activating hypotonic low-Cl- conditions and also suppressed phosphorylation 
of other residues, Thr46 and Thr55 (Pacheco-Alvarez et al., 2006; 
Richardson et al., 2008). Numerous studies have investigated the regulatory 
role of WNK4 on NCC regulation. Immunoprecipitation studies have 
demonstrated a direct interaction between WNK4 and NCC, whilst WNK1 
does not affect NCC directly (Cai et al., 2006; Wilson et al., 2003; Yang et al., 
2005). However, the role of WNK4 as a positive or negative regulator on 
NCC activity continues to remain controversial. Initial in vitro experiments in 
oocyte expression models and mammalian cells showed significantly 
suppressed NCC-mediated Na+ uptake and reduced NCC surface 
expression, suggesting WNK4 is a negative regulator of NCC (Cai et al., 
2006; Wilson et al., 2003; Yang et al., 2003). In addition, an interaction 
between WNK1 and WNK4 has been reported and have shown that WNK1 
suppresses the inhibitory effect of WNK4 on NCC activity (Yang et al., 2005). 
In contrast, various in vivo studies using WNK4 mutant animals have 
implicated WNK4 as a positive regulator of NCC activity and an important 
contributor in PHAII pathogenesis, which will be discussed later (see Section 
1.4.3.4) (Castaneda-Bueno et al., 2012; Takahashi et al., 2014).  
 
1.4.3.2.4 NKCC cotransporters 
SPAK and OSR1 have also been identified as regulators of the bumetanide-
sensitive Na+-K+-2Cl- cotransporters, NKCC1 and NKCC2 (Moriguchi et al., 
2005; Piechotta et al., 2002, 2003).  
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NKCC1 was the first substrate for SPAK and OSR1 kinases to be identified 
(Dowd and Forbush, 2003; Piechotta et al., 2002, 2003). In vitro studies 
revealed SPAK and OSR1, in response to hyperosmotic stress or low 
intracellular Cl-, to effectively phosphorylate 3 highly conserved sites located 
within the NKCC1 N-terminal domain; Thr184, Thr189 (essential for 
activation in NKCC1) and Thr202 (Darman and Forbush, 2002; Moriguchi et 
al., 2005; Vitari et al., 2006). Both kinases interact with NKCC1 via their CCT 
domains on the RFx[V/I] motif located within the N-terminal domain of 
NKCC1 (Delpire and Gagnon, 2007; Piechotta et al., 2003; Vitari et al., 
2006). The importance of this interaction was demonstrated upon mutation of 
these binding motifs (or the SPAK/OSR1 kinases to prevent activation by 
WNKs), which resulted in the inhibition of SPAK/OSR1 binding and activation 
of NKCC1 (Gagnon et al., 2007; Thastrup et al., 2012). As well as 
maintaining Na+, K+ and Cl- homeostasis, NKCC1 and its regulation by the 
WNK cascade has been confirmed in the regulation of vascular tone and 
contractile responses (Garg et al., 2007; Meyer et al., 2002; Susa et al., 
2012). 
 
The region of NKCC1 containing the 3 residues phosphorylated by SPAK 
and OSR1 have shown to be highly conserved in NKCC2 and NCC (Darman 
and Forbush, 2002; Moriguchi et al., 2005; Richardson et al., 2011; Vitari et 
al., 2006), implicating this transporter in the WNK-SPAK/OSR1 regulatory 
pathway. In validation of this hypothesis, yeast two-hybrid screening 
confirmed NKCC2 interaction with SPAK and OSR1, and further experiments 
showed phosphorylation of the N-terminal of NKCC2 at these 3 sites in 
response to hypotonic low-Cl- conditions (Moriguchi et al., 2005; Piechotta et 
al., 2002; Richardson et al., 2011). In addition, an in vitro study using oocytes 
overexpressing the WNK3 kinase has also demonstrated NKCC2 activation 
via interaction with SPAK and OSR1 (Ponce-Coria et al., 2008; Rinehart et 
al., 2005), further linking NKCC2 in the WNK regulatory cascade. Like NCC, 
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NKCC2 is also a target for loop diuretics as a treatment for hypertension, and 
its regulation via the upstream WNK-SPAK/OSR1 signalling cascade has 
been shown to play a major role in blood pressure homeostasis. 
 
1.4.3.3 Regulators of the WNK-SPAK/OSR1-NCC phosphorylation 
cascade 
The WNK-SPAK/OSR1-NCC phosphorylation cascade is highly adaptable to 
changes in dietary electrolyte intakes (Na+ and K+) and hormones 
(vasopressin, aldosterone and angiotensin II). Phosphorylation of 
SPAK/OSR1 and NCC were shown to be activated when mice were fed on a 
low-Na+ diet which was correlated with increased aldosterone levels, the 
reverse was observed when mice were placed on a high-Na+ diet, thus 
enabling adjustment of Na+ excretion to dietary salt intake (Chiga et al., 
2008). This regulation is abolished in PHAII. Reponses to changes in dietary 
salt have been shown to arise from the subcellular redistribution of NCC in 
the DCT. Immunogold staining and immunoelectron microscopy in rat DCT 
cells show pronounced NCC localisation at the apical membrane in rats fed a 
low-Na+ diet, whilst NCC under a high-Na+ diet resides in subapical vesicles 
(Sandberg et al., 2006). Aldosterone-mediated NCC activation by the serum- 
and glucocorticoid-regulated kinase, SGK1, has also been described 
previously (Rozansky et al., 2009; Vallon et al., 2009; Webster et al., 1993). 
Up-regulation and phosphorylation of NCC in response to a low-Na+ diet is 
significantly impaired in homozygous SGK1 mutant mice (Vallon et al., 2009), 
illustrating another component of NCC regulation. Dietary K+ intake also 
regulates this signalling cascade. Low-K+ diet causes the activation of the 
WNK-SPAK/OSR1-NCC signalling, whilst, high-K+ diets decrease cascade 
signalling (Vallon et al., 2009). As dysfunction of this cascade results in either 
hyper- or hypokalemia in PHAII and Gitelman syndrome, respectively, it is 
			
59				
therefore reasonable to assume that this cascade also plays a role in K+ 
homeostasis, however the mechanisms involved are still not yet clear.  
 
The WNK signalling cascade is also regulated by hormonal factors. In 
addition to aldosterone, angiotensin II (AngII) has been reported to activate 
this signalling cascade (Castaneda-Bueno et al., 2012; San-Cristobal et al., 
2009; Talati et al., 2010), however the mechanisms are still not well 
understood. In vitro oocyte expression models show AngII increases NCC-
mediated Na+ uptake (San-Cristobal et al., 2009). The addition and infusion 
of AngII to mpkDCT cells and mouse kidneys, respectively, demonstrated an 
increase in NCC and SPAK/OSR1 phosphorylation (Talati et al., 2010). In 
addition, AngII infusion in mice lacking WNK4 exhibited mild Gitelman-like 
phenotypes with reduced NCC phosphorylation, due to impaired 
SPAK/OSR1 phosphorylation (Castaneda-Bueno et al., 2012), thereby 
identifying AngII (or rather the renin-AngII-aldosterone (RAA) system) as a 
WNK4-SPAK-dependent regulator of NCC. Vasopressin is another hormone 
reported to stimulate NCC activity. It is well known that vasopressin regulates 
Na+ reabsorption in the kidney via NKCC2, however, short-term 
administration of vasopressin in rats has also been shown to enhance NCC 
phosphorylation and abundance at the plasma membrane (Mutig et al., 2010; 
Pedersen et al., 2010). 
 
1.4.3.4 Pseudohypoaldosteronism II (PHAII) 
1.4.3.4.1 WNK1/WNK4 
In summary, the WNK-SPAK/OSR1-NCC phosphorylation cascade has the 
capability to respond to changes in stimuli by stimulating the phosphorylation 
of NCC accordingly, underlining the importance of the WNK signalling 
cascade in the kidney for homeostatic regulation of electrolyte transport and 
blood pressure under different pathophysiological conditions. Numerous in 
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vitro and in vivo studies have been conducted to determine the importance of 
this pathway and NCC function in the pathogenesis of hereditary forms of 
hypertension. 
 
Wilson et al., first identified mutations in the WNK1 and WNK4 kinases as 
being responsible for the autosomal dominant inherited form of hypertension, 
PHAII (Fig.1.4b) (Wilson et al., 2001). Mutations in WNK1 are comprised of 
large intronic deletions in intron 1 that result in gain-of-function mutations 
(Wilson et al., 2001). Transgenic mouse models of WNK1 PHAII-causing 
mutations exhibit increased full-length WNK1 transcription and expression in 
the kidney, an increase in NCC phosphorylation and display all the clinical 
characteristics of PHAII, including hypertension, hyperkalemia, metabolic 
acidosis and hypercalciuria (Vidal-Petiot et al., 2013).  
 
PHAII-causing mutations in WNK4 are missense and cluster within a short, 
highly conserved acidic domain (Wilson et al., 2001). Four missense PHAII-
causing mutations have been identified in PHAII kindreds; E562K, D564A, 
Q565E and R1185C (Wilson et al., 2001). The effects of WNK4 and its 
PHAII-causing mutations has been extensively studied in in vitro oocyte 
expression models and genetically-modified mouse models, however, as 
previously mentioned, the influence of WNK4 on NCC activity is still a topic of 
controversy. Oocytes expression models overexpressing WNK4 have shown 
to inhibit NCC-mediated Na+ uptake by reducing NCC abundance at the 
apical membrane (Wilson et al., 2003; Yang et al., 2003). Some studies have 
shown the inhibitory effects of WNK4 on NCC are kinase-dependent (Wilson 
et al., 2003), while others report the effect of WNK4 to be kinase-
independent (Yang et al., 2005). Functional studies have revealed a direct 
association between WNK1 and WNK4 and claim that WNK1 acts by 
suppressing WNK4 inhibitory effects on NCC activity (Yang et al., 2005). 
However, there is little in vivo evidence to support the conclusion of WNK4 
acting as a negative regulator. One exception is a study by Lalioti et al., who 
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generated WNK4 transgenic mice harbouring a single copy of the wild-type 
WNK4 gene, which exhibited a Gitelman-like phenotype (Lalioti et al., 2006). 
However, a major limitation of this study is that whether WNK4 levels were 
increased or whether the observed negative effect on NCC was dependent 
on WNK4 levels was not clarified, thus, conclusions from this study must be 
considered with caution, particularly with the pitfalls of using transgenic mice. 
In contrast, numerous in vivo studies of WNK4 knockout and PHAII-causing 
WNK4 knock-in mouse models have swayed the functionality of WNK4 on 
NCC activity towards an activating role (Castaneda-Bueno et al., 2012; Lalioti 
et al., 2006; Ohta et al., 2009; Takahashi et al., 2014; Wakabayashi et al., 
2013; Yang et al., 2010a, 2007). WNK4D561A/+ knock-in mice display 
increased apical expression of pNCC as well as its upstream regulators, 
SPAK/OSR1, and exhibited the PHAII phenotype (Yang et al., 2010a, 2007). 
An increase in pNCC levels and PHAII phenotype was also observed in 
transgenic mice expressing the Q562E PHAII WNK4 mutant, which could be 
reversed when bred with mice lacking NCC (Lalioti et al., 2006). The 
opposite was observed in WNK4 hypomorphic and WNK4 knockout mice 
which exhibit a significant decrease in pNCC levels as well as the clinical 
phenotypes reminiscent of Gitelman syndrome (Castaneda-Bueno et al., 
2012; Takahashi et al., 2014). Furthermore, a study by Wakabayashi et al., 
generated several lines of WNK4 transgenic mice using the same method as 
the study by Lalioti et al., (Lalioti et al., 2006), with different levels of WNK4 
overexpression (Wakabayashi et al., 2013). They observed a significant 
increase in WNK4 levels that was associated with increased phosphorylation 
of SPAK/OSR1 and NCC and their mice also mimicked the PHAII phenotype 
(Wakabayashi et al., 2013). These mouse models thereby identify WNK4 as 
a positive regulator of the WNK-SPAK/OSR1-NCC phosphorylation cascade 
in vivo and that the PHAII-causing missense mutations are gain-of-function 
mutations which increase NCC activity at the apical membrane (Fig.1.4c). 
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1.4.3.4.2 KLHL3/CUL3 
Alongside WNK1 and WNK4, using whole-exome sequencing and combined 
linkage analysis in PHAII kindreds, two further genes, Kelch-like 3 (KLHL3) 
and Cullin 3 (CUL3), were identified in the cascades (Boyden et al., 2012; 
Louis-Dit-Picard et al., 2012). Several studies investigating the roles of 
KLHL3/CUL3 and the WNK kinases have been conducted in order to, not 
only to provide an insight into their molecular contribution to PHAII 
pathogenesis, but also to identify potential targets for anti-hypertensive 
therapy and have confirmed their involvement in the regulation of the WNK-
SPAK/OSR1-NCC phosphorylation cascade.  
 
KLHL3 is a member of the Kelch-like protein family, it contains a bric-a-brac, 
tramtrack, broad complex (BTB) domain, a BTB and C-terminal Kelch 
(BACK) domain, and a kelch domain containing 6 kelch repeats (Lai et al., 
2000; Louis-Dit-Picard et al., 2012). KLHL3 interacts with CUL3 to form an 
E3 ubiquitin ligase complex. PHAII-causing mutations within KLHL3 are 
either recessive or dominant whilst mutations in CUL3 are dominant and are 
the result of skipping exon 9 (Boyden et al., 2012; Louis-Dit-Picard et al., 
2012). It has been previously identified that WNK1 and WNK4 are substrates 
of KLHL3/CUL3 (Ohta et al., 2013; Shibata et al., 2013; Wakabayashi et al., 
2013; Wu and Peng, 2013). Immunoprecipitation studies have confirmed an 
interaction between KLHL3/CUL3 with WNK4 and have postulated a role for 
this ubiquitin ligase in maintaining WNK4 protein levels (and therefore its 
stimulatory influence on NCC) by subjecting it to ubiquitination and lysosomal 
degradation (Fig.1.4a) (Mori et al., 2013; Ohta et al., 2013; Shibata et al., 
2013; Wakabayashi et al., 2013). PHAII-causing mutations abolishes this 
binding between KLHL3 and WNK4 therefore impairing WNK4 degradation 
(Fig.1.4c). Known PHAII-causing mutations in different KLHL3 domains have 
also been studied to determine the severity of mutations with regards to 
maintaining WNK4 protein levels. Mutations in the BTB and BACK domain 
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result in the impairment of protein stability and the ability of KLHL3 to binding 
to CUL3, whilst mutations in the kelch domain impair the ability of KLHL3 to 
bind and regulate WNK1 and WNK4 (Mori et al., 2013; Wu and Peng, 2013). 
Nevertheless, impairment of KLHL3 to bind to either CUL3 or WNK4 all result 
in the same consequence; loss of WNK4 protein level maintenance due to 
diminished KLHL3/CUL3-mediated degradation, which result in an increase 
in WNK4 levels within the cell, and thus, enhancement of downstream 
activation of the WNK-SPAK/OSR1-NCC pathway. This increase in WNK4, 
as well as pNCC protein levels has been confirmed in WNK4D561A/+ and in 
KLHL3R528H/+ PHAII mouse models (Susa et al., 2014; Wakabayashi et al., 
2013). 
 
1.4.3.4.3 SPAK/OSR1 
As well as the PHAII consequences linked with mutations in WNK1/WNK4 
and KLHL/CUL3, mutations in the SPAK/OSR1 intermediates between the 
WNK kinases and NCC have also shown to have significant effects on blood 
pressure. Mutant SPAK knock-in mice that cannot be activated by WNK 
kinases exhibit a salt-dependent decrease in blood pressure, NCC and 
NKCC2 phosphorylation and are mildly hypokalemic under Na+-restriction 
(Rafiqi et al., 2010). Homozygous SPAK knockout mice also exhibit 
hypotension and significant electrolyte abnormalities that recapitulate 
Gitelman syndrome, as well as marked reductions in pNCC levels with 
blunted responses to dietary Na+-restriction and thiazide diuretic 
administration (McCormick et al., 2011; Yang et al., 2010b). Interestingly, 
genetic cross studies of WNK4D561A/+ PHAII mice with SPAK-/- knockout mice 
show normalised blood pressure, response to thiazides, plasma and urine 
biochemistries and similar levels of total NCC, pNCC, total NKCC2 and 
phosphorylated NKCC2 (pNKCC2) as the wild-type controls, thus, eliminating 
the PHAII phenotype and suggesting that SPAK deficiency can correct for 
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PHAII WNK4 mutations (Chu et al., 2013). In addition, mutation and 
disruption of the CCT domain of SPAK which recognises the RFx[V/I] motifs 
in its upstream activators and downstream substrates is associated with a 
significant reduction in pNCC and pNKCC2 levels and the typical features of 
Gitelman syndrome, including hypotension, upon dietary Na+-restriction 
(Zhang et al., 2015). Therefore, this effective lowering of blood pressure 
upon SPAK-NCC disruption may provide a promising new target for future 
anti-hypertensive therapy. 
 
1.4.3.5 WNK-SPAK/OSR1 signalling cascade: Extrarenal roles 
As well as regulating Na+, K+ and blood pressure homeostasis in the kidneys, 
the WNK-SPAK/OSR1 signalling cascade has been shown to be involved in 
the regulation of arterial tone. In this regard, the main transporter thought to 
be involved is NKCC1. NKCC1 is reported to play a major role in the 
regulation of vascular tone through establishing an outward Cl- gradient and 
membrane depolarisation which causes the opening of voltage-gated Ca2+ 
channels, leading to smooth muscle contractility (Akar et al., 2001; Garg et 
al., 2007; Meyer et al., 2002). NKCC1-mediated vascular smooth muscle 
contractions are stimulated by the vasoconstrictors, AngII and phenylephrine, 
and are inhibited by the nitrovasodilators, nitric oxide and nitroprusside (Akar 
et al., 1999). Inhibition of NKCC1 significantly reduces contraction of the 
aorta, therefore, NKCC1 is believed to also contribute to blood pressure 
maintenance. Studies with NKCC1 knockout mice exhibit significant 
reductions in blood pressure and showed abolished suppressive actions of 
bumetanide infusion on phenylephrine-stimulated vascular smooth muscle 
cell contractions (Garg et al., 2007; Koltsova et al., 2009; Meyer et al., 2002), 
thereby supporting the hypothesis of NKCC1 influencing blood pressure via 
the regulation of vascular smooth muscle cells. WNK1 and WNK3 have also 
been identified in vascular smooth muscles cells and have been shown to 
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phosphorylate the downstream substrate, SPAK, which in turn, 
phosphorylates NKCC1 (Bergaya et al., 2011; Moriguchi et al., 2005; Susa et 
al., 2012; Vitari et al., 2006). Animal studies using heterozygous WNK1 
mutant mice show decreased NKCC1 phosphorylation and vasoconstrictive 
responses in the aorta, which were confirmed through decreased blood 
pressure responses following stimulation with phenylephrine and the loss of 
pressure-induced contractile responses in thoracic aortic rings and 
mesenteric arteries (Bergaya et al., 2011; Susa et al., 2012). Similarly, SPAK 
knockout mice also show decreased NKCC1 phosphorylation in aortic 
tissues and impaired aortic contractility in response to phenylephrine and 
bumetanide (Yang et al., 2010b). More recently, the regulation of the WNK-
SPAK/OSR1-NKCC1 signalling cascade in the aorta was additionally found 
to be mediated by dietary Na+ intake and AngII, as both phosphorylated 
SPAK and NKCC1 were significantly increased in mice fed a low-Na+ diet 
and in mice infused with AngII (Zeniya et al., 2013). Thus, the WNK-
SPAK/OSR1 signalling cascade plays a major role in regulating the influence 
of NKCC1 on smooth muscle contractility and further emphasises the 
importance of the WNK-SPAK/OSR1 signalling cascade in controlling blood 
pressure. 
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Figure 1.4. The WNK-SPAK/OSR1-NCC phosphorylation cascade and its contribution in PHAII pathogenesis. A schematic diagram of 
the WNK-SPAK/OSR1-NCC phosphorylation cascade showing the regulation of the sodium chloride cotransporter, NCC. A) Under normal 
conditions, upon activation via hyperosmotic stresses, WNK1 and WNK4 phosphorylate and activate the SPAK/OSR1 kinases which then go on 
to phosphorylate and activate NCC, mediating its trafficking towards the apical membrane where it facilitates NaCl reabsorption. WNK4 levels 
are maintained by ubiquitin-tagged degradation by interactions with KLHL3/CUL3 ubiquitin ligases. In PHAII, B) gain-of-function mutations in 
WNK1 result in the overactivation of the WNK-SPAK/OSR1 signalling pathway which increases pNCC expression at the apical membrane and 
NaCl reabsorption. C) Mutations in WNK4, KLHL3 or CUL3 impair WNK4 ubiquitination/degradation by loss of interactions with KLHL3/CUL3, 
which leads to uncontrolled rises in WNK4 levels. This increase in WNK4 levels results in the overactivation of the WNK-SPAK/OSR1 signalling 
pathway and ultimately, leads to augmented NaCl reabsorption in the kidney.  
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1.4.4 Calcineurin inhibitors 
There is sufficient evidence to support the involvement of the WNK-
SPAK/OSR1-NCC phosphorylation cascade in blood pressure regulation. 
Imbalances in this cascade result in PHAII and Gitelman syndrome renal 
disorders that elicit increased Na+ reabsorption or increased Na+ excretion, 
respectively. Interestingly, the clinical features associated with PHAII are also 
observed in renal transplant patients treated with CNIs, suggesting that the 
molecular mechanisms underlying PHAII pathogenesis could explain the 
sodium retentive and hypertensive effects of CNIs. Based on this 
observation, CNI-treated animal studies have been conducted to explore this 
link. One such study confirmed the PHAII-like phenotype in wild-type mice 
treated with FK506 for two weeks; with mice displaying salt-sensitive 
hypertension, hyperkalemia, metabolic acidosis and hypercalciuria, which 
could be reversed by thiazide administration (Hoorn et al., 2011). This 
hypertensive effect was not induced in NCC knockout mice and was 
exaggerated in NCC-overexpressing mice (Hoorn et al., 2011). On a 
molecular level, FK506 treatment increased renal pNCC protein abundance 
as well as WNK3, WNK4 and SPAK. These findings were also extended to 
CNI-treated renal transplant patients where the examination of renal biopsies 
using immunohistochemical analysis revealed increased apical expression of 
pNCC (Hoorn et al., 2011). In further support, a study using rats treated with 
another CNI, CsA, for two weeks demonstrated an increase in blood 
pressure, as well as hyperkalemia and hypercalciuria, and a significant 
increase in renal WNK4, NCC and pNCC protein abdunance (Melnikov et al., 
2011). These findings thereby demonstrate that CNI-induced hypertension is 
largely mediated through increased NCC activation.  
 
Recently, new evidence has come into light to suggest that the CNI-
enhancing effects on NCC may be due to CNIs inhibiting calcineurin-
mediated dephosphorylation of sodium transporters in the kidney. Mice fed 
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on a high-K+ diet (to activate calcineurin activity) showed rapid de-
phosphorylation of NCC, which was significantly inhibited by FK506- and W7- 
(calmodulin inhibitor) treatment (Shoda et al., 2017). In either treatment, 
there was no significant difference in WNK4, OSR1 and SPAK expression, 
suggesting that the rapid reduction of pNCC expression under high-K+ intake 
is independent of the WNK-SPAK/OSR1 signalling cascade and is instead 
largely mediated by the phosphatase activity of calcineurin. In addition, 
disruption of the FKBP12 protein in mice, followed by treatment with FK506, 
results in a decline in blood pressure and renal pNCC abundance, and 
further analysis in FK506-treated HEK-293 cells demonstrated inhibited 
dephosphorylation of NCC (Lazelle et al., 2016). Intriguingly, the abundance 
of WNK4 and SPAK in FK506-treated FKBP12 mutant mice was similar to 
that of the controls, further promoting the hypothesis that CNIs induce 
hypertension predominantly by inhibiting calcineurin-mediated 
dephosphorlyation of NCC. Studies with CsA-administered animals have also 
observed a significant increase in pNKCC2 abundance (Borschewski et al., 
2016; Esteva-Font et al., 2007). This has been further corroborated in urinary 
exosome analysis of hypertensive CNI-treated renal transplant patients 
where a high level of NKCC2 and NCC expression was observed in 
comparison to non-CsA and normotensive control patients (Esteva-Font et 
al., 2014; Rojas-Vega et al., 2015). In conclusion, it is well established that 
CNI-induced hypertension is largely mediated through increased NCC (and 
possibly NKCC2) activation and therefore implicates calcineurin as an 
important modulator of Na+ homeostasis and blood pressure. However, 
whether these effects are dependent on the WNK-SPAK/OSR1 signalling 
cascade still remains to be clarified.  
1.5 CNI-induced hypertension: Vascular tone 
 
Hemodynamic changes play a major role in CNI-induced hypertension 
(Fig.1.5). This has been observed in numerous animal studies whereby CsA 
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infusion in rats causes a significant fall in renal blood flow and a rise in 
vascular resistance (Kaye et al., 1993; Murray et al., 1985). The cause of 
these hemodynamic alterations is speculative but implicates several 
pathophysiological changes that, as a result, complicates its clinical use.  
 
There is evidence to suggest that CNIs elicit vasoconstrictive effects that are 
responsible for its nephrotoxic and arterial hypertensive outcomes (English et 
al., 1987; Golub and Berger, 1987; Kaye et al., 1993; Lamb and Webb, 1987; 
Lanese and Conger, 1993; Xue et al., 1987). Preclinical models of CsA-
treated rats show a significant decline in GFR and a progressive decrease in 
the diameter of the renal afferent arteriole (English et al., 1987), consistent 
with the notion that the renal response to CsA is an ischemic or glomerular 
process rather than via direct tubular injury. Various in vitro experiments in 
isolated rat vascular ring segments, tail arteries, portal veins and thoracic 
aortic tissues treated with CsA have demonstrated augmented contractile 
responses upon transmural or sympathetic nerve stimulation (Golub and 
Berger, 1987; Lamb and Webb, 1987; Xue et al., 1987), confirming the direct 
actions of CNIs on vascular smooth muscle and/or on adrengeric 
neurotransmission.  
 
Several studies have reported the CNI-induced vasoconstrictive effects to be 
mediated through the overproduction and release of the vasoconstrictor, 
endothelin (Cauduro et al., 2005; Cavarape et al., 1998; Lanese and Conger, 
1993; Takeda et al., 1992, 1995, 1999). In cultured human endothelial cells, 
incubation with CsA induced endothelin synthesis, which could be inhibited 
by the protein synthesis inhibitor, cycloheximide (Bunchman and Brookshire, 
1991). This suggests that CsA may directly induce endothelin activity in 
systemic or renal vasculature. This was also illustrated in in vivo rat studies 
in which treatment with CsA and FK506 resulted in, not only elevated blood 
pressure, but also increased endothelin synthesis in the mesenteric artery. 
This could be partially prevented following co-treatment with an endothelin 
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receptor antagonist (Takeda et al., 1992, 1995, 1999). Furthermore, CsA 
exposure in isolated rat arterioles caused a direct release of endothelin from 
the endothelium alongside a concentration-dependent decrease in lumen 
diameter of the afferent arteriole, all of which could be inhibited by an 
endothelin receptor antagonist (Lanese and Conger, 1993). In clinical 
settings, renal transplant patients receiving CsA treatment also displayed 
significantly higher levels of endothelin compared to control patients 
(Cauduro et al., 2005). These studies provide evidence to suggest an 
important role for endothelin in CsA-induced vascular smooth muscle 
contractions. 
 
There is also evidence that suggests that CNIs may act by impairing 
vasodilation as opposed to stimulating vasoconstriction (Richards et al., 
1989; Roullet et al., 1994; Stein et al., 1995). In human subcutaneous 
resistance vessels, CsA incubation decreases the rate of spontaneous 
relaxation and inhibits endothelium-dependent relaxation (Richards et al., 
1989). However, endothelium-independent relaxation was augmented in 
response to the vasodilator, sodium nitroprusside, and blunted 
vasoconstrictive response to noradrenaline and K+ upon CsA treatment was 
also observed (Richards et al., 1989), suggesting the hypertensive effects of 
CsA may, in part, be due to inhibited endothelium-dependent resistance 
vessel relaxation. Similar findings have been observed in isolated aortic rings 
from rats treated with CsA (Cartier et al., 1994). Chronic exposure of CsA 
significantly decreased maximal endothelium-dependent relaxation 
responses to acetylcholine. However, in this case, endothelium-independent 
relaxations to sodium nitroprusside was not effected in CsA- or vehicle-
treated groups and both endothelium-dependent and independent 
vasoconstriction was observed in CsA-treated animals in response to 
serotonin, aggregating platelets and norepinephrine (Cartier et al., 1994). 
This suggested that exposure to CsA may contribute to altering 
vasoregulation by decreasing endothelial-relaxing factors and increasing 
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production of endothelial-constricting factors. Supporting studies in isolated 
rat mesenteric artery vessels have shown impaired CsA-induced vasodilation 
via the inhibited production of the vasodilator, nitric oxide (NO) (Marumo et 
al., 1995; Morris et al., 2000; Oriji and Keiser, 1998). Analysis of the effect of 
CsA on NO synthase induction confirmed significantly reduced expression of 
inducible nitric oxide synthase mRNA and nitrate/nitrite accumulation 
(metabolites of NO) in rat smooth muscle cells (Marumo et al., 1995). In 
addition, acetylcholine-induced endothelium-dependent relaxation was 
significantly inhibited by 65% in thoracic aortic rings from CsA-treated rats 
compared to untreated controls (Oriji and Keiser, 1998). These hypertensive 
and inhibitory effects of CsA were found to be reversible in both in vivo and in 
vitro experiments by pretreatment with L-arginine, a precursor of NO (Oriji 
and Keiser, 1998). Clinical studies in renal transplant patients receiving CsA 
also confirmed the impaired vasodilatory effect, which was attributed to a 
reduction in endothelial basal and stimulated NO synthesis (Morris et al., 
2000). Although these inhibitory effects of CNIs on NO synthesis in vascular 
smooth muscle have mostly been demonstrated for CsA, a decrease in both 
the level and activity of endothelial NO synthase in the aorta of rats has also 
been observed for FK506 (Takeda et al., 1999).   
 
Another proposed mechanism by which CNIs induce hypertension, via 
changes in vascular tone, involves activation of the RAA system. Supporting 
studies have found CsA to increase plasma renin secretion/production and 
cystolic Ca2+ concentration and efflux in cultured human vascular smooth 
muscle cells when stimulated with AngII (Avdonin et al., 1999; Kurtz et al., 
1988). This was accompanied by a two-fold increase in the number of 
angiotensin II type 1 receptors suggesting that CsA upregulates the 
transcription of AngII receptors, and therefore AngII action, in human 
vascular smooth muscle cells which likely leads to vasoconstriction. This 
effect was also observed in CsA-treated rats; whereby CsA treatment caused 
a significant increase in SBP that was paralleled with enhanced aortic 
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contractile responses to AngII which could also be counteracted by 
administration of the RAA inhibitors, losartan and captopril, or inhibitors of 
vasoconstriction, prostanoids or endothelin receptors (Hoskova et al., 2014; 
Nasser et al., 2016). However, it remains unclear if and how CNIs induce 
AngII production and activation of the RAA system. 
 
1.6 CNI-induced hypertension: Sympathetic nervous system 
 
The sympathetic nervous system (SNS) plays an important role in the 
regulation of blood pressure. Activation of sympathetic activity mediates 
vasoconstrictive and renal sodium absorptive actions which may be 
accelerated during hypertension development. It has been suggested that 
CNI-induced rises in blood pressure and nephrotoxicity may be associated 
with, to a substantial extent, the excitation of the SNS (Fig.1.5) (Scherrer et 
al., 1990).  
 
Studies have been conducted to record sympathetic action potentials/nerve 
firing using intraneural microelectrodes to confirm CNI-induced sympathetic 
activation. In cardiac transplant recipients who were being treated with CsA, 
measurements of sympathetic neural activation showed significantly 
increased rates of sympathetic nerve firing as well as a rise in mean arterial 
pressure (MAP) (Scherrer et al., 1990). However, in other human studies, 
sustained use of CNIs has reported either unaltered sympathetic activity or 
short-lived sympathetic activation (Hausberg et al., 2006; Kaye et al., 1993; 
Klein et al., 2010; Stein et al., 1995). Analysis of muscle sympathetic nerve 
activity (MSNA) and blood pressure before and after withdrawal of CsA in 
renal transplant patients showed that, although MAP decreased significantly 
after CsA withdrawal, which is in line with the CNI-induced effects on blood 
pressure, MSNA was unchanged at both time points, suggesting that CNI 
treatment may not cause sympathetic nerve activation to elicit blood pressure 
elevations (Hausberg et al., 2006). However, the patients in this study were 
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receiving low doses of CsA that was accompanied by low CsA whole-blood 
trough levels, so it is possible that higher doses of CsA may elicit 
sympathetic activation. In other experiments, acute CsA administration at 
both normal and high doses showed increased MSNA, however, sustained 
treatment with CsA resulted in MSNA suppression (Klein et al., 2010). Acute 
administration of FK506 did not affect MSNA or MAP, however, the subjects 
used in this study were healthy volunteers and so the effects observed for 
CsA and FK506 cannot be applied under conditions of compromised organ 
dysfunction (Klein et al., 2010). Whilst these studies in humans may or may 
not implicate augmented sympathetic activation in the pathogenesis of CNI-
induced hypertension, these findings are only correlational and do not 
provide experimental evidence of this association. 
 
In contrast, numerous studies have provided supporting evidence using rat 
models that the hypertensive responses to CsA treatment are 
sympathetically mediated. Animal studies have clearly demonstrated both 
CsA and FK506 infusion induces sympathetic nerve activity which is 
paralleled by an increase in blood pressure and renal vascular resistance 
(Lyson et al., 1993; Morgan et al., 1991; Moss et al., 1985; Zhang and Victor, 
2000a; Zhang et al., 2000b). These effects are abolished upon elimination of 
sympathetic discharge (Morgan et al., 1991). Administration of 
rapamycin/sirolimus, an immunosuppressant that forms a complex with 
FKBP12 but does not interact with calcineurin, failed to induce sympathetic 
activation and increase blood pressure (Lyson et al., 1993), suggesting that 
the regulation of sympathetic nerve activity may be tightly linked to 
calcineurin-mediated inhibition of T-cell signalling. In addition, these CNI-
induced elevations have also confirmed CNI-induced sodium-retention 
outcomes due to activation of the SNS, which was abolished upon renal 
denervation (Moss et al., 1985). Further animal studies have gone on to 
suggest that CNIs increase sympathetic nerve activity through increasing 
renal afferent nerve activation (Moss et al., 1985; Zhang and Victor, 2000a), 
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by acting on renal sensory nerve endings mediated by vesicle 
phosphoproteins such as synapsins (which are essential for neurotransmitter 
release), rather than on central synapses (Zhang et al., 2000b). Therefore, in 
summary (Fig.1.5), activation of afferent renal nerve activity and SNS may 
be a primary mechanism by which CNIs induce hypertension, resulting in 
renal vasoconstriction, decreased GFR, increased renal vascular resistance 
and renal tubular sodium reabsorption. However, the mechanisms by which 
CNIs activate sympathetic activity are still not fully elucidated. 
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Figure 1.5. A mechanistic model for the pathogenesis of CNI-induced hypertension. CNIs influence abnormal rises in blood pressure 
through provoking hemodynamic alterations by vasoconstriction, impaired vasodilatory responses, activation of renal sympathetic nerve 
activity/SNS (which may also stimulate vasoconstriction), and increased renal sodium retention by activation of the WNK-SPAK/OSR1-NCC 
signalling pathway. 
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1.7 CNIs: Post-transplant Diabetes Mellitus (PTDM) 
 
Post-transplant diabetes mellitus (PTDM), or new-onset diabetes after renal 
transplantation (NODAT), is a recognised common and severe complication 
after transplantation.  
 
The incidence of PTDM among non-diabetics have reported to range 
between 2–25% of renal allograft recipients within the first 3 years post-
transplant and is associated with decreased graft and patient survival and 
increased cardiovascular mortality (Cosio et al., 2001, 2005; Kasiske et al., 
2003; Porrini et al., 2008a; Woodward et al., 2003). Analyses of risk factors 
have shown PTDM to be dependent on older age, age at time of transplant, 
increased weight/BMI, pre-transplant hypertriglyceridemia (elevated 
triglyceride), elevated total serum cholesterol and pre- and post-transplant 
hyperglycemia (elevated blood glucose) (Cosio et al., 2001, 2002, 2005; 
Porrini et al., 2008b). Pre- and post-transplant hyperglycemia were 
particularly identified as strong predictors of PTDM and highly associated 
with post-transplant cardiac events and disease (Cosio et al., 2005). Pre- and 
post-transplant hypomagnesemia were also suggested to be risk factors for 
PTDM development (Sinangil et al., 2016; Van Laecke et al., 2009).  
 
Although there are multiple factors that contribute to the risk of PTDM, CNIs 
have been identified as the dominant factor (Boudreaux et al., 1987; Heisel 
et al., 2004; Kasiske et al., 2003; Roth et al., 1989; Woodward et al., 2003). 
Data recorded from randomised trials and meta-analysis have reported 
significantly higher incidences of PTDM in patients receiving FK506 than CsA 
(Araki et al., 2006; Heisel et al., 2004; Kasiske et al., 2003; Woodward et al., 
2003). Follow up studies have shown the prevalence of PTDM over the first 2 
years post-transplant was almost 30% and 18% in FK506- and CsA-treated 
renal transplant patients, respectively (Woodward et al., 2003). Interestingly, 
in renal transplant recipients, FK506 was shown to be more diabetogenic 
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than CsA but only in patients with elevated pre-transplant triglyceride levels 
(Porrini et al., 2008b) . Although it is clear that CNIs are major risk factors for 
PTDM development, the detailed pathophysiological mechanisms underlying 
their diabetogenic affects remains to be clarified.  
 
A vast majority of studies evaluating these CNI-induced PTDM effects in 
renal transplant recipients, diabetic animals and cell line models have drawn 
attention to pancreatic b-cell dysfunction and impaired insulin synthesis and 
secretion as the main mode of action (Helmchen et al., 1984; Hirano et al., 
1992; Redmon et al., 1996; Tamura et al., 1995). In rats, FK506 caused a 
dose-dependent, but reversible, impairment in insulin secretion and lowered 
insulin levels in the pancreas (Hirano et al., 1992). These studies also 
reported both severe morphological and functional alterations in pancreatic 
b-cells following CNI-treatment (Helmchen et al., 1984; Hirano et al., 1992), 
which may correspond to decreased pancreatic and plasma insulin content, 
leading to hypergylcemia. Similar observations were found in insulin-
secreting b-cell lines, where FK506 exposure demonstrated a reversible, 
time- and dose-dependent decrease in insulin secretion which was 
accompanied by a dose-dependent decrease in insulin content and mRNA 
levels (Redmon et al., 1996; Tamura et al., 1995). These findings indicate 
that CNIs may directly act by reversibly inhibiting insulin gene expression, 
synthesis and secretion and, therefore, may portray a role for calcineurin in 
regulating glucose homeostasis. In validation, NFAT, FKBP12 and 
calcineurin protein expression have all been confirmed in pancreatic b-cells, 
and later analysis in the rat insulin I (INS1) gene revealed 3 putative NFAT 
binding sites located within the promoter and also confirmed NFAT-DNA 
binding activity (Lawrence et al., 2001; Tamura et al., 1995). Activation of this 
promoter was inhibited by FK506 but not by the immunosuppressant 
rapamycin indicating specificity towards calcineurin (Lawrence et al., 2001). 
In further support, mice with a b-cell specific deletion of the regulatory B 
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subunit of calcineurin developed age-dependent diabetes characterised by 
severe hyperglycemia, decreased b-cell proliferation, via decreased 
expression of b-cell transcription factors, decreased pancreatic insulin 
production and hypoinsulinemia, all of which could be rescued upon 
conditional expression of nuclear NFAT1 (Heit et al., 2006). These studies 
thereby suggest that calcineurin/NFAT signalling specifically regulates insulin 
gene expression and involves multiple factors that mediate b-cell function, 
and implicates that disruption of this pathway largely contributes to the 
diabetogenic effects of FK506. 
 
As mentioned, previous studies have suggested that the diabetic-onset 
effects of FK506 is greater in comparison to CsA but only in patients with 
elevated pre-transplant triglyceride levels, which serves as an indicator of 
insulin resistance (Porrini et al., 2008b). In recent studies using insulin-
resistant obese Zucker rat models, FK506 treatment inhibited b-cell 
proliferation and insulin gene expression, whilst none of the lean Zucker rats 
developed diabetes (Rodriguez-Rodriguez et al., 2013; Triñanes et al., 
2017). This was partially recovered or improved upon CNI withdrawal or after 
conversion to CsA (Rodriguez-Rodriguez et al., 2013; Rodríguez-Rodríguez 
et al., 2015; Triñanes et al., 2017). The conclusions drawn from these studies 
suggest that the exacerbated diabetogenic effects of FK506 by b-cell 
dysfunction, impaired insulin transcription and secretion are dependent on a 
pre-existing insulin resistant background, which may underlie PTDM 
development. These studies also establish calcineurin as a regulator of 
insulin synthesis and thus, glucose homeostasis. Unfortunately, the question 
remains as to the underlying mechanisms by which calcineurin regulates 
insulin transcription and what other b-cell factors are affected upon 
calcineurin inhibition.  
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1.8 Aims of this thesis 
 
The prevalence of post-transplant hypertension, nephrotoxicity and PTDM 
development is continuously growing and yet our knowledge of the regulatory 
pathways upon which CNIs act remains limited. The elucidation of the 
mechanisms underlying CNI-induced hypertension would allow a deeper 
understanding of its pathogenesis following transplantation and its 
implications for primary hypertension, another common form of hypertension, 
as well as aiding future prevention and therapeutic strategies. 
 
The research described in this thesis aims to further facilitate our current 
understanding of CNI-induced blood pressure alterations via the sodium 
retention side effect as well as to determine whether calcineurin, the target of 
CNIs, is therefore a regulator of sodium homeostasis and blood pressure. 
This has been investigated through three approaches.  
 
Previous studies have shown that CNIs induce the activation and 
phosphorylation of the renal NCC cotransporter to increase sodium 
reabsorption in the kidney, however, there are many other transporters and 
channels located throughout the kidney and gastrointestinal tract which also 
regulate sodium (re)absorption. Experiments were therefore designed to 
investigate the effects of CNIs on sodium transport in different regions of the 
nephron and gastrointestinal tract (Chapter III). 
 
CNIs are also major risk factors for PTDM and are known to provoke other 
electrolyte abnormalities that mimic the clinical features of other conditions 
which, together, resemble metabolic syndrome. Experiments were therefore 
designed to establish a mouse model of metabolic syndrome by CNI-
treatment and confirm whether CNI treatment may predispose individuals to 
this condition (Chapter IV). 
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Finally, this investigation also sought to optimise a urinary exosome isolation 
technique to determine whether NCC/pNCC excretion levels in CNI-
administered transplant patietns parallel immunohistochemical analyses, in 
hopes of providing a new non-invasive method to assist disease diagnosis 
(Chapter V). 
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Chapter II 
Materials and Methods 
2  
2.1 Animal Studies 
2.1.1 Ethical Approval 
 
All procedures were carried out in accordance with the UK Animals Scientific 
Procedures Act 1986, Amendment Regulations 2012. All protocols were 
approved by the University College London (Royal Free Campus) 
Comparative Biology Unit Animal Welfare and Ethical Review Body 
(AWERB) committee and performed in accordance with project licenses PPL 
70/8064 and PPL 70/7647.  
 
Mice used were male littermates (8 - 10 weeks, weighing between 20 – 25g) 
of a C57BL/6J background and were housed under a 12:12-hour light-dark 
cycle and maintained in ventilated metabolic cages with ad libitum access to 
food and water. Mice were fed a standard maintenance diet (RM1 (E) SQC, 
Specialised Diets Services, Witham, UK). Body weight was closely monitored 
and measured regularly. Loss of over 20% of their initial body weight resulted 
in termination of the experiment by an approved Schedule 1 method.  
 
At the end of the treatments, mice were placed under terminal anaesthesia 
via intraperitoneal (I.P) injection of pentobarbitone sodium (40 – 50mg/kg, 
Pentoject, Animalcare Ltd, York, UK) in 0.9% (w/v) sterile saline. Deep 
anaesthesia was achieved through monitoring of corneal and pedal reflexes 
before obtaining terminal blood samples by cardiac puncture (using a 23G 
needle) and final urinary samples by bladder puncture (using a 25G needle). 
Cervical dislocation was then performed and death confirmed before 
removing the kidneys and intestinal segments. 
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2.1.2 CNI Treatment 
 
For treatment studies, mice were administered a daily dose of either 2mg/kg 
Tacrolimus (FK506, LC Laboratories, Woburn, MA USA) or vehicle via I.P 
injections for two weeks. FK506/vehicle was dissolved in 10% (v/v) ethanol, 
10% (v/v) Tween20 and 0.9% (w/v) sterile saline. 
 
Alongside, mice were either fed a standard maintenance diet (RM1 (E) SQC, 
Specialised Diets Services, Witham, UK), or, as a “high-salt” alternative, 
maintenance diet supplemented with 1.5% (w/w) sodium chloride (NaCl).  
 
2.1.3 Metabolic Syndrome  
 
To induce metabolic syndrome, 3-week old male mice had ad libitum access 
to a high-fat diet (containing 60% energy-from-fat (58Y1, TestDiet, London, 
UK)), or standard maintenance diet for ten weeks (Table.2.1). Aside from the 
differences in fat/energy content, both diets contained similar nutritional 
profiles with regards to sodium, potassium, chloride, magnesium, calcium 
and phosphate. 
 
Energy from: 
Standard maintenance 
diet High-fat diet 
Kcal % Kcal % 
Protein 0.575 17.49 0.924 18.1 
Fat 0.244 7.42 3.140 61.6 
Carbohydrates 2.470 75.09 1.035 20.3 
 
Table 2.1. Breakdown of the energy derivation from the standard maintenance 
and high-fat diets. The standard maintenance diet provides 3.29 kcal/g energy and 
the 60% fat diet provides 5.10 kcal/g energy. For the standard maintenance diet, 
most of the energy is provided in the form of carbohydrates to compensate for the 
lower fat component. 
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Over the 10-week period, food and water intake and body weight were 
closely monitored. From week 8, mice were administered a daily dose of 
either 2mg/kg FK506 or vehicle by I.P injections for the remaining 2 weeks. 
Towards the last 5 days of treatment, mice were housed in metabolic cages 
to enable 24-hour urine collections. 
 
2.1.4 Plasma and Urine Biochemistry 
 
Blood samples were spun at 7,500 x g at 4°C for 5 minutes, the plasma was 
collected, and immediately snap frozen in liquid nitrogen. Urine samples 
were immediately snap frozen following collection. Measurements for 
triglycerides, high-density lipoproteins (HDLs), urate, magnesium, calcium 
and bicarbonate were carried out at the Department of Clinical Biochemistry 
(Royal Free Hospital, London, UK). 
 
2.1.5 Plasma and Urine Biochemistry: Sodium 
 
Sodium concentrations were measured using a sodium enzymatic assay kit 
(Dialab, Alpha Laboratories, Hampshire, UK) according to the manufacturer’s 
instructions. Absorbance at 405nm was measured on a microplate reader 
(DTX 880 Multimode Detector, Beckman Coulter, High Wycombe, UK). The 
principle of this assay determines sodium through the enzymatic activity of 
the sodium-dependent β-galactosidase which uses o-nitrophenyl-β-D-
glycoside (ONPG) as a substrate (Fig.2.1). The absorbance measured for 
the product, o-nitrophenyl, at 405nm, is proportional to the sodium 
concentration. 
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Figure 2.1. Sodium assay principle. 
 
 
2.1.6 Plasma and Urine Biochemistry: Creatinine 
 
Creatinine concentrations were measured according to Jaffe’s method with 
the use of a colorimetric assay (Bonsnes and Taussky, 1945; Toora and 
Rajagopal, 2002). To obtain a calibration curve, creatinine standards at 0, 
0.02, 0.04, 0.08, 0.17, 0.33, and 0.67µg/ µl were prepared. Urine samples 
were used at a 1:20 dilution in distilled water whilst plasma samples were 
used neat. Standards and samples were added to 100µl distilled water and 
20µl trichloroacetic acid (TCA, from a 20% stock solution), left to precipitate 
at room temperature (25°C) for 10 minutes before centrifuging at 3000 rpm 
for 10 minutes at 25°C. The supernatant (100µl) was taken and added to 
0.75M NaOH and 0.04M picric acid (50µl each) and left to react in the dark 
for 20 minutes at room temperature before reading the absorbance at 
520nm. The principle of this assay relies on the reaction between creatinine 
and picric acid, under alkaline conditions, to form a chromogenic complex, 
resulting in a colour change to yellow/orange (Fig.2.2). The absorption at 
520nm of this complex is proportional to the creatinine concentration. 
 
 
Figure 2.2. Creatinine assay principle. 
ONPG O-nitrophenyl + galactose
Na+
β-galactosidase
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2.1.7 Plasma and Urine Biochemistry: Glucose 
 
Glucose concentrations were measured using a glucose oxidase assay 
(Huggett and Nixon, 1957). Glucose standards at 0, 2.5, 5, 7.5, 10, 12.5, 15 
and 20 mM were prepared. Standards and samples (1µl) were added to 20µl 
distilled water and 160µl of glucose oxidase reagent (phosphate buffered 
saline (PBS, Sigma Aldrich, Dorset, UK), 0.025% (w/v) glucose oxidase, 
0.00006% (w/v) peroxidise and 0.0001% (w/v) o-dianisidine) and left at room 
temperature for 1 hour before reading absorbance at 450nm. The principle of 
this assay is based upon the conversion of glucose to gluconic acid and 
hydrogen peroxide (H2O2) by glucose oxidase. This is then followed by the 
oxidation of o-dianisidine which leads to a colour change to orange/brown 
(Fig.2.3). 
 
 
 
Figure 2.3. Glucose assay principle. 
 
 
2.1.8 Plasma and Urine Biochemistry: Phosphate 
 
Phosphate concentrations were measured using a phosphate colorimetric 
assay kit (BioVision, California, US) according to the manufacturer’s 
instructions. This assay utilises complex formation between malachite green 
and ammonium molybdate with phosphate ions to form a chromogenic 
complex which can be measured at 650nm (Fig.2.4). 
 
Glucose + H2O2 Gluconic acid + H2O2
Glucose oxidase
H2O2 + o-Dianisidine
Oxidised o-Dianisidine
(orange/brown)
Peroxidase
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Figure 2.4. Phosphate assay principle. 
 
 
2.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
2.2.1 RNA Extraction 
 
Whole mouse kidneys were harvested and the surrounding capsule was 
removed. Intestinal contents were removed and the mucosa was collected 
from defined regions of the intestinal tract; duodenum (beginning at the 
stomach and ending at the ligament of Treitz), jejunum (beginning from the 
ligament of Treitz and ending at half the length of the remaining small 
intestine), ileum (the remaining distal section of the small intestine ending at 
the cecum) and the colon (beginning at the cecum to the end of the intestinal 
tract). Each of the intestinal segments were flushed through with ice-cold 
saline to remove contaminants, opened up along an ice-cold glass surface 
and then, using glass microscope slides, the mucosa was scraped away. 
Both kidney and intestinal tissues were immediately snap frozen in RNAlater 
Stabilization Solution (ThermoFisher Scientific, Paisley, UK). Total RNA was 
extracted using TRIzol reagent (Ambion Life Technologies, ThermoFisher 
Scientific, Paisley, UK) according to the manufacturer’s instructions, using 
100mg of tissue following homogenisation in liquid nitrogen with a pestle and 
mortar. The concentration and purity of the extracted RNA was determined 
using the Nanodrop (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). 
 
 
 
Phosphate + ammonium molybdate Chromogen(green)
Malachite green
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2.2.2 cDNA Synthesis 
 
One microgram of isolated RNA was subjected to DNase treatment using a 
DNase I Amplification kit (Invitrogen Life Technologies, Paisley, UK) 
according to the manufacturer’s instructions. This was followed by cDNA 
synthesis using a qPCRBIO cDNA synthesis kit (PCR Biosystems, London, 
UK) according to the manufacturer’s instructions. A reverse transcriptase 
negative control was included for all samples. 
 
2.2.3 RT-PCR 
 
All primers used for RT-PCR were purchased from Qiagen (Qiagen, 
Manchester, UK) or Sigma (Sigma Aldrich, Dorset, UK) and are described in 
Tables.2.2 and 2.3. RT-PCR was performed in duplicates, alongside a non-
template negative control and the housekeeping gene b-actin using the 
qPCRBIO SyGreen Mix Lo-ROX (PCR Biosystems, London, UK) on a 
LightCycler96 (Roche Diagnostics Ltd, West Sussex, UK). RT-PCR cycle 
conditions are described in Table.2.4. All data collected were normalised to 
b-actin. 
 
2.2.4 Agarose Gel Electrophoresis 
 
In order to determine successful RNA extraction and primer efficiency, RNA 
and final RT-PCR products were run via agarose gel electrophoresis. For 
RNA samples, the gel was prepared by dissolving 1% (w/v) agarose in 150ml 
1x TAE (40mM TRIS-Base, 20mM acetic acid, 1mM EDTA, pH 8.3), with the 
addition of 5µl (0.003% (v/v)) ethidium bromide solution (Gibco BRL, 
ThermoFisher Scientific, Paisley, UK) for visualisation of samples upon 
imaging. For RT-PCR products, a 2% (w/v) agarose gel was prepared. To 
assist sample loading and visualise migration, RNA sample-loading buffer 
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(without ethidium bromide, Sigma Aldrich, Dorset, UK) was added to the 
extracted RNA samples, and for RT-PCR products a 5x loading dye (5x DNA 
loading buffer, blue, Bioline, London UK) was added. One kb or 100 bp 
ladders (New England Biolabs, Herts, UK) were run alongside samples as 
size markers. Samples were run at 75V for 1 hour and imaged with a UV 
transiluminator (PEQLAB Biotechnologie, Erlangen, Germany). 
 
2.3 Antibodies 
 
All primary and secondary antibodies used in immunofluorescence and 
western blot applications have been described in Table.2.5 and 2.6, 
respectively, including their source, dilution and species specificity. 
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Primer (Assay) Name Gene Target species Catalog number Amplicon length (bp) 
Mm_Prkwnk1_1_SG WNK1 Mouse QT00170604 64 
Mm_Prkwnk4_1_SG WNK4 Mouse QT00109403 77 
Mm_Slc12a3_1_SG NCC Mouse QT00110600 112 
Mm_Klhl3_2_sg KLHL3 Mouse QT01056657 131 
Mm_Cul3_1_SG CUL3 Mouse QT00108010 150 
Mm_Slc9a3_2_SG NHE3 Mouse QT01039829 101 
Mm_Slc5a1_1_SG SGLT1 Mouse QT00112679 120 
Rn_RGD:620889_1_SG NaPi-IIb Rat QT00188594 83 
Rn_Slc34a3_1_SG NaPi-IIc Rat QT00185633 125 
Mm_Slc12a1_2_SG NKCC2 Mouse QT02521057 150 
Mm_Scnn1g_1_SG ENaC-γ Mouse QT00126168 81 
Mm_Slc26a4_1_SG Pendrin Mouse QT00131908 77 
Mm_Slc4a8_1_SG NDCBE Mouse QT00138621 115 
Mm_Slc2a2_1_SG GLUT2 Mouse QT00103537 105 
Mm_Actb_1_SG Actin Mouse QT00095242 149 
 
Table 2.2. Qiagen primers utilised for RT-PCR.  
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Gene  Accession number 
Forward 
sequence 
Reverse 
sequence Target species 
Amplicon length 
(bp) 
NaPi-IIa NM_013030 951 - 969 1315 - 1300 Rat 364 
PiT1 NM_031148 768 - 787 1007 - 988 Rat and mouse 239 
SGLT2 NM_022590 838 - 857 1088 - 1069 Rat 231 
 
Table 2.3. Sigma primers utilised for RT-PCR. 
 
Stage Condition 
Pre-incubation 
Denaturation 95°C, 600 seconds 
Three-step Amplification 
Primer annealing and 
extension 
cDNA synthesis 
95°C, 10 seconds 
60°C, 10 seconds 
72°C, 10 seconds – 35 cycles 
Melting 
Reaction termination 95°C, 10 seconds. 
 
Table 2.4. Conditions used for RT-PCR. 
			
91				
2.4 Immunofluorescence  
2.4.1 Perfusion Fixation 
 
Anesthetised mice were perfused, via transcardial perfusion, through the left 
ventricle with heparin sodium in 0.9% saline (1000units/ml, Workhardt, 
Wrexham, UK), followed by 4% (w/v) paraformaldehyde (PFA) in PBS. 
Kidney tissue was harvested and post-fixed in 4% PFA/PBS overnight at 
4°C. 
 
2.4.2 Paraffin-embedding 
 
PFA-fixed tissue was washed in distilled water for 1 hour at room 
temperature followed by sequential incubations in increasing concentrations 
of isopropanol; 50%, 75%, 90%, and 100% (v/v), every 2 hours at room 
temperature, before an overnight incubation in equal parts 100% isopropanol 
and melted paraffin (Sigma Aldrich, Dorset, UK) at 62°C. Tissue was then 
placed in pure melted paraffin at 62°C for up to 2 days to allow the wax to 
perfuse through the whole tissue, before arranging and setting on a plastic 
grid for sectioning. Tissues were sectioned using a microtome (HM335E, 
Microm, Minnesota, USA) at a thickness of 8 – 10µm and mounted onto 
gelatin-coated slides. 
 
2.4.3 Immunofluorescence Staining 
 
Paraffin-embedded tissues were de-paraffinised in 2 washes of xylene (10 
minutes each) and then in short washes (3 – 5 minutes each) of decreasing 
concentrations of ethanol; 100%, 90%, 70% and 50%, followed by washing in 
distilled water for 10 minutes and a brief wash in PBS.  
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Following de-paraffinisation, sections were placed in pre-heated (95 - 100°C) 
citrate buffer (10mM sodium citrate, pH 6) for 10 minutes, and washed under 
running water for 10 minutes. The sections were then blocked in 10% donkey 
serum in PBS for 30 minutes. After blocking and washing with PBS, the 
sections were incubated with primary antibody in PBS or block, alongside a 
negative control (PBS or block only), at a 1:100 dilution overnight at 4°C. As 
an additional control, primary antibodies were incubated alongside a marker 
for defined regions of the renal tubule (calbindin for the DCT or AQP2 for the 
CD). After subsequent washing with PBS (3x 5 – 10 minutes), sections were 
then incubated with their corresponding secondary antibodies at a 1:1000 
dilution in PBS for 1 hour at room temperature in the dark, washed with PBS 
(3x 5-10 minute washes) and mounted with mounting medium (Vectashield 
hardest mounting medium, Vector Laboratories Ltd, Peterborough, UK). 
 
2.4.4 Confocal Microscopy  
 
Fluorescence signals were detected with a Leica DMI4000b fluorescence 
microscope (Leica Microsystems, Milton Keynes, UK). Confocal images were 
captured using a Nikon Eclipse Ti inverted confocal microscope (Nikon UK 
Ltd, Surrey, UK) and analysed using the NIS-elements (Nikon UK Ltd, 
Surrey, UK) and ImageJ (ImageJ, Maryland, USA) software. 
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Table 2.5. Primary and secondary antibodies used for immunofluorescence. 
 
 
 
Primary antibodies 
Name Company Catalog Number Species Dilution 
Species 
Specificity 
Calbindin (D28K) Santa Cruz Biotechnology, Heidelberg, Germany sc-7691 
Goat 
polyclonal 1:100 
Mouse  
Human 
Phospho-NCC 
Threonine 58  
(pNCC T58) 
A kind gift from Omar Tutakhel and Dr Rene 
Bindels, Physiomics Radboud University, The 
Netherlands 
N/A Rabbit polyclonal 1:100 
Mouse 
Human 
Secondary antibodies 
Alexa-Fluor 488 
Donkey anti-rabbit Invitrogen, ThermoFisher Scientific, Paisley, UK A21206  1:1000 
Mouse 
Human 
Alex-Fluor 594 
Donkey anti-goat Invitrogen, ThermoFisher Scientific, Paisley, UK A11058  1:1000 
Mouse  
Human 
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Primary antibodies 
Name Company Catalog Number Species Dilution 
Species 
Specificity 
b-Actin Santa Cruz Biotechnology, Heidelberg, Germany sc-69879 Mouse monoclonal 1:500 
Mouse 
Human 
AIP1/ALIX Merck Millipore, Hertfordshire, UK ABC40 Rabbit polyclonal 1:500 Human 
a-ENaC StressMarq Biosciences, Victoria, Canada SPC-403D Rabbit polyclonal 1:1000 
Mouse 
Human 
GLUT2 Santa Cruz Biotechnology, Heidelberg, Germany sc-7580 Goat polyclonal 1:1000 Mouse 
Na+K+ATPase-a Santa Cruz Biotechnology, Heidelberg, Germany sc-28800 Rabbit polyclonal 1:1000 
Mouse 
Human 
NaPi-IIa A kind gift from Prof. Carsten Wagner and Dr. Nilufar Moebbi, University of Zurich, Switzerland N/A 
Rabbit 
polyclonal 1:3000 
Mouse 
Human 
NaPi-IIb A kind gift from Prof. Carsten Wagner and Dr. Nilufar Moebbi, University of Zurich, Switzerland N/A 
Rabbit 
polyclonal 1:2000 
Mouse 
Human 
NaPi-IIc Abcam, Cambridge, UK ab155986 Rabbit monoclonal 1:1000 Mouse 
NHE3 Santa Cruz Biotechnology, Heidelberg, Germany sc-16103-R Rabbit polyclonal 1:1000 Mouse 
NCC  MRC Protein Phosphorylation Unit, Dundee, UK S703C Sheep polyclonal 1:500 
Mouse 
Human 
Phospho-NCC 
Threonine 60 
(pNCC T60) 
MRC Protein Phosphorylation Unit, Dundee, UK S995B Sheep polyclonal 1:300 
Mouse 
Human 
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Table 2.6. Primary and secondary antibodies used for Western blotting.
NKCC2 MRC Protein Phosphorylation Unit, Dundee, UK S838B Sheep polyclonal 1:1000 Mouse 
Phospho-NKCC2 A kind gift from Prof. Carsten Wagner, University of Zurich, Switzerland N/A 
Rabbit 
Polyclonal 1:1000 Mouse 
PiT1 
Custom-made antibody from Davids 
Biotechnolgie, Regensburg, Germany 
Targeted for the rat Pit1 sequence: 
SLVAKGQEGIKWSELIK 
N/A Rabbit polyclonal 1:100 Mouse 
SGLT1 Santa Cruz Biotechnology, Heidelberg, Germany sc-20584 Goat polyclonal 1:1000 Mouse 
SGLT2 Santa Cruz Biotechnology, Heidelberg, Germany sc-98975 Rabbit polyclonal 1:1000 Human 
SGLT2 Santa Cruz Biotechnology, Heidelberg, Germany sc-47402 Goat polyclonal 1:1000 Mouse 
Anti-TSG101 AbCam, Cambridge, UK ab83 Mouse monoclonal 1:500 Human 
Secondary antibodies 
Donkey anti-goat Santa Cruz Biotechnology, Heidelberg, Germany sc-2033  1:1000 Mouse Human 
Donkey anti-rabbit GE Healthcare Life Sciences, Buckinghamshire, UK NA9340V  1:1000 
Mouse  
Human 
Rabbit anti-sheep Invitrogen Life Technologies, Paisley, UK 618620  1:1000 Mouse Human 
Goat anti-mouse Sigma Aldrich, Dorset, UK A4416  1:5000 Mouse Human 
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2.5 Western Blot Analysis 
2.5.1 Tissue Lysis and Preparation 
 
Snap frozen mouse kidney and intestinal muscosal tissues were thawed and 
homogenised using a turrax homogeniser (Ultra Turrax homogeniser, Janke 
& Kunkel, Staufen, Germany), on ice, in homogenisation buffer (300 mM 
sucrose, 5 mM EDTA, pH 7.5) containing phosphatase and protease 
inhibitors (1x cOmplete mini (Roche Life Sciences, West Sussex, UK), 1x 
PhosSTOP (Roche Life Sciences, West Sussex, UK) and 3 mM 
phenylmethanesulfonyl fluoride (PMSF)) at setting 10 for 1 minute and 30 
seconds. Homogenates were centrifuged at 2000 x g for 1 minute at 4°C, 
followed by addition of 1% Triton X-100 and incubation for 10 minutes at 4°C. 
Samples were then centrifuged at 2000 x g for 5 minutes at 4°C. A sample of 
the resulting supernatant (taken as the whole cell/ post-nuclear supernatant 
(PNST) fraction) was stored at -80°C, and the remaining supernatant was 
subjected to ultracentrifugation using the Beckman Coulter Optima MaxX-XP 
ultracentrifuge (Beckman Coulter, High Wycombe, UK), at 150,000 x g for 45 
minutes at 4°C. The resulting supernatant was kept as the cytosolic fraction 
and the final pellet was resuspended and sonicated in 200 µl distilled water 
using an ultrasonic processor (UP200S, Hielscher Ultrasounnd Technology, 
Teltow, Germany), both fractions were stored at -80°C and protein 
concentrations were determined using the Bradford protein assay. 
 
2.5.2 Kidney Brush Border Membrane Vesicle (BBMV) Preparation 
 
Renal BBM vesicles were prepared as described previously (Biber et al., 
1981). All buffers used in this preparation were supplemented with Kallikrein 
inhibitor units (KIU) aprotinin (Nordic Pharma, Reading, UK) and 0.085% 
(w/v) PMSF/DMSO protease inhibitors and kept at 4°C. Snap frozen mouse 
kidneys were thawed, weighed and submerged in homogenising buffer 
containing; 300mM mannitol, 5mM ethylene glycol-bis(2-amino-ethylether)-
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N,N,N’,N’-tetraacetic acid (EGTA), 12mM Tris/HCl, pH 7.4,  at a 20ml per g 
ratio. The kidneys were then homogenised, using a turrax homogensiser, at 
half speed for 2 minutes on ice, followed by the addition of cold distilled water 
(at a 28ml per 20ml of homogenising buffer used) and MgCl2 (from a 1.2M 
stock) to a final concentration of 12mM, and stirred (at low speed) on ice for 
15 minutes. Prior to the addition of MgCl2, a sample of the homogenate 
fraction was kept. The solution was then centrifuged at 2000 x g for 15 
minutes at 4°C and the supernatant re-centrifuged at 33,000 x g for 30 
minutes at 4°C. The resulting pellet was resuspended in resuspension buffer 
1 containing; 150mM mannitol, 2.5mM EGTA, 6Mm Tris/HCl, pH 7.4, using a 
hand-operated glass-Teflon homogeniser for about 10 cycles. MgCl2 was 
added to a final concentration of 12mM and stirred on ice for 15 minutes. The 
low and high-speed centrifugations as described above were repeated. The 
resulting pellet was then resuspended in resuspension buffer 3 containing; 
300mM mannitol, 2.5mM EGTA and 12mM Tris/HCl, pH 7.4, using a hand-
operated homogeniser and centrifuged at 33,000 x g for 30 minutes at 4°C. 
The final pellet, containing the BBM vesicles was resuspended in 
resuspension buffer 3 to a protein concentration of 3 – 6mg/ml using 10-12 
passes through a pipette tip. The protein concentration and activity of 
alkaline phosphatase for the initial homogenate fraction and BBM vesicles 
were determined to confirm enrichment of this marker enzyme. All fractions 
were stored at -80°C. 
 
2.5.3 Intestinal Brush Border Membrane Vesicle Preparation 
 
Intestinal BBM vesicles were prepared from the proximal (duodenum and 
jejunum fractions) and distal (ileum) segments as described previously 
(Kessler et al., 1978). All buffers used in this preparation were supplemented 
with EDTA-free protease inhibitor (Roche Life Sciences, West Sussex, UK) 
and kept at 4°C. Mucosal samples were added to homogenising buffer 
containing; 50mM mannitol, 2mM 4-(2-hydroxyethtl)-1-
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piperazineethanesulfonic acid (HEPES), pH 7.1, at a 28ml per g ratio, and 
homogenised, using the turrax homogeniser, at half speed three times for 20 
seconds followed by 5 second intervals in between. A sample of the 
homogenate fraction was kept. MgCl2 (from a 1M stock) was added to a final 
concentration of 10mM and stirred (at low speed) on ice for 20 minutes. The 
solution was then centrifuged at 4600 x g for 10 minutes at 4°C and the 
supernatant re-centrifuged at 41,600 x g for 30 minutes at 4°C. The resulting 
pellet was resuspended, using 10-12 passes through a pipette tip, in 
resuspension buffer containing; 300mM mannitol, 20mM HEPES, 0.1mM 
MgSO4, pH 7.2, at a 20ml per g ratio. The suspension was centrifuged at 
9300 x g for 15 minutes at 4°C and the supernatant re-centrifuged at 41,600 
x g for 30 minutes at 4°C. The final pellet, containing the BBM vesicles, was 
resuspended in resuspension buffer to a protein concentration of 3 – 6mg/ml 
using 10 – 12 passes through a pipette tip. The protein concentration and 
activity of alkaline phosphatase for the initial homogenate fraction and BBM 
vesicles were determined to confirm enrichment of this marker enzyme. All 
fractions were stored at -80°C. 
 
2.5.4 Protein Quantification 
 
Protein concentrations of the different fractions were measured using the 
Bradford protein assay (Bradford, 1976). Standards at; 0, 0.15, 0.30, 0.45, 
0.60, 0.75 and 0.9mg/ml, were prepared from stock solutions of BSA 
(1mg/ml) in 0.1M NaOH. Samples were diluted either at 1:10 or 1:100 in 
0.1M NaOH. Both standards and protein samples (5µl) were added to 200µl 
Bradford reagent (0.01 % (w/v) Coomassie brilliant blue g-250, 5% (v/v) 
ethanol and 10% (v/v) orthophosphoric acid) and the absorbance was read at 
595nm. The principle of this assay is based on the binding of proteins to 
coomassie dye, under acidic conditions, resulting in a colour change from 
brown to blue (Fig.2.5). The absorption at 595nm of this complex is 
proportional to the protein concentration. 
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Figure 2.5. Bradford assay principle. 
 
 
2.5.5 Alkaline Phosphatase Assay 
In order to ensure the kidney and intestinal BBM vesicles extracted were free 
from contamination from basolateral membrane and subcellular components, 
an alkaline phosphatase assay was used to calculate an enrichment value 
for this enzyme in the BBM vesicles, relative to the initial homogenate, as a 
measure of purity. Alkaline phosphatase activity was measured as previously 
described (Forstner et al., 1968) in the initial homogenate, at a 1:1 dilution in 
distilled water (1:20 for proximal and 1:1 for distal small intestinal samples), 
and in the final BBM vesicles, at a 1:20 dilution (1:200 for proximal and 1:20 
for distal small intestinal samples). Standards at 0, 50, 100, 150, 200, 250 
and 300nM of p-Nitrophenol (p-NP) were prepared. Following sample and 
standard preparations, 50µl of each (in duplicates) were transferred to a 
fresh tube and 250µl of alkaline substrate buffer (0.652% (w/v) p-Nitrophenyl 
phosphate (p-NPP) dissolved in buffer containing; 50mM glycine, 5mM 
MgCl2, 1mM zinc acetate, pH 9.4) was added. The standards and samples 
were incubated at 37°C for 15 minutes before terminating the reaction with 
the addition of 1.25ml of 0.001M NaOH. The solutions were transferred to a 
96-well plate and absorbance was read at 405nm. The principle of this assay 
is based on the rate of hydrolysis of the p-NPP substrate by alkaline 
phosphatase, under alkaline conditions, to produce p-Nitrophenol, which 
gives a yellow colour change (Fig.2.6). BBM vesicle and homogenate 
alkaline phosphatase activity and protein concentrations were used to 
calculate the enrichment factor (Fig.2.7). 
Protein + Coomassie G-250 Protein-Dye Complex
(blue)
			
100				
 
 
Figure 2.6. Alkaline phosphatase assay principle. 
 
 
 
Figure 2.7. Enrichment factor calculation. 
 
An enrichment value between 6 – 8 for kidney and 10 – 15 for intestinal BBM 
vesicles were regarded as pure. 
 
2.5.6 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Mouse kidney and intestinal PNST, cytosolic and membrane lysates (at 50 – 
100µg), human cortex PNST (at 25µg), BBM vesicles (at 20 - 30µg) and 
homogenate (at 30 - 50µg) protein samples were solubilised in 2x Laemmli 
sample buffer (BioRad, Hemel Hempstead, UK) in a 1:1 buffer: sample ratio 
and run on a 10% SDS-PAGE gel  (AE-6530M mPAGE electrophoresis tank, 
LabTech International Ltd, East Sussex, UK) in running buffer (25mM TRIS-
Base, 200mM glycine, 0.1% (v/v) SDS) at 20mA per gel for about 1 hour. 
Protein samples were run alongside a kaleidoscope prestained SDS-PAGE 
standard molecular weight marker (BioRad, Hemel Hempstead, UK). 
Separated proteins were transferred onto a methanol-activated 
p-Nitrophenyl Phosphate p-Nitrophenol(yellow)
Alkaline Phosphatase
Pi
Enrichment Factor    = 
BBM Vesicle Alkaline Phosphatase
BBM Vesicle Protein
Homogenate Protein
Homogenate Alkaline Phosphatase
X
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polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hemel Hempstead, 
UK) using a BioRad trans-blot SD semi-dry transfer cell (BioRad, Hemel 
Hempstead, UK), in transfer buffer (25mM TRIS-BASE, 200mM glycine, 
0.1% (v/v) SDS, 10% (v/v) methanol), at 15V for 1 hour 15 minutes. 
Membranes were blocked in 6% (w/v) milk in PBS-Tween (PBST, 0.1% (v/v) 
Tween20 in PBS) for 1 hour at room temperature and then rinsed in PBST, 
followed by an overnight incubation with primary antibody (Table.2.6) in 
PBST at 4°C. Membranes were washed with PBST (1x 15 minutes, 3x 5 
minutes) followed by a 1 hour incubation with the corresponding secondary 
antibody (Table.2.6) in PBST at room temperature, the membranes were 
then washed again with PBST (1x 15 minutes, 3x 5 minutes). To visualise, 
enhanced chemiluminescence solution (ECL, 2.5mM 3-
aminophthalhydrazide, 0.4mM p-coumaric acid, 100mM Tris-HCl, 200mM 
NaCl, 30% hydrogen peroxide, pH 8.5) was added over the membrane and 
detected using a BioRad Fluor-S MultiImager (BioRad, Hemel Hempstead, 
UK). Densitometry was measured using the BioRad Multi-Analyst software 
(Bio-Rad, Hemel Hempstead, UK) and analysed using the Graphpad Prism 
software. 
 
Following visualisation, membranes were stripped in stripping buffer (Takara 
Bio Europe SAS, France) for 5 – 10 minutes at room temperature, followed 
by washing in PBST (3x 5 minutes), and then blocked in 6% (w/v) milk/PBST. 
The membrane was then re-probed for b-actin. 
 
2.5.7 Gel Staining: Silver Nitrate 
 
Following SDS-PAGE, gels were placed in fixing solution (40% (v/v) ethanol, 
10% (v/v) acetic acid) for 35 minutes, followed by washing in distilled water 
for 30 minutes – overnight. Gels were sensitised in 0.02% (w/v) sodium 
thiosulfate for 1 minute and then washed in distilled water. Cold silver nitrate 
solution (0.1% (w/v) silver nitrate supplemented with 0.02% (v/v) 
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formaldehyde) was added and incubated for 20 minutes and then washed 
again in distilled water. Developing solution (3% (w/v) sodium carbonate 
supplemented with 0.01% (v/v) formaldehyde) was added until sufficient 
staining was achieved, after which, staining was terminated by transferring 
the gel to a 5% acetic acid (v/v) solution and stored in 1% acetic acid (v/v) 
solution. 
 
2.6 Clinical Studies 
2.6.1 Ethical approval 	
The protocols used in this study received full ethical approval from the Royal 
Free Hampstead NHS Trust, NHS Research Ethics Committee (Project ID: 
7727) and informed consent was received from all patients and control 
subjects. Twelve patients who had previously undergone renal 
transplantation and were currently being administered tacrolimus were 
recruited; these patients were receiving an oral dosage between 2 – 10mg, 
twice a day. Alongside, four patients diagnosed with Gitelman syndrome 
were also recruited. All patients and controls were age- and gender-matched 
to avoid bias (Table.2.7 and 2.8).		
2.6.2 Human Plasma and Urine Biochemistry 
 
Blood and urine samples were routinely collected on the day of renal 
biopsies (for CNI-treated renal transplant patients) and analysed by the 
Department of Clinical Biochemistry (Royal Free Hospital, London, UK). 
 
2.6.3 Urinary Exosome Isolation 
 
Urine samples were collected from patients and age-/gender-matched 
healthy subjects. Protease inhibitors (cOmplete Protease Inhibitor Cocktail, 
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Roche Diagnostics Ltd, West Sussex, UK) were immediately added to the 
urine samples and stored at -80°C. Twenty millilitres or 100 ml of collected 
urine was centrifuged at 17,000 x g for 15 minutes at 25°C (Allegra 64R 
Centrifuge, Beckman Coulter, High Wycombe, UK). The supernatant was 
transferred to ultracentrifuge tubes, whilst the pellet was re-suspended with 
200µl isolation solution (250mM sucrose, 10mM triethanolamine-HCL, pH 
7.6) and 50µl 3.24M dithiothreitol (DTT), incubated at room temperature for 2 
minutes, vortexed thoroughly and then centrifuged at 17,000 x g for 15 
minutes at 25°C. The resulting supernatant was collected and combined with 
the supernatant obtained from the previous spin and centrifuged at 200,000 x 
g for 2 hours at 25°C. The supernatant was discarded and the final exosome 
pellet was dissolved in 100µl of 2x laemmli sample buffer. All samples were 
stored at -80°C until further use. Urinary creatinine levels were determined 
for normalisation between samples and, prior to gel loading, samples were 
heated at 65°C for 15 minutes. 
 
 
ID 
Number 
Patient Matched Control 
Gender Age (Years) Gender Age 
1 M 33 M 33 
2 M 39 M 41 
3 M 37 M 33 
4 M 39 M 34 
5 M 56 M 55 
6 M 41 M 45 
7 M 46 M 46 
8 M 62 M 55 
9 M 71 M 63 
10 F 27 F 27 
11 F 32 F 31 
12 F 32 F 31 
 
Table 2.7. Age- and gender-matched controls for renal transplant patients 
currently receiving CNI medication. 
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ID 
Number 
Patient Matched Control 
Gender Age (Years) Gender Age 
1 F 35 F 31 
2 F 39 F 35 
3 F 43 F 44 
4 M 34 M 34 
 
Table 2.8. Age- and gender-matched controls for Gitelman syndrome patients. 
 
 
2.7 Statistical analysis 
  
The data are summarised as the mean ± standard error of the mean (SEM). 
An N number of 5 – 6 samples were used for each treatment group. 
Statistical analysis was performed using the GraphPad Prism software 
(GraphPad Prism, California, USA). Unpaired T-test was used for 
comparisons between two groups and, for multiple comparisons, a one-way 
ANOVA with the Bonferroni post-test was used. Significance was 
represented as: *P < 0.05, **P < 0.01, ***P < 0.001. 
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Chapter III 
The effects of calcineurin inhibitors on renal and intestinal 
sodium transport 
3  
3.1 Introduction  
3.1.1 Sodium retention via the WNK-SPAK/OSR1-NCC pathway in 
Pseudohypoaldosteronism II and CNI treatment 
 
The WNK-SPAK/OSR1 signalling pathway has been extensively proven to 
be an important regulator of blood pressure. Its involvement in PHAII 
pathogenesis is the result of increased sodium reabsorption via activation of 
the thiazide-sensitive sodium chloride cotransporter, NCC. Mutations in 
WNK1 and WNK4 kinases were first identified as responsible for PHAII. 
These mutations result in an increase in their protein levels, and ultimately, 
activation of downstream signalling (Wilson et al., 2001). Two additional 
PHAII-causing genes, KLHL3 and CUL3, were later identified (Boyden et al., 
2012; Louis-Dit-Picard et al., 2012), however, their contribution to the PHAII 
phenotype is due to the inability to maintain intracellular WNK4 levels via 
ubiquitination/degradation (Mori et al., 2013; Shibata et al., 2013; 
Wakabayashi et al., 2013; Wu and Peng, 2013). The consequence of these 
mutations is the enhanced activation of the WNK-SPAK/OSR1 signalling 
pathway, which leads to increased NCC expression at the apical membrane 
of the DCT where it facilitates sodium reabsorption and contributes to 
elevated blood pressure.   
 
Numerous mouse models of PHAII have been generated and have confirmed 
these conclusions (Chiga et al., 2011; Susa et al., 2014; Wakabayashi et al., 
2013; Yang et al., 2010a, 2007). PHAII WNK4D561A/+ and KLHL3R538H/+ knock-
in mouse models display impaired WNK4 degradation via the loss of WNK4-
KLHL3/CUL3 interactions, which is paralleled with increased WNK4 protein 
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as well as the phosphorylated forms of SPAK, OSR1 and NCC (Susa et al., 
2014; Wakabayashi et al., 2013). Further studies also showed that these 
PHAII phenotypes and augmented apical expression of pNCC could be 
restored upon partial interruption of the signalling between WNK and 
SPAK/OSR1 kinases (Chiga et al., 2011; Chu et al., 2013; McCormick et al., 
2011; Rafiqi et al., 2010; Yang et al., 2010b).  
   
As already mentioned, CNIs have been demonstrated to induce hypertension 
by enhanced NCC activation leading to increased sodium retention and 
reabsorption (Hoorn et al., 2011; Melnikov et al., 2011). FK506-treated mice 
exhibited all the clinical features of PHAII as well as increased 
phosphorylation and apical expression of NCC and its upstream regulators 
WNK4 and SPAK (Hoorn et al., 2011). This was also explored further in 
clinical settings, where immunohistochemical analysis of renal biopsies from 
CNI-treated renal transplant recipients showed increased pNCC localisation 
at the apical membrane of the DCT (Hoorn et al., 2011). With these findings 
in mind, using this model of an acquired form of PHAII, the detailed 
pathogenic mechanisms of both PHAII and post-transplant hypertension 
onset can be studied and, in particular, the role for calcineurin in blood 
pressure and sodium homeostasis. 
 
3.1.2 WNK-SPAK/OSR1 regulation of renal and intestinal sodium 
transporters 
 
It is well known that the downstream targets of WNK-SPAK/OSR1 kinases 
include the NCC and NKCC transporters (Anselmo et al., 2006; Dowd and 
Forbush, 2003; Moriguchi et al., 2005; Ponce-Coria et al., 2008; Richardson 
et al., 2008, 2011; Vitari et al., 2006). In addition to these, SPAK and/or 
OSR1 are also known to regulate the function of other sodium-coupled 
transporters and channels in the kidney and gastrointestinal tract.  
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This includes the renal and intestinal Na+/Pi cotransporters, NaPi-IIa and 
NaPi-IIb, respectively (Fezai et al., 2015; Pathare et al., 2012a). Voltage 
clamp experiments in oocyte expression models injected with cRNA 
encoding NaPi-IIa showed a significant up-regulation of phosphate-induced 
currents following co-expression with OSR1 (Pathare et al., 2012a). 
Additional in vivo analysis in WNK-resistant OSR1 mice, revealed decreased 
serum phosphate concentrations and increased urinary phosphate excretion, 
which was paralleled by a significant reduction in NaPi-IIa protein abundance 
at the BBM (Pathare et al., 2012a), specifying OSR1 as a stimulator of NaPi-
IIa in the kidney. More recent voltage clamp oocyte experiments have also 
identified SPAK and OSR1 kinases as stimulators of the intestinal NaPi-IIb 
transporter (Fezai et al., 2015).  
 
Studies using these WNK-resistant OSR1 mice have also shown that the 
sodium transport function of the NHE3 exchanger is altered in the small 
intestines (Pasham et al., 2012). Measurements of transport activity in these 
mutant mice showed higher intestinal NHE3 activity in comparison to wild-
type littermates (Pasham et al., 2012), proposing OSR1 as a potential 
negative regulator of NHE3. Furthermore, co-expression studies with oocytes 
have reported that WNK4 inhibits ENaC and that this inhibition is reversed in 
PHAII-causing WNK4 mutations (Ring et al., 2007a). This was likewise 
observed in Ussing chamber experiments. In the colonic epithelium of PHAII-
mutant WNK4 and WNK-insensitive OSR1 mutant mice, an increase in 
sodium flux and ENaC activity was observed compared to wild-type 
littermates (Pasham et al., 2012; Ring et al., 2007a). Recently, SPAK was 
also identified to play a role in the regulation of ENaC activity; oocyte co-
expression of ENaC with either wild-type or constitutively active SPAK 
induced a significant increase in amiloride-sensitive currents but not when 
co-expressed with WNK-insensitive and catalytically inactive SPAK (Ahmed 
et al., 2015). Moreover, colonic amiloride-sensitive currents were significantly 
			
108				
lower in WNK-insensitive SPAK mutant mice compared to wild-type 
littermates (Ahmed et al., 2015), supporting a stimulatory role for ENaC.   
 
Studies in oocytes and mice have also demonstrated SPAK as a negative 
regulator of the sodium-coupled glucose cotransporter, SGLT1. Co-
expression of SGLT1 with wild-type SPAK or constitutively active SPAK 
caused a significant decrease in glucose-dependent currents, whilst co-
expression with WNK-insensitive or catalytically inactive SPAK did not (Elvira 
et al., 2014). This was paralleled in WNK-insensitive SPAK mutant mice 
where intestinal electrogenic glucose transport was significantly higher 
compared to their wild-type littermates. Furthermore, analysis from 
chemiluminescence experiments indicated that the SPAK-induced inhibition 
of SGLT1 was attributed to a decrease in SGLT1 insertion into the cell 
membrane (Elvira et al., 2014).  
 
In summary, these studies not only support the WNK-SPAK/OSR1 signalling 
pathway as an important regulator of NCC- and NKCC-mediated sodium 
transport in the kidney, but also implies these kinases participate in the 
regulation of other epithelial transport processes in both the kidney and 
gastrointestinal tract. The up- or down-regulation of these sodium-coupled 
transporters/channels has not been fully investigated under CNI-treated 
conditions. It is possible that any alterations in these transporters that may 
occur may contribute further to sodium retention or other clinical 
abnormalities associated with CNI use. 
 
3.1.3 Aims of this study 
 
In the work described, analyses of sodium-coupled transporters and sodium 
channels in renal and intestinal tissues were performed in a mouse model of 
CNI-induced sodium retention. This analysis was conducted at a translational 
level in vehicle or FK506-treated mice fed either a standard or high-salt diet. 
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The aims of this chapter were to confirm the previously observed effects of 
CNIs on sodium and acid-base transport proteins and to investigate the 
currently unknown effects of CNIs on other renal and intestinal sodium 
transporters/channels. This was done in order to gain a further understanding 
as to which transporters might be up- or down-regulated, or even unaffected, 
in the sodium retentive actions of CNI use. This chapter also aimed to 
determine whether the sodium-mediated transport of the accompanying 
electrolyte may contribute to the associated electrolyte abnormalities of CNI-
treatment such as metabolic acidosis, hypophosphatemia and 
hyperglycemia.  
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3.2 Materials and Methods 
3.2.1 Animals 
 
Male C57BL/6J mice, aged 8 weeks (weighing between 20 – 25g), were 
used in accordance with the Animals Scientific Procedures Act 1986, 
Amendment Regulations 2012. All protocols were approved by the University 
College London (Royal Free Campus) Comparative Biology Unit Animal 
Welfare and Ethical Review Body (AWERB) committee and performed in 
accordance with project license PPL 70/8064. 
 
3.2.2 FK506 treatment and/or high-salt diet 
 
Full procedures have been described in Section.2.1.2. Mice were 
administered either vehicle or FK506 at a dose of 2 mg/kg/day via I.P 
injection for two weeks and supplemented with either standard maintenance 
diet or a high-salt (HS) diet (standard maintenance diet supplemented with 
1.5% (w/w) NaCl). 
 
At the end of the experiments, mice were placed under terminal anaesthesia 
and checked for withdrawal to corneal and pedal reflexes before sample 
collection. Terminal blood samples were collected by cardiac puncture and 
urinary samples were collected by bladder puncture. Cervical dislocation was 
performed and death was confirmed by cessation of heartbeat before 
removing renal and intestinal tissues. 
 
3.2.3 Plasma biochemistry 
 
Plasma samples were collected, as described in Section.2.1.4, and 
biochemical analysis for sodium, creatinine, glucose and phosphate was 
performed as described in Sections 2.1.5 - 2.1.8.  
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3.2.4 Immunofluorescence analysis 
 
Anesthetised mice were perfused with 4% PFA/PBS and kidney tissue was 
harvested, processed, paraffin-embedded, stained and imaged as described 
in Section.2.4, using the primary and corresponding secondary antibodies 
listed in Table.2.5. A negative control was run alongside where the primary 
antibody was omitted. 
 
3.2.5  Protein preparations from kidney and intestinal mucosa tissues 
 
Protein samples from kidney tissues were prepared using the technique 
described in Section.2.5.1, or subjected to BBM vesicle preparations as 
described in Section.2.5.2. Snap-frozen small intestinal mucosa samples 
were thawed and subjected to BBM vesicle preparations described in 
Section.2.5.3 and large intestinal mucosal samples were processed as 
described in Section.2.5.1. Total protein concentration was determined using 
the Bradford assay as described in Section.2.5.4. For BBMV and 
homogenate samples, purity was assessed using an alkaline phosphatase 
assay as described in Section.2.5.5. 
 
3.2.6 Western blot analysis 
 
Western blot protocols were carried out as described in Section.2.5.6. Whole 
kidney homogenate (100µg), kidney/small intestinal BBMV (25µg) or 
kidney/small intestinal homogenate (50 µg), and large intestinal homogenate 
(100µg) protein samples were run on an SDS-PAGE gel. Samples were then 
transferred onto a PDVF membrane and incubated with the primary antibody 
and their corresponding secondary antibodies listed in Table.2.6. Following 
visualisation, membranes were then stripped and re-probed for b-Actin. 
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Densitometry was measured and samples were normalised to b-actin. 
Unfortunately, due to the lack of access to overexpressing and/or knockdown 
mouse models, no further positive or negative controls were used in western 
blot applications. 
 
3.2.7 Statistical analysis 
 
Data are presented as mean ± SEM, relative to b-actin. N refers to the 
number of samples within each group. Significance was determined by one-
way ANOVA with Bonferroni post-hoc, relative to vehicle-treated mice. *P < 
0.05, **P < 0.01, ***P < 0.001. 
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3.3 Results 
3.3.1 Physiological parameters  
 
Mice were administered a daily intraperitoneal injection of 2 mg/kg of FK506 
for 14 days and supplemented with either a standard or high-salt (HS) diet. 
There were no observed differences between groups in mouse survival, 
gross physical appearance and organ morphology. Body weight was 
measured daily and body weight changes were calculated to monitor 
fluctuations during the course of treatment.  
 
Weight gain tended to be higher in the vehicle- and vehicle/HS-treated 
groups whilst mice treated with FK506 or FK506/HS tended to drop in weight 
(Fig.3.1a). Comparisons of body weight changes between groups on the final 
day of treatment showed a significantly lower gain in body weight in 
FK506/HS-treated mice compared to vehicle-treated mice on a standard diet 
(Fig.3.1b). There was also a significant difference, under high-salt 
conditions, between vehicle and FK506 groups. No significant difference was 
observed between vehicle- and FK506-treated mice, and mice fed on a high-
salt diet suggesting that FK506- or high-salt alone does not affect body 
weight, whilst a combination likely attributes to the comparably greater 
reduction in body weight observed. However, this loss in body weight was 
overall relatively minor (~5% on day 14) and did not exceed the outlined 
humane endpoint (>20% of initial body weight) and so is unlikely to influence 
the data outcome. 
 
On both standard and high-salt diets, plasma electrolytes were not 
significantly different between vehicle and FK506-treated mice (Table.3.1), 
which implies that the FK506 treatment used in this model may not have 
prompted the clinical phenotypes commonly associated with CNI use. 
Unfortunately, due to limited volumes of plasma obtained, plasma FK506 
levels could not be measured to confirm FK506 delivery and presence in the 
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circulatory system. Furthermore, plasma potassium and bicarbonate levels 
could also not be measured to confirm the associated hyperkalemia and 
metabolic acidosis phenotypes, respectively. Mean plasma creatinine was 
significantly higher than previously observed in mice using the Jaffe’s method 
(~10-44 µmol/L) (Dunn et al., 2004; Meyer et al., 1985; Palm and Lundblad, 
2005). However, this reference range is relatively large and arises from the 
significant overestimations for plasma creatinine reported with this method 
due to its low specificity and sensitivity. The use of high-performance liquid 
chromatography (HPLC) has been recommended for plasma creatinine 
measurements in rodents (Dunn et al., 2004; Meyer et al., 1985; Palm and 
Lundblad, 2005). It should also be noted that animals were not placed in 
metabolic cages and due to the unreliability of urine collection, via bladder 
puncture, no urinary biochemical analysis could be performed and so any 
sodium retaining effects caused by FK506 administration cannot be 
confirmed in this study.  
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Figure 3.1. Body weight. Vehicle (n = 13), FK506 (n = 14), vehicle/HS (n = 10) and 
FK506/HS (n = 10) treated mice were weighed daily throughout the course of 
treatment to monitor changes in body weight.  A) The change in body weight over 
the 14-day treatment period with vehicle or FK506 ± high-salt (HS) diet was 
calculated and compared. B) Comparisons of the change in body weight on the final 
day (Day 14) of treatment. All data are presented as the mean percentage (%) 
change in body weight, normalised to initial weight at Day 1, ± SEM. Significance 
was determined by one-way ANOVA with Bonferroni post-test. * P < 0.05.  
 
 
Table 3.1. Plasma biochemistry. Effects of FK506 and HS diet on plasma 
electrolytes. Values are presented as the mean ± SEM. Significance was 
determined by one-way ANOVA with Bonferroni post-test, relative to vehicle-injected 
mice. 
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3.3.2 NCC/pNCC expression following FK506-treatment 
 
In the present study, direct confirmation of FK506-induced changes in blood 
pressure, via telemetry devices, were not available. The use of tail cuff 
measurements was not considered for this study as this method can induce 
further stress/anxiety on the mice, which may lead to inaccurate results, and 
also readings obtained from this approach do not reflect central arterial 
pressure. Therefore, as an indirect measure, the consequential effects of 
FK506 on sodium reabsorption via the NCC cotransporter was determined. 
Protein levels for total and phosphorylated NCC (pNCC) were measured in 
whole kidney tissues from vehicle- and FK506-treated mice fed a standard 
diet or provided with a high-salt diet with the aim of producing a hypertensive 
response (Chiga et al., 2008). As shown, no significant changes in total NCC 
was observed in any of the treatment groups (Fig.3.2a). This was also shown 
for pNCC (Fig.3.2b). Unexpectedly, the addition of a high-salt diet with or 
without FK506 treatment also did not affect pNCC levels (Fig.3.2b).    
 
Although the expected increase in pNCC under CNI-induced conditions was 
not significant in this study, there is an obvious trend for increased pNCC in 
the FK506-treated group compared to vehicle. To confirm that FK506 was 
indeed affecting pNCC levels in the kidney and to support and extend the 
western blot findings, immunohistochemical analysis was performed to 
compare the effects of FK506 on the abundance and localisation of NCC in 
the DCT. Low power immunofluorescence revealed a pronounced increase 
in pNCC staining at the apical membrane in the DCT in FK506-treated mice 
compared with the vehicle group (Fig.3.3a). High power microscopy further 
confirmed localised pNCC staining to the apical membrane of the DCT, as 
identified by D28K-positive staining (Fig.3.3b). These findings are in line with 
previous observations and confirm that FK506 is affecting sodium 
reabsorption in these mice through the up-regulation of pNCC expression at 
the apical membrane. This confirms the likely establishment of a CNI-
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induced sodium retentive, and possibly hypertensive, model for this study 
and was therefore used for the analysis of other sodium transporters within 
the kidney and gastrointestinal tract.  
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Figure 3.2. Effects of FK506 on the NCC cotransporter. Representative western 
blots showing the effects of vehicle- or FK506-treatment ± HS diet on A) NCC and 
B) phosphorylated NCC protein levels. C) b-Actin was run as a loading control. NCC 
is detected at ~130–160 kDa (arrow), pNCC is detected ~130 kDa (arrow) and b-
actin is detected ~42 kDa (arrow). Densitometric analyses (right) were performed for 
each group and normalised to b-actin. Values are presented as the mean ± SEM (n 
= 5–6). Significance was determined by one-way ANOVA with Bonferroni post-test.  
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Figure 3.3. Effects of FK506 on NCC phosphorylation and distribution. A) Representative low power immunofluorescence images of renal 
tissue from vehicle and FK506-treated mice showing pNCC expression and localisation (arrows) at the apical membrane colocalised with 
calbindin (D28K), a marker for DCT tubules. n = 3 per group. Images were taken at a 20x magnification. Negative controls were included 
whereby the primary antibody was omitted. B) Confocal immunofluorescence images of renal tissue from vehicle and FK506-treated mice 
showing pNCC expression (arrows) colocalised with D28K. Images were taken at a 10x magnification. Scale bars measure 50 µm.  
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3.3.3 Alterations in protein abundance of key sodium transporters in 
the kidney following FK506 treatment 
 
Alongside NCC and NKCC2, other renal and intestinal sodium-coupled 
transporters have been reported as downstream targets of the WNK-
SPAK/OSR1 cascade and suggests these transporters may also be affected 
by CNIs. This includes the proximal tubular NHE3 Na+/H+ exchanger, the 
NaPi-IIa and NaPi-IIc type II Na+/Pi cotransporters and the SGLT2 and 
SGLT1 Na+/glucose cotransporters, all of which were investigated in the CNI-
treated mouse model. To validate the changes observed for these renal and 
intestinal sodium transporters, protein analyses were performed using 
antibodies which have been previously shown in other studies to change 
under disease conditions in both western blot and immunohistochemistry 
applications, including SGLT1 in Zucker fa/fa obese rats (Aime et al., 2014) 
and NaPi-IIa in phosphaturia-induced rats (Marks et al., 2008). 
 
The NHE3 exchanger is not only one of the major sodium transporters in the 
PT but is also a regulator of acid-base balance. Protein dysregulation of 
NHE3 may therefore potentially contribute to the associated metabolic 
acidotic side effect of CNI treatment, as well as sodium retention. Western 
blot and densitometric analyses showed a significant decrease in NHE3 
protein abundance in BBMVs of FK506-treated and vehicle/HS-treated mice 
compared with vehicle-treated mice (Fig.3.4).  
 
The NaPi-IIa and NaPi-IIc transporters are also recognised as regulators of 
acid-base balance and phosphate reabsorption in the kidney. Dysregulation 
of protein abundances for these transporters result in abnormal phosphate 
reabsorption processes and may also contribute to the sodium retentive side 
effect of CNI-treatment and the hypophosphatemic clinical symptoms. Thus, 
protein abundances of these transporters were also measured in all four 
treatment groups and were found not to be significantly different following 
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FK506-treatment or in combination with a high-salt diet (Fig.3.5). A slight 
trending decrease in NaPi-IIc protein abundance was observed in FK506-
treated mice compared to the vehicle group (Fig.3.5b), but this did not reach 
statistical significance. 
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Figure 3.4. Expression of the renal Na+/H+ exchanger, NHE3, after FK506 
treatment. Representative western blots for the NHE3 exchanger in kidney BBMVs 
from mice treated with vehicle or FK506 and maintained on a standard or HS diet for 
two weeks. b-actin (arrow) was run as a loading control. NHE3 is detected ~80–100 
kDa (arrow). Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM (n = 5–6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. *P < 
0.05. 
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Figure 3.5. Expression of the renal type II Na+/Pi cotransporters after FK506 
treatment. Representative western blots for the A) NaPi-IIa and, B) NaPi-IIc 
cotransporters in kidney BBMVs from mice treated with vehicle or FK506 and 
maintained on a standard or HS diet for two weeks. C) b-actin (arrow) was run as a 
loading control. NaPi-IIa is detected ~70–75 kDa (arrow) and NaPi-IIc is detected 
~64 kDa (arrow). Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM (n = 5–6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. 
 
 
NaPi-IIc
Ve
hi
cl
e
FK
50
6
Ve
hi
cl
e/
H
S
FK
50
6/
H
S0
1
2
3
4
 
R
el
at
iv
e 
de
ns
ity
 (A
.U
.)
NaPi-IIa
Ve
hi
cl
e
FK
50
6
Ve
hi
cl
e/
H
S
FK
50
6/
H
S0.0
0.5
1.0
1.5
2.0
 
R
el
at
iv
e 
de
ns
ity
 (A
.U
.)250
150
100
50
37
NaPi-IIa
75
25
Vehicle FK506 FK506/HSVehicle/HS
A)
B)
C)
207
119
31
23
NaPi-IIc
82
Vehicle FK506 FK506/HSVehicle/HS
37
25
Actin
50
Vehicle FK506 FK506/HSVehicle/HS
			
125				
The SGLT cotransporters, particularly SGLT2, are the main transporters 
involved in glucose reabsorption in the kidney and may be involved in the 
onset of CNI-induced post-transplant diabetes. Analyses of the renal protein 
abundance for these transporters revealed no significant changes for both 
SGLT2 and SGLT1 in all treatment groups (Fig.3.6). A trending increase was 
seen for SGLT1 in the high-salt groups compared with the vehicle group 
(Fig.3.6b), but this did not reach statistical significance. These observations 
do, however, support the biochemical data where no significant elevations in 
plasma glucose were observed between all four groups (Table.3.1). In 
addition, no significant differences in protein abundance was seen for the 
basolateral GLUT2 glucose transporter in all treatment groups (Fig.3.7). 
 
In the TAL, NKCC2 is the main sodium transporter. Like NCC, it is also under 
the regulation of the WNK-SPAK/OSR1 signalling pathway and is activated 
upon phosphorylation by SPAK/OSR1 kinases. Following FK506-treatment 
with or without the supplement of the high-salt diet, no significant differences 
in protein abundance were observed for both total and phosphorylated 
NKCC2 (Fig.3.8). 
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Figure 3.6. Expression of the renal Na+-glucose cotransporters after FK506 
treatment. Representative western blots for the A) SGLT2 and, B) SGLT1 
Na+/glucose cotransporters in kidney BBMVs from mice treated with vehicle or 
FK506 and maintained on a standard or HS diet for two weeks. C) b-actin (arrow) 
was run as a loading control. SGLT2 is detected ~70–77 kDa (arrow) and SGLT1 is 
detected ~75 kDa. Densitometric analyses (right) were performed for each group 
and normalised to b-actin. Values are presented as the mean ± SEM (n = 5–6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. 
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Figure 3.7. Expression of the renal glucose transporter, GLUT2, after FK506 
treatment. Representative western blots for the GLUT2 transporter in whole kidney 
homogenate fractions from mice treated with vehicle or FK506 and maintained on a 
standard or HS diet for two weeks. b-actin (arrow) was run as a loading control. 
GLUT2 is detected ~60-62 kDa (arrow). Densitometric analyses (right) were 
performed for each group and normalised to b-actin. Values are presented as the 
mean ± SEM (n = 5–6). Significance was determined by one-way ANOVA with 
Bonferroni post-test. 
 
 
 
 
GLUT2
Ve
hi
cl
e
FK
50
6
Ve
hi
cl
e/
H
S
FK
50
6/
H
S0.0
0.5
1.0
1.5
2.0
2.5
 
R
el
at
iv
e 
de
ns
ity
 (A
.U
.)
207
119
82
31
GLUT2
23 
Vehicle FK506 FK506/HSVehicle/HS
31
Actin
23 
Vehicle FK506 FK506/HSVehicle/HS
			
128				
 
 
 
Figure 3.8. Expression of the renal Na+-K+-2Cl- cotransporter, NKCC2, after 
FK506 treatment. Representative western blots for the Na+-K+-2Cl- cotransporter, 
A) NKCC2 and its phosphorylated form, B) pNKCC2, in whole kidney homogenate 
fractions from mice treated with vehicle or FK506 and maintained on a standard diet 
or HS diet for two weeks. C) b-actin (arrow) was run as a loading control. Both forms 
are detected ~120–130 kDa (arrow). Densitometric analyses (right) were performed 
for each group and normalised to b-actin. Values are presented as the mean ± SEM 
(n = 6). Significance was determined by one-way ANOVA with Bonferroni post-test. 
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The sodium channel, ENaC, regulates sodium transport in the distal segment 
of the nephron. Treatment with FK506 was associated with a significant 
decrease in the a-subunit of ENaC (Fig.3.9). This significance was also 
observed in FK506-treated mice maintained on the high-salt diet. The b- and 
g-ENaC subunits were not tested in this study. 
 
 
 
 
 
 
Figure 3.9. Expression of the renal Na+ channel, ENaC, after FK506 treatment. 
Representative western blots for the a-subunit of the ENaC Na+ channel in whole 
kidney homogenate fractions from mice treated with vehicle or FK506 and 
maintained on a standard or HS diet for two weeks. b-actin (arrow) was run as a 
loading control. aENaC is detected ~85 kDa. Densitometric analyses (right) were 
performed for each group and normalised to b-actin. Values are presented as the 
mean ± SEM (n = 5–6). Significance was determined by one-way ANOVA with 
Bonferroni post-test. ** P < 0.01. 
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3.3.4 Alterations in protein abundance of key sodium transporters in 
the gastrointestinal tract following FK506 treatment 
 
Sodium transport proteins were also examined in small and large intestinal 
tissues from FK506-treated mice. As some of the sodium transporters 
expressed in the kidney are also differentially expressed in the intestines, 
alterations in these transporters following FK506 treatment were investigated 
in the different segments of the intestines and were compared to the renal 
observations to determine whether the effects of FK506 may be tissue-
specific. 
 
BBMVs were prepared from mucosa scrapes from proximal and distal small 
intestinal tissues, and homogenate fractions were prepared from large 
intestinal tissues. Both proximal and distal small intestinal sodium 
transporters include NHE3, SGLT1, NaPi-IIb and PiT1. The large intestine 
contains the NHE3 exchanger and the ENaC channel. Protein abundances 
for all these transporters were analysed. 
  
In contrast to the kidney observations, western blot analysis showed no 
significant differences in NHE3 protein abundance in all treatment groups in 
the proximal small intestine (PSI) (Fig.3.10).  
 
Similarly, no changes in protein levels were observed for SGLT1 and GLUT2 
(Fig.3.11). However, GLUT2 was not expected to be expressed at the BBM 
under these conditions. 
 
The NaPI-IIb and PiT1 Na+/Pi cotransporters were also detected in BBMVs 
prepared from the PSI and displayed no significant changes in protein 
expression following FK506 treatment (Fig.3.12). However, it should be 
noted that the SEM values are relatively high for PiT1. This, along with the 
relatively low detection for NaPi-IIb in this segment, is most likely due to the 
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discrepancy surrounding NaPi-IIb and PiT1 protein localisation in the mouse 
small intestine, which is predominantly in the distal small intestine (DSI). 
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Figure 3.10. The effects of FK506 on NHE3 expression in the proximal small 
intestine (PSI). Representative western blots of the NHE3 exchanger (arrow) in PSI 
BBMVs from mice treated with vehicle or FK506 and maintained on a standard or 
HS diet for two weeks. b-actin (arrow) was run as a loading control. Densitometric 
analyses (right) were performed for each group and normalised to b-actin. Values 
are presented as the mean ± SEM (n = 6). Significance was determined by one-way 
ANOVA with Bonferroni post-test. 
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Figure 3.11. The effects of FK506 on SGLT1 and GLUT2 expression in the PSI. 
Representative western blots of the A) Na+/glucose cotransporter, SGLT1, and B) 
glucose transporter, GLUT2, in PSI BBMVs from mice treated with vehicle or FK506 
and maintained on a standard diet or HS diet for two weeks. C) b-actin (arrow) was 
run as a loading control. Densitometric analyses (right) were performed for each 
group and normalised to b-actin. Values are presented as the mean ± SEM (n = 6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. 
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Figure 3.12. The effects of FK506 on NaPi-IIb and PiT1 expression in the PSI. 
Representative western blots of the Na+/Pi cotransporters, A) NaPi-IIb and, B) PiT1 
in PSI BBMVs from mice treated with vehicle or FK506 and maintained on a 
standard diet or HS diet for two weeks. C) b-actin (arrow) was run as a loading 
control. NaPi-IIb is detected ~105–110 kDa and PiT1 is detected ~75-80 kDa 
(arrow). Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM (n = 6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. 
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In western blot analyses for the sodium transporters in the distal small 
intestine, similar observations were found. No changes were seen in protein 
expression of the NHE3 exchanger following all treatments (Fig.3.13).  
 
 
 
 
 
 
 
Figure 3.13. The effects of FK506 on NHE3 expression in the distal small 
intestine (DSI). Representative western blots of the NHE3 exchanger (arrow) in DSI 
BBMVs from mice treated with vehicle or FK506 and maintained on a standard or 
HS diet for two weeks. b-actin (arrow) was run as a loading control. Densitometric 
analyses (right) were performed for each group and normalised to b-actin. Values 
are presented as the mean ± SEM (n = 5-6). Significance was determined by one-
way ANOVA with Bonferroni post-test. 
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No significant differences were found for the SGLT1 cotransporter in this 
segment (Fig.3.14) and GLUT2 could not be detected in these protein 
samples. 
 
 
 
 
 
 
 
Figure 3.14. The effects of FK506 on SGLT1 expression in the DSI. 
Representative western blots of the SGLT1 Na+/glucose cotransporter (arrow) in 
DSI BBMVs from mice treated with vehicle or FK506 and maintained on a standard 
or HS diet for two weeks. b-actin (arrow) was run as a loading control. Densitometric 
analyses (right) were performed for each group and normalised to b-actin. Values 
are presented as the mean ± SEM (n = 5-6). Significance was determined by one-
way ANOVA with Bonferroni post-test. 
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No significant differences were also observed for the Na+/Pi cotransporters, 
NaPi-IIb and PiT1 (Fig.3.15), in all treatment groups.  
 
Figure 3.15. The effects of FK506 on NaPi-IIb and PiT1 expression in the DSI. 
Representative western blots of the Na+/Pi cotransporters, A) NaPi-IIb and, B) PiT1 
(arrows), in DSI BBMVs from mice treated with vehicle or FK506 and maintained on 
a standard diet or HS diet for two weeks. C) b-actin (arrow) was run as a loading 
control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM (n = 5-6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. 
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As the large intestinal segment does not have villi, protein analyses were 
performed on homogenate samples prepared from large intestinal mucosal 
scrapes. The NHE3 exchanger could not be detected, whilst ENaC protein 
expression was unaffected in all treatment groups (Fig.3.16).  
 
 
 
 
 
Figure 3.16. The effects of FK506 on ENaC expression in the large intestine 
(LI). Representative western blots for the a-subunit of the ENaC Na+ channel in 
large intestinal homogenate fractions from mice treated with vehicle or FK506 and 
maintained on a standard or HS diet for two weeks. b-actin (arrow) was run as a 
loading control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM (n = 5). 
Significance was determined by one-way ANOVA with Bonferroni post-test.  
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In summary, the data obtained from these western blot analyses clearly 
demonstrate that the sodium transport proteins in the gastrointestinal tract 
are not affected by FK506 treatment. Taken together, treatment with FK506 
is associated with a renal-specific response where sodium reabsorption is 
enhanced predominantly by increased pNCC expression at the apical 
membrane of the DCT. 
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3.4 Discussion   
 
Hypertension following renal transplantation is a commonly encountered 
complication and poses a significant risk for cardiovascular and renal 
disease, graft failure and patient death. Extensive research has 
demonstrated that the administration of CNI immunosuppressants are the 
main risk factors for hypertension development (Campistol et al., 2004; 
Chapman et al., 1987; Curtis et al., 1988; Kiberd, 1989; Ponticelli et al., 
1993). Further reports have indicated that the overactivation of the NCC 
cotransporter plays a major role in CNI-induced hypertension (Hoorn et al., 
2011; Melnikov et al., 2011). The work described in this chapter focused on 
characterising the effects of these CNIs on renal and intestinal sodium-
dependent transporters, other than NCC, using a mouse model of CNI-
treatment. The aim was to investigate whether novel and additional 
transporters may potentially contribute to enhanced sodium retention and the 
secondary PHAII-like electrolyte abnormalities, via their accompanying ions, 
after CNI treatment.  
 
3.4.1 Establishment of a CNI-induced model of sodium retention  
 
Tacrolimus (FK506) is used as an alternative immunosuppressant to CsA 
owing to its lower rate of allograft rejection (Grimm et al., 2006; Kim et al., 
2004; Krämer et al., 2005; Margreiter, 2002; Webster et al., 2005). However, 
the use of these drugs is still associated with elevations in blood pressure. 
Studies in CNI-treated rodents have shown that CNIs exerts their effects by 
increasing the abundance of phosphorylated (activated) NCC, pNCC, and its 
upstream regulators, WNK4 and SPAK, leading to increased sodium 
reabsorption in the kidney and hypertension (Hoorn et al., 2011; Melnikov et 
al., 2011). Additional clinical side effects observed in CNI administered renal 
transplant patients and rodents, include hyperkalemia, metabolic acidosis 
and hypophosphatemia, all of which are characteristic of human PHAII. 
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Therefore, due to these similarities, rodent models of CNI-induced 
hypertension may be used as a model of PHAII and provide important 
insights into the progression and treatment of hypertension following renal 
transplantation and in the pathogenesis of PHAII and other forms of blood 
pressure-related conditions such as essential hypertension. 
 
Protein abundance of pNCC demonstrated an increasing trend following 
FK506 treatment. Although this was not statistically significant in this study, 
further analysis using immunohistochemistry supported previous findings of 
increased pNCC expression following FK506 treatment (Hoorn et al., 2011; 
Melnikov et al., 2011). It is possible that the absence of significance between 
vehicle- and FK506-treated groups may be due to a number of limitations. 
First, a relatively small sample size (n = 5-6) was used in this study and so 
may not be representative of the actual effects of FK506 treatment, although, 
the sample size used was comparable with those previously reported (Hoorn 
et al., 2011). Second, total protein was analysed from samples prepared from 
whole kidney tissue and not from isolated cortical segments, which may have 
masked any changes in protein abundance under the investigated 
conditions. Further studies are required for protein analyses from isolated 
segments to allow for precise comparisons of pNCC expression under the 
investigated conditions and would eliminate any masked changes in protein 
abundance influenced by total protein concentrations from whole kidney 
tissue.  
 
The supplementation of a high-salt diet with or without FK506 treatment did 
not affect pNCC protein abundance. This is in contrast to previous studies 
who have shown the phosphorylation states of NCC and its upstream 
regulators, SPAK/OSR1, are regulated by dietary salt and are decreased 
under high-salt conditions (Chiga et al., 2008). However, this regulation is 
lost in PHAII WNK4 mutant knock-in mice (Chiga et al., 2008), which was 
initially expected to happen with CNI treatment in this study. It is possible that 
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the salt content of the high-salt diet may have not been be high enough, in 
comparison to the maintenance diet, to elicit a significant regulatory response 
by pNCC and is therefore able to maintain sodium homeostasis at baseline 
levels. Although, as no changes were seen with FK506 treatment and the 
addition of the high-salt diet, it is also possible that the FK506 dosage used 
here may not have been sufficient enough to overcome the dietary salt 
regulation of pNCC, or, as the FK506/HS group displayed the most loss in 
body weight during and at the end of the treatment course, it is possible that 
another pathway might be compensating for this change and therefore 
counteracting the actions of FK506. Overall, these findings suggest the CNI 
treatment regimen used in this study was suboptimal. However, data from 
protein localisation analyses provided sufficient evidence for the presence of 
CNI-induced sodium retention in this model and allowed for further 
investigations. 
 
3.4.2 Analysis of FK506 treatment on renal and intestinal sodium 
transporters 
 
Additional clinical symptoms of PHAII includes metabolic acidosis which is 
also a common side effect in renal transplant patients and is significantly 
correlated with CNI administration, particularly with FK506 (Keven et al., 
2007; Schwarz et al., 2006). Under chronic metabolic acidosis, the kidneys 
adapt through coordinated responses to increase H+ and NH4+ excretion, 
increase luminal buffer titration and reduce (or eliminate) urinary base. These 
actions occur by 1) increased NHE3 activity and protein, which increases H+ 
excretion for the titration of a number of H+ acceptors, and 2) decreased 
NaPi-IIa protein, which reduces phosphate uptake (Ambühl et al., 1998; 
Ambuhl et al., 1996; Amemiya et al., 1995; Laghmani et al., 1997; Soleimani 
et al., 1992; Wu et al., 1996). Additionally, previous mouse studies have 
demonstrated stimulated sodium-dependent phosphate uptake at the BBM of 
the small intestine, particularly at the ileum, by increased NaPi-IIb protein, in 
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response to metabolic acidosis-induced conditions (Stauber et al., 2005). 
This reduction in NaPi-IIa protein is paralleled with increased urinary 
phosphate excretion (phosphaturia) and subsequent hypophosphatemia 
which are conditions associated with metabolic acidosis and CNI use, as 
demonstrated in FK506-treated rats (Mohebbi et al., 2009; Moorhead et al., 
1974). This marked reduction was similarly observed for NaPi-IIa mRNA 
expression in CsA-treated rats and in cultured proximal tubule cell lines even 
when supplemented with a low-phosphate diet or medium, respectively, 
which is a known regulator of NaPi-IIa expression (Levi et al., 1994; Moz et 
al., 2004). These studies implicate the involvement of calcineurin in the 
regulation of renal acid-base balance and phosphate absorption. Supporting 
studies in calcineurin Ab-/- mice displayed a marked decrease in NaPi-IIa 
mRNA levels and also show impaired compensatory responses to a low-
phosphate diet and medium in both kidney tissue and cells, respectively, 
further suggesting an important role for calcineurin in responses to low-
phosphate stimuli (Moz et al., 2004).  
 
In contrast to these findings, FK506 treatment caused a significant decrease 
in renal NHE3 and had no effect on the renal Na+/Pi cotransporters, NaPi-IIa 
and NaPi-IIc, the intestinal Na+/Pi cotransporters, NaPi-IIb and PiT1, and 
plasma phosphate. The absence of changes seen for these Na+/Pi transport 
proteins are not known but it is clear from these observations that metabolic 
acidosis was not induced in this model. However, in previous studies, FK506-
treated rats also failed to show signs of acid-base disturbance unless 
challenged with an acid load to induce metabolic acidosis and observed a 
lower abundance of NHE3 at baseline conditions (Mohebbi et al., 2009). This 
may explain the absence of acid-base imbalance in this study and suggests 
this reduction in NHE3 may be a regulatory response to transient metabolic 
acidosis, as well as a feedback mechanism for the upregulation of pNCC at 
the DCT. In further support, recent studies in tubule-specific NHE3 knockout 
mice displayed an increase in pNCC and aENaC abundance under NaCl 
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restriction and proposed a role for these transporters in compensatory 
responses in the absence of NHE3 to maintain sodium balance (Fenton et 
al., 2017). This coordinated feedback mechanism may also explain for the 
downregulation of renal aENaC following FK506 treatment.  
 
Post-transplant diabetes mellitus (PTDM) is a serious complication after renal 
transplantation. Treatment with CNIs, especially FK506, have been 
associated as a risk factor for PTDM (Grimm et al., 2006; Heisel et al., 2004; 
Kasiske et al., 2003; Kim et al., 2004; Pirsch et al., 1997; Woodward et al., 
2003). As previously mentioned, SGLT2 mediates the majority of glucose 
reabsorption in the kidney and its mutation in both patients and animal 
models causes glycosuria as a result of impaired glucose reabsorption 
(Calado et al., 2004; Heuvel et al., 2002; Magen et al., 2005; Santer et al., 
2003; Vallon et al., 2011). SGLT2 inhibitors are currently used as an 
antidiabetic drug for type 2 diabetes mellitus to reduce renal glucose 
reabsorption and plasma glucose levels, and have been recently found to be 
effective in improving FK506-induced hyperglycemia and protect against 
renal injury (Jin et al., 2017). Previous investigations in rats treated with 
FK506 revealed a significant increase in SGLT2 expression which was 
alleviated by treatment with an SGLT2 inhibitor and also led to increased 
plasma insulin levels, pancreatic islet size and glucose-stimulated insulin 
secretion (Jin et al., 2017). Additionally, FK506 treatment has shown to 
increase intestinal permeability (transport across the BBM), glucose 
absorption in the jejunum and up-regulated intestinal SGLT1 expression (Li 
et al., 2015; Yanchar et al., 1996). In these studies, blood glucose and insulin 
levels were significantly higher in FK506-treated mice, which led 
investigators to suggest a gradual resistance to insulin induced by FK506 
use (Li et al., 2015). These studies demonstrate that CNIs influence SGLT2 
protein and/or function, which may contribute towards PTDM development 
and insulin resistance in renal transplant patients. However, in this study, 
FK506 treatment did not appear to affect renal glucose homeostasis. No 
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elevations in plasma glucose were observed following FK506 administration 
and no changes were seen for renal SGLT2, and for renal and intestinal 
SGLT1 cotransporters. This was also the same for the facilitative GLUT2 
transporter. It is possible that the two-week treatment course with FK506 in 
this study may not have been long enough to induce changes in glucose 
absorption processes and, as plasma insulin levels were not measured, it 
was not possible to detect any early signs of insulin resistance. However, the 
findings for these transport proteins, along with the other proteins analysed, 
further confirm the unreliability of the CNI treatment model used. 
 
There are conflicting findings on the exact impact of CNIs on NKCC2 
expression and whether NKCC2 is in fact regulated by calcineurin. Prior 
studies have observed no changes in either total NKCC2 and pNKCC2 
protein abundances following FK506 treatment in mice, which was also 
observed in the present study. In more recent investigations, augmented 
phosphorylation of NKCC2 was observed in CsA-treated rats, but only with 
concomitant stimulation by arginine vasopressin (AVP), suggesting that 
additional factors may need to be present for CNIs to exert their effects 
(Blankenstein et al., 2017; Borschewski et al., 2016). Moreover, the 
evaluation of the upstream NKCC2-phosphorylating kinases, SPAK and 
OSR1, did not show significant activation in microdissected TAL tubules 
following CsA treatment in comparison to the DCT, suggesting activation of 
NKCC2 in the TAL upon CNI administration may be via a SPAK/OSR1-
independent pathway or by direct inhibition of calcineurin-mediated 
phosphatase activity (Borschewski et al., 2016). Interestingly, NKCC2 
phosphorylation by the AMP-activated protein kinase, AMPK, under osmotic 
stresses and low intracellular chloride conditions has been demonstrated, 
which may be a contributing regulatory pathway in the TAL under CNI-
treated conditions (Fraser et al., 2007; Richardson et al., 2011). Further 
studies in oocyte expression models have also shown the participation of 
AMPK in the regulation of electrogenic sodium-dependent glucose transport, 
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via SGLT1 (Sopjani et al., 2010), and renal tubular phosphate transport, via 
NaPi-IIa (Dërmaku-Sopjani et al., 2013), suggesting a potentially universal 
role for AMPK in sodium transport processes. In addition, previous work has 
insinuated an antagonistic link between calcineurin and AMPK, and 
speculates that calcineurin suppresses AMPK-dependent signalling (He et 
al., 2014; Park et al., 2011). If this is the case, then the relieved suppression 
of AMPK by CNIs may lead to increased activation of the NKCC2 transporter, 
however, current understandings as to how calcineurin regulates AMPK 
remains rudimentary. With regards to the present study, no significant 
changes were observed for NKCC2 and pNKCC2 following FK506 treatment. 
Although, it should be noted that, in prior studies, NKCC2 protein analyses 
were performed in microdissected mouse TAL tubules (Borschewski et al., 
2016), and so the data observed in the present study may be the result of 
total protein samples from whole kidney preparations masking the proportion 
composed of NKCC2 and thereby concealing any significant changes in 
protein expression. These observations may also be the result of the model 
used in this study. Further confirmation of these interpretations by examining 
NKCC2/pNKCC2 protein expression in isolated cortical and medullary 
segments and/or microdissected tubules are therefore required. 
 
A significant decrease in protein abundance was observed for the amiloride-
sensitive epithelial sodium channel, ENaC, in mouse kidneys following 
FK506 treatment with and without the supplement of the high-salt diet. 
Research regarding the effects of CNIs, and thus calcineurin-mediated 
regulation, on ENaC expression is very complex but limited. Previous in vitro 
analysis using patch clamp techniques showed a significant increase in 
ENaC activity by CsA, however, this stimulatory effect was not confirmed to 
be calcineurin-mediated as, in another study, FK506 did not affect basal 
ENaC activity (Wang et al., 2009; Yue et al., 2000). ENaC expression is 
regulated by a number of kinases including the serum/glucocorticoid-
regulated kinase 1, SGK1 (Chen et al., 1999). Following stimulation of 
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aldosterone-induced mineralocorticoid receptor (MR)-mediated expression of 
SGK1, WNK1 phosphorylates this kinase, which in turn, leads to 
phosphorylation and suppression of the inhibitory actions of the ubiquitin 
ligase, Nedd4-2, and WNK4 on ENaC expression (Chen et al., 1999; 
Debonneville et al., 2001; Heise et al., 2010; Ring et al., 2007b; Snyder et al., 
2004; Xu et al., 2005). This pathway has also been demonstrated to regulate 
NHE3 (Fuster et al., 2007; Grahammer et al., 2006), SGLT1 (Dieter et al., 
2004; Grahammer et al., 2006; Shojaiefard et al., 2007), NaPi-IIb (Palmada, 
2004), and NCC (Arroyo et al., 2011; Ronzaud et al., 2013; Rozansky et al., 
2009; Vallon et al., 2009), suggesting that SGK1 may be an important 
universal mediator for aldosterone-dependent sodium transport processes. 
PHAII is typically associated with low or normal plasma aldosterone which 
may explain for the downregulation of both ENaC and NHE3 transport 
proteins following FK506 treatment. Treatment with CNIs has also shown to 
induce aldosterone resistance in renal transplant patients, which is also 
associated with the clinical diagnosis for PHAII, via the down-regulation of 
MR (Heering et al., 2004). The likely explanation for the observed decrease 
in ENaC is due to a compensatory mechanism to account for increased 
sodium reabsorption at the upstream DCT segment via pNCC, rather than 
direct interactions with FK506. The decrease observed following a 
combination of FK506 and the high-salt diet is also most likely a 
compensatory mechanism owing to decreased aldosterone levels under high 
dietary salt conditions. Nevertheless, without confirmation of a 
downregulation in MR expression and levels of plasma aldosterone or 
attenuated ENaC transport activity, a reduction in channel expression in 
response to aldosterone cannot be ruled out. 
 
3.4.3 Gastrointestinal-renal signalling 
 
The experiments performed in this study aimed to identify further renal and 
intestinal sodium transport proteins involved in CNI-induced sodium 
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retention, which were also known to be regulated by the WNK-SPAK/OSR1 
pathway. In addition, these experiments were also used to determine any 
interplay between the kidneys and gastrointestinal tract, which has been 
previously reported for a number of electrolytes such as phosphate, 
potassium and sodium (Berndt et al., 2007; Carey, 1978; Lee et al., 2007; 
Lennane et al., 1975; Rabinowitz et al., 1988). In a study by Berndt et al, a 
significant increase in urinary phosphate excretion was shown within 20 
minutes of duodenal infusion of 1.3M phosphate in rats (Berndt et al., 2007). 
This effect was found to be phosphate specific and unaffected by stomach 
infusion (Berndt et al., 2007), suggesting the presence of a gastrointestinal-
renal signalling axis for phosphate, whereby the intestines act as a 
‘phosphate sensor’ which then signals the kidney to adjust phosphate 
reabsorption and excretion accordingly. However, recent reports have 
challenged this phosphate gastrointestinal-renal signalling mechanism (Lee 
et al., 2017; Thomas et al., 2017). A study by Lee et al, showed that 
duodenal infusion of phosphate at physiological concentrations (10 mM) had 
no effect on plasma phosphate concentrations, PTH and urinary phosphate 
excretion (Lee et al., 2017), opposing the previously proposed signalling 
between the gastrointestinal tract and kidneys (Berndt et al., 2007). However, 
there is stronger evidence for this gastrointestinal-renal signalling axis for 
potassium and sodium. Intragastric potassium infusion in rats, combined with 
a potassium-deficient diet, showed a significant increase in renal potassium 
excretion and suppressed elevations in plasma potassium concentrations 
(Lee et al., 2007). A similar effect was seen in humans and rats who display 
profound natriuresis following sodium loading (Carey, 1978; Lennane et al., 
1975; Mu et al., 1995). These findings are consistent with the existence of a 
sodium sensing mechanism in the gastrointestinal tract which was suggested 
to be mediated by the intestinal natriuretic peptides, guanylin and 
uroguanylin (Carrithers et al., 2002; Fukae et al., 2002; Lorenz et al., 2003). 
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Taken together, the sodium retaining effects of CNI-treatment was expected 
to either activate this gastrointestinal-renal signalling axis and mediate 
compensatory responses for increased sodium reabsorption by pNCC, or 
potentially disrupt this signalling interplay and prevent this adaptation. In the 
present study, a significant downregulation was only observed for renal 
NHE3 and ENaC transport proteins with FK506 treatment and/or the high-
salt diet, which were most likely compensatory responses for increased 
pNCC-mediated sodium retention at the DCT. However, no significant 
differences were seen for any of the intestinal transport proteins studied, 
even though the components of the WNK-SPAK/OSR1 cascade are 
expressed in this organ and have been shown to regulate the intestinal 
sodium transporters (Ahmed et al., 2015; Elvira et al., 2014; Fezai et al., 
2015; Pasham et al., 2012; Pathare et al., 2012a; Verissimo and Jordan, 
2001; Wilson et al., 2001). It is clear from these findings that the 
downregulation for renal NHE3 and ENaC transport proteins are mediated by 
intra-renal signalling and are not consistent with gastrointestinal-renal 
signalling, which supports earlier discussions that the CNI treatment 
conditions used was not sufficient enough to induce an intestinal response. 
At the same time, it should also be noted that sodium transport across the 
intestinal BBM was not measured so an increase in the transport activity of 
these proteins cannot be ruled out and requires further investigations. 
 
3.4.4 Conclusions  
 
To date, this is currently the first report to simultaneously investigate the 
protein abundances of renal and intestinal sodium transporters/channels in 
the kidney and intestine of FK506-treated mice. It is apparent that the 
overactivation of NCC, by CNIs, is the sole contributor to enhanced sodium 
reabsorption/retention in the kidney, and therefore, elevations in blood 
pressure. Although a hypertensive response was not determined, the 
detection of enhanced pNCC expression at the apical membrane of the DCT 
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was used to assume increased sodium reabsorption/retention in these mice 
and provided sufficient evidence to support using the model for further 
analyses of other sodium transporters that may contribute to this side effect.  
 
Taken together, FK506 treatment, under normal or high dietary salt 
conditions, was associated with significant downregulation of NHE3 and 
ENaC protein expression in the kidney, most likely as a feedback mechanism 
to compensate for enhanced sodium reabsorption by pNCC. No significant 
changes were observed for other sodium-coupled transporters in the kidney, 
though this may be attributed to the protein preparation protocols used. In 
addition, no change in protein abundance was observed for the intestinal 
sodium-coupled transporters, which may be suggestive of a renal-specific 
effect of FK506. However, as the clinical symptoms associated with CNIs 
and PHAII were not observed in this study, it is likely that the FK506-
treatment regimen used was not an optimally established model of CNI-
induced sodium retention and requires re-analysis. Additionally, as AMPK 
and SGK1 signalling pathways are also involved in WNK-SPAK/OSR1-
independent regulation of these sodium transporters, their influence on these 
transporters cannot be ruled out and so requires further investigations under 
CNI treatment.  
 
In conclusion, the present study used a mouse model of CNI treatment, in an 
attempt to investigate the influences of CNIs on renal and intestinal sodium 
transport proteins. Although the model proved not to be optimal for drawing 
conclusions from the observations seen, it is clear that CNI treatment alone 
did not have a significant impact on renal and intestinal sodium transport 
proteins, and the changes observed in this study were most likely 
compensatory to pNCC activation. Therefore, these findings along with 
previous CNI-treated rodent models points to the conclusion that CNIs exert 
their effects only in the presence of other stimuli. 
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Chapter IV 
Investigation of calcineurin inhibitors as a risk factor for 
Metabolic Syndrome 
4  
4.1 Introduction  
4.1.1 Metabolic syndrome 
 
Metabolic syndrome is characterised by a cluster of clinical dysfunctions and 
biochemical abnormalities, which include obesity, hypertension, 
hyperglycemia, impaired glucose metabolism, insulin resistance and 
hyperlipidemia. The current clinical diagnosis for metabolic syndrome is 
defined by the presence of any three of the following traits; abdominal 
obesity (waist circumference >102 cm for men and >88 cm for women), 
hypertriglyceridemia (³150 mg/dl (1.69 mmol/l)), low serum high-density 
lipoproteins (HDL, <40 mg/dl (1 mmol/l) for men and <50 mg/dl (1.3 mmol/l) 
for women), high blood pressure (³140/90 mmHg) and high fasting glucose 
levels (³110 mg/dl (³5.6 mmol/l)) (National Cholesterol Education Program 
(NCEP), 2012; National Institute for Health and Care Excellence (NICE), 
2011).  
 
Metabolic syndrome is common after renal transplantation and is an 
associated risk factor for cardiovascular disease (CVD), chronic graft 
dysfunction, graft loss, and patient death (Espinola-Klein et al., 2007; 
Pedrollo et al., 2016; Porrini et al., 2006; de Vries et al., 2004). Its prevalence 
among renal transplant patients has been reported to vary widely in 
numerous retrospective cross-sectional studies, ranging from between 14.9% 
to as high as 63% (Courivaud et al., 2007; Ford et al., 2002; Israni et al., 
2012; Kishikawa et al., 2009; Luan et al., 2010; Porrini et al., 2006; de Vries 
et al., 2004). The development of these metabolic syndrome-affiliated 
conditions results from a complex association of different environmental, 
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genetic and metabolic factors. Multivariate analysis of clinical predictors 
associated with its development has shown to vary between studies and 
have included; older age, male gender, high pre-transplant body mass index 
(BMI), post-transplant weight gain and increased post-transplant BMI 
(Courivaud et al., 2007; Luan et al., 2010). Immunosuppression regimens, 
via CNIs, are associated with these individual parameters and may therefore 
play an important role in the increased risk and prevalence of metabolic 
syndrome after transplantation and contribute to long-term morbidity. This 
high prevalence and consequential outcome strongly underscores the urgent 
need for efforts directed towards early detection of metabolic syndrome 
development in this patient group and targeted therapeutic interventions.  
 
In the following sections, these individual components will be further 
discussed in terms of their association with metabolic syndrome development 
after renal transplantation and as a consequence of the immunosuppression 
therapy recieved. 
 
4.1.2 Obesity 
 
Obesity is considered one of the main phenotypic hallmarks of metabolic 
syndrome and greatly contributes to insulin resistance, hyperinsulinemia and 
hyperlipidemia. The development or worsening of obesity has demonstrated 
to play a major role in metabolic syndrome pathogenesis after kidney 
transplantation. An increase in BMI following transplantation has revealed a 
strong correlation with glucose intolerance, dyslipidemia and hypertension 
which can result in a further escalated risk for CVD, as well as an increased 
risk of delayed graft function, acute rejection, allograft failure and mortality 
(Ducloux et al., 2005; El-Agroudy et al., 2004; Gore et al., 2006; Kovesdy et 
al., 2010; Luan et al., 2010; Meier-Kriesche et al., 2002). Though the 
prevalence of obesity before and after renal transplantation varies regionally, 
a significant universal increase in post-transplant weight is commonly 
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observed. In a retrospective review of transplant patients at 1 year after renal 
transplantation, 43% of patients were found to be obese and 57% of patients 
experienced an average weight gain of 10% (Johnston et al., 1993). 
Additionally, multivariate analysis revealed that patients with an increase in 
BMI of more than 5% at 1 year post-transplantation have a ~3-fold increased 
risk of graft loss (Ducloux et al., 2005). It is clear that BMI can have a long-
term impact on graft function and thus, early evaluation of BMI should allow 
for individual interventions, such as the incorporation of dietary restrictions to 
prevent excessive post-transplant weight gain and minimise these associated 
risks. However, further prospective clinical trials are required to assess the 
impact of dietary and pharmacological interventions on graft survival in renal 
transplant patients. Immunosuppression has not been found to be directly 
associated with elevations in BMI (Ducloux et al., 2005), and so it is likely 
that their main contribution in this regard may be to provoke the associated 
insulin resistance, hyperlipidemia and hypertensive conditions. 
 
4.1.3 Hyperlipidemia/Hypercholesterolemia 
 
Hyperlipidemia is also common in renal transplant patients and often co-
exists with obesity and hyperinsulinemia. More than 60% of renal transplant 
patients develop hyperlipidemia, characterised by elevated total- and low-
density lipoprotein (LDL)-cholesterol, either alone or in combination with 
hypertriglyceridemia (Del Castillo et al., 2004; Ong et al., 1994; Tse et al., 
2004). Post-transplant hyperlipidemia has shown to persist even at 5 years 
post-transplantation, and has also been linked to increased risks for CVD as 
well as mortality, allograft rejection and graft failure (Ong et al., 1994; 
Wissing et al., 2000). Both CsA and FK506 have been demonstrated to 
induce hyperlipidemia in numerous clinical studies. CsA-treated renal 
transplant patients display significant elevations in triglycerides, total 
cholesterol and LDL levels with variable effects on HDL levels (Ligtenberg et 
al., 2001; McCune et al., 1998; Pirsch et al., 1997; Vincenti et al., 2007). 
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Treatment with FK506, however, appears to have a less pronounced effect 
on lipid profiles compared to CsA. In a US multicentre randomised trial, 
FK506-treated renal transplant patients had significantly lower levels of total 
cholesterol, LDLs and triglycerides compared to CsA-treated patients (Pirsch 
et al., 1997), and these parameters remained low even at 5 years post-
transplantation (Vincenti et al., 2002). Similar findings have also been found 
in European multicentre studies (Grimm et al., 2006; Krämer et al., 2005; 
Margreiter, 2002). Interestingly, conversion from CsA to FK506 has been 
associated with significant improvements in lipid and cardiovascular profiles 
(Artz et al., 2003; Baid-Agrawal et al., 2004; McCune et al., 1998). In a 
multicentre study, renal transplant patients receiving CsA treatment who 
were then randomised to FK506 displayed significant reductions in total 
cholesterol and LDLs by around 16-17% and 22-25%, respectively, but 
showed no changes in triglyceride and HDL levels, and no effects on renal 
allograft function and glycemic control (Artz et al., 2003; Baid-Agrawal et al., 
2004; Ligtenberg et al., 2001; McCune et al., 1998). Others have observed a 
significant decrease, by 18%, in triglycerides following conversion to FK506 
(Artz et al., 2003). Therefore, both CNIs are associated with hyperlipidemia 
development in renal transplant patients but with FK506 having greater 
improvements in lipid profiles, less hypertension and reduced rates of acute 
rejection. 
 
4.1.4 Hypertension 
 
As discussed in detail in Sections.1.2 and 1.3, hypertension is very common 
following transplantation and is highly correlated with long-term graft survival, 
CVD and patient mortality (Campistol et al., 2004; Kasiske et al., 2004; Opelz 
et al., 1998). Post-transplant hypertension, as well as its associated 
detrimental effects, has been widely demonstrated to be aggravated by the 
administration of CNIs. The CsA-induced hypertensive effects are 
multifactorial, inducing stimulated vasoconstriction, increased sympathetic 
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nerve activity and activation of the renin-angiotensin system (Avdonin et al., 
1999; English et al., 1987; Kurtz et al., 1988; Scherrer et al., 1990; Xue et al., 
1987). Although FK506 causes similar actions to CsA, FK506 has shown to 
be associated with a lower incidence of allograft rejection and post-transplant 
hypertension, as well as a higher rate of patient/graft survival, compared to 
CsA (Grimm et al., 2006; Kim et al., 2004; Krämer et al., 2005; Margreiter, 
2002; Webster et al., 2005).  
 
4.1.5 Post-transplant diabetes mellitus 
 
As discussed in detail in Section.1.7, PTDM is another common 
complication by CNI use, affecting between 2 – 25% of initially non-diabetic 
renal transplant patients and rendering them vulnerable to risks of decreased 
graft / patient survival and increased CVD (Boudreaux et al., 1987; Cosio et 
al., 2001, 2005; Heisel et al., 2004; Kasiske et al., 2003; Porrini et al., 2008a, 
2008b; Roth et al., 1989; Vincenti et al., 2007; Woodward et al., 2003). 
Increased prevalence of PTDM has been associated with the type of 
immunosuppressant used, African American ethnicity, BMI, age, family 
history of diabetes, pre-transplant hypertriglyceridemia, elevated total serum 
cholesterol and prior abnormalities in glucose metabolism and insulin 
resistance (Cosio et al., 2001, 2002, 2005; Kasiske et al., 2003; Porrini et al., 
2008b). Both CsA and FK506 predispose renal transplant patients to PTDM 
through mechanisms such as B-cell toxicity, inhibited insulin synthesis and 
release, and increased insulin resistance (Boots et al., 2002; Helmchen et 
al., 1984; Hirano et al., 1992; Redmon et al., 1996; Tamura et al., 1995). 
However, the diabetogenic effects of CNIs are not fully defined. Multiple 
registry analyses, clinical studies and single centre cohorts have shown that 
the risks for PTDM differs between the two immunosuppressants; FK506 is 
associated with a much higher incidence of PTDM than CsA (Boots et al., 
2002; Heisel et al., 2004; Kamar et al., 2007; Kasiske et al., 2003; Pirsch et 
al., 1997; Roland et al., 2008; Sato et al., 2003; Vincenti et al., 2007; 
			
156				
Woodward et al., 2003). Further studies have shown that conversion from 
FK506 to CsA is associated with an improvement in glucose metabolism, 
with a remission rate of 42% at 1 year after conversion (Ghisdal et al., 2008). 
However, though these studies imply the conversion from FK506 to CsA may 
result in improved glucose control, CsA is also associated with a higher 
incidence of hypertension and hyperlipidemia in comparison to FK506, 
suggesting the need for individualisation of the immunosuppressive regimen 
in order to balance its efficacy and toxicity. 
 
4.1.6 Other clinical features 
 
Additional clinical features observed with metabolic syndrome and are also 
associated with CNI immunosuppression include hypomagnesemia, 
hypophosphatemia and hyperuricemia. 
 
Hypomagnesemia is a frequent complication in transplant patients and is a 
known side effect of CNIs (Andoh et al., 1996; McDiarmid et al., 1993; Nozue 
et al., 1992). Hypomagnesemia is also common in patients with diabetes, 
occurring in 25–47% of these patients (Lima et al., 2009a, 2009b; Mather et 
al., 1979). Previous cross-sectional studies have shown both dyslipidemia 
and hypertension were related to lower serum Mg2+ levels (Guerrero-Romero 
and Rodríguez-Morán, 2002). Furthermore, low serum Mg2+ was also found 
in 65.6% of individuals with metabolic syndrome suggesting, as confirmed 
through multivariate analysis, a strong independent relationship between 
lower serum Mg2+ levels and metabolic syndrome (Guerrero-Romero and 
Rodríguez-Morán, 2002, 2006). In a retrospective single-centre study, renal 
transplant patients on CNIs showed significantly lower Mg2+ levels during the 
first month post-transplantation and these patients were found to develop 
PTDM much faster (Van Laecke et al., 2009), suggesting hypomagnesemia 
as an independent predictor of PTDM. Numerous multicentre studies have 
also observed that hypomagenesmia was more frequent in patients treated 
			
157				
with FK506 than CsA (Margreiter, 2002; Van Laecke et al., 2009; Webster et 
al., 2005), although the mechanisms for the effects of CNIs on Mg2+ is not 
fully clear. Prior studies in FK506-treated rats displaying hypomagnesemia 
was associated with excessively high fractional excretion of Mg2+, suggesting 
impaired Mg2+ reabsorption (Andoh et al., 1996; Lote et al., 2000). 
Additionally, mRNA expression of the renal Mg2+ channel, TRPM6, was 
significantly reduced in FK506-treated rats, indicating that FK506-induced 
downregulation of Mg2+ transport proteins may be responsible for excessive 
Mg2+ wasting and in the pathogenesis of hypomagnesemia (Nijenhuis et al., 
2004). 
 
Hypophosphatemia is another common condition encountered following renal 
transplantation, affecting >90% of patients (Ambühl et al., 1999; Bhan et al., 
2006; Moorhead et al., 1974). It is believed that the mechanisms contributing 
to post-transplant hypophosphatemia are related to the dysregulation of 
tubular phosphate reabsorption, as a consequence of increased PTH and 
FGF23 levels (Bhan et al., 2006; Falkiewicz et al., 2003; Farrington et al., 
1979; Mohebbi et al., 2009; Moz et al., 2004). In animal models, FK506 
treatment has been previously associated with a significant decrease in the 
expression of the renal NaPi-IIa cotransporter (Mohebbi et al., 2009; Moz et 
al., 2004), which likely contributes to phosphate wasting in CNI-treated 
patients. However, the degree of contribution of these immunosuppressive 
drugs to hypophosphatemia development has not been found to be greatly 
significant. In a study of 72 renal transplant patients, those receiving CsA 
monotherapy did not experience significant hypophosphatemia in 
comparison to patients receiving a combination of azathioprine and 
prednisolone (Higgins et al., 1990), suggesting CsA may not affect 
phosphate handling. Furthermore, in a study of 40 renal transplant patients 
receiving CsA (studied at 1, 6, 12, 24, 30 and 36 months after 
transplantation) and 20 patients receiving FK506 (studied 3 months after 
transplantation), treatment with FK506 was associated with a significantly 
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higher tubular phosphate reabsorption rate at all time points studied 
compared to CsA, indicative of a faster recovery from impaired tubular 
phosphate reabsorption (Falkiewicz et al., 2003). It is possible that 
immunosuppressive drug treatment may affect plasma phosphate or urinary 
phosphate excretion via an indirect mechanism. However, further analyses 
are required to fully define the role of CNI immunosuppression in the 
development of hypophosphatemia following renal transplantation. 
 
Hyperuricemia is also common after renal transplantation, occurring in 25 - 
80% of patients (Armstrong et al., 2005; Gores et al., 1988; Kahan et al., 
1987; Kalantar et al., 2011; Lin et al., 1989; Malheiro et al., 2012; Zurcher et 
al., 1996). Its high prevalence has shown to be correlated with prolonged use 
of CNIs, especially with CsA, and is significantly linked to reduced renal graft 
survival, chronic allograft nephropathy development and cardiovascular 
events (Akalin et al., 2008; Gerhardt et al., 1999; Lin et al., 1989; Marcen et 
al., 1992). The adverse effects of CsA on uric acid excretion were observed 
shortly after its introduction into clinical use, however, the mechanism by 
which this occurs remains to be fully elucidated. A number of studies have 
arrived at a variety of conclusions and have mostly implicated CsA in 
impaired renal tubular handling of uric acid. Clearance studies in CsA-treated 
adult and paediatric transplant patients have shown CsA-induced 
hyperuricemia to be related to decreased GFR, lower urinary clearance and 
fractional excretion of uric acid as a consequence of increased net proximal 
tubular uric acid absorption (Hoyer et al., 1988; Laine and Holmberg, 1996; 
Lin et al., 1989; Zurcher et al., 1996). Some investigations have examined 
the effects of FK506 on hyperuricemia development in comparison to CsA 
and have found no differences between both immunosuppressants in 
increasing serum uric acid levels (Kanbay et al., 2005; Spartà et al., 2006). 
However, the specific mechanisms underlying these CNI-induced alterations 
in uric acid handling and the relationship between hyperuricemia and other 
manifestations of CNI-induced nephrotoxicity are still not well defined.   
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Overall, despite their intention-to-treat, CNI administration continues to 
induce hypertension along with the conditions associated with metabolic 
syndrome, thereby limiting their efficacies and obstructing graft and patient 
survival.  
 
4.1.7 Mouse models of diet-induced metabolic syndrome 
 
Metabolic syndrome is a multifactorial condition and because its presentation 
differs among patients as a function of the components of this syndrome, 
different treatments must be tailored for different patients. For this to be 
accomplished, rodent models of metabolic syndrome are required to study 
the underlying mechanisms for metabolic syndrome development. Currently, 
a number of animal models have been established which mimic, as faithfully 
as possible, all the multiple components underlying human metabolic 
syndrome coexisting in these patients. However, currently no studies have 
investigated the potential use of CNI treatment as a model of metabolic 
syndrome, despite its evident associations with the individual components 
that comprise the syndrome. 
 
Currently, the use of diets which are high in fat are generally accepted to 
generate rodent models of metabolic syndrome to induce the insulin 
resistance and obesity components under conditions which are most 
comparable to actual worldwide diets. Comparisons of the effects of high-fat 
and high-sucrose diets have shown significantly increased feeding efficiency, 
weight gain, plasma glucose and insulin levels in mice fed a high-fat diet 
whilst a high-sucrose diet did not (Black et al., 1998; Surwit et al., 1995). This 
indicates that dietary fat, not sucrose, is the critical stimulus for the 
development of hyperglycemia and hypersinsulinemia (Black et al., 1998; 
Surwit et al., 1995). Studies in rats and various mouse strains have also 
shown that an increase in dietary fat content and central adiposity displays 
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several correlations to human metabolic syndrome (Surwit et al., 1988; West 
et al., 1992; Woods et al., 2003). In particular, the C57BL/6J mouse strain 
has proven to be the best model for studying metabolic syndrome. Numerous 
studies comparing the effects of high-fat diets on C57BL/6J mice with other 
mouse strains have demonstrated its high susceptibility to developing obesity 
(hyperlipidemia and hypercholesterolemia), hyperinsulinemia, hyperglycemia 
and hypertension when allowed ad libitum access to high-fat diets, whilst 
other strains are relatively resistant to these effects (Gallou-Kabani et al., 
2007; Surwit et al., 1988, 1995; Winzell and Ahren, 2004). In addition, the 
development of glucose intolerance and diabetes induced by high-fat diets in 
this strain has shown to closely parallel the progression of diabetes and 
obesity in humans, whereby the prevalence of diabetes and impaired glucose 
tolerance was more common in obese subjects, making this mouse strain 
well suited for studying metabolic syndrome (West and Kalbfleisch, 1971). 
 
4.1.8 Aims of this study 
 
It is evident that the detrimental impacts of CNIs on hyperglycemia, 
hyperlipidemia and hypertension may play a role in the development and 
increasing prevalence of metabolic syndrome. However, the pathophysiology 
of metabolic syndrome with CNI treatment has not yet been investigated.  
 
The aims of this chapter were to establish a CNI-induced model of metabolic 
syndrome in attempts to understand the underlying mechanisms in both CNI-
treated and metabolic syndrome states. In the work described, high-fat diet-
fed mice were used as a model of metabolic syndrome and compared with 
FK506-treated mice. Biochemical analysis on both plasma and urine samples 
were performed to confirm the clinical features of metabolic syndrome and 
changes in renal and intestinal transport proteins were assessed at both 
transcriptional and translational levels. Further aims of this study were to also 
identify potential transport proteins that may contribute to the phenotypic 
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features of metabolic syndrome. Additionally, the conclusions drawn from 
Chapter 3 suggest that CNIs require the presence of another stimulus to 
exert its effects. Therefore, this study was also carried out to determine 
whether CNI treatment alone mirrors metabolic syndrome or whether CNIs 
may predispose renal transplant patients to metabolic syndrome 
development in combination with increased dietary fat intake / an obese 
background. 
 
This study was conducted with an aim of aiding future studies by 
understanding the mechanisms involved in metabolic syndrome development 
in CNI-treated renal transplant patients as well as determining which renal 
and intestinal transporters may also contribute to its pathogenesis. This study 
hopes to facilitate future studies that may allow the design of an effective 
immunosuppressive regimen with minimal metabolic complications. 
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4.2 Materials and methods 
4.2.1 Animals 
 
Male C57BL/6J mice, aged 3 weeks (weighing between 13 – 17g), were 
used in accordance with the Animals Scientific Procedures Act 1986, 
Amendment Regulations 2012. All protocols were approved by the University 
College London (Royal Free Campus) Comparative Biology Unit Animal 
Welfare and Ethical Review Body (AWERB) committee and performed in 
accordance with project license PPL 70/7647. 
 
4.2.2 Metabolic syndrome mouse model 
 
Full procedures have been described in Section.2.1.3. Mice were provided 
with ad libitum access to a high-fat diet, containing 60% energy-from-fat, or a 
standard maintenance diet, containing 7.4% energy-from-fat, for ten weeks. 
At week 8, mice were administered either vehicle or FK506 at a dose of 2 
mg/kg/day, via I.P injections, for the remaining two weeks. For the final five 
days of the experimental period, mice were housed and acclimatised in 
metabolic cages to obtain 24-hour urine collections prior to the final day.  
 
At the end of the experiment, mice were placed under terminal anaesthesia 
and checked for withdrawal to corneal and pedal reflexes before sample 
collections. Terminal blood samples were collected by cardiac puncture and 
urinary samples were collected by bladder puncture. Cervical dislocation was 
performed and death was confirmed by cessation of heartbeat before 
removing renal and intestinal tissues. 
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4.2.3 Plasma and urine biochemistry 
 
Plasma and urine samples were collected, as described in Section.2.1.4, 
and biochemical analyses for sodium, creatinine, glucose and phosphate 
were performed as described in Sections.2.1.5 - 2.1.8. Measurements for 
triglycerides, HDLs, urate, magnesium, calcium and bicarbonate levels were 
carried out by Dr. Anjly Jain in the Department of Clinical Biochemistry 
(Royal Free Hospital, London, UK). 
 
4.2.4 RT-PCR 
 
RT-PCR protocols were carried out as described in Section.2.2. Whole 
kidney and intestinal mucosa samples from proximal and distal intestinal 
tissues were collected and snap-frozen in an RNA stabilising solution and 
subjected to RNA extraction as described in Section.2.2.1, using 100 mg of 
tissue. RNA concentration and purity was confirmed using the Nanodrop and 
run on an agarose gel, as described in Section.2.2.4. Isolated RNA was then 
subjected to cDNA synthesis protocols as described in Section.2.2.2, using 
1–1.5 µg RNA and included a reverse transcriptase negative control. 
Samples and controls, in duplicates, were then subjected to RT-PCR 
analysis as described in Section.2.2.3, using primers listed in Tables.2.2 
and 2.3, under the conditions described in Table.2.4. 
 
4.2.5 BBMV preparations from kidney and intestinal mucosal tissues 
 
BBMVs were prepared from previously snap-frozen whole kidney and 
intestinal mucosa tissues using the techniques described in Section.2.5.2 
and 2.5.3, respectively. Large intestinal mucosal samples were processed as 
described in Section.2.5.1. Total protein concentration was determined using 
the Bradford assay as described in Section.2.5.4. For BBMVs and 
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homogenate fractions, purity was assessed using an alkaline phosphatase 
assay as described in Section.2.5.5. 
 
4.2.6 Western blot analysis 
 
Western blot protocols were carried out as described in Section.2.5.6. 
Kidney and intestinal BBMVs (25 µg) or homogenate samples (50 – 100 µg) 
were run on an SDS-PAGE gel. Large intestinal homogenate samples were 
loaded at 100 µg. Samples were then transferred onto a PDVF membrane 
and incubated with the primary antibodies and their corresponding secondary 
antibodies listed in Table.2.6. Following visualisation, membranes were then 
stripped and re-probed for b-Actin. Densitometry was measured and samples 
were normalised to b-actin. As mentioned, due to the lack of access to 
overexpressing and/or knockdown mouse models, no further positive or 
negative controls were used in western blot applications. 
 
4.2.7 Statistical analysis 
 
Data are presented as mean ± SEM, relative to b-actin. N refers to the 
number of samples within each group. Significance was determined by one-
way ANOVA with Bonferroni post-test, relative to vehicle-treated mice on the 
standard or high-fat diet or as stated. *P < 0.05, ** P < 0.01, *** P < 0.001. 
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4.3 Results 
4.3.1 Physiological parameters 
 
Mouse models of metabolic syndrome and CNI treatment were established in 
order to investigate whether immunosuppression with CNIs may influence 
the development of the conditions associated with metabolic syndrome. To 
establish a mouse model of metabolic syndrome, mice were placed on a 
high-fat (HF) diet for 10 weeks with the aim of inducing obesity and known 
metabolic syndrome-affiliated conditions, such as insulin resistance. This 
was followed by treatment with vehicle or FK506 for 14 days, commencing 
on the 8th week, and housing in metabolic cages for the remaining 5 days for 
24-hour urine collections. 
 
Body weight was measured regularly and body weight changes were 
calculated to monitor fluctuations during the course of treatment. 
Supplementation with the high-fat diet over the course of 10 weeks was 
associated with a continuous rise in body weight (Fig.4.1a). At the end of the 
treatment, these mice had gained an overall ~2.1-fold increase in body 
weight (30.32 ± 0.76g and 31.17 ± 0.78g for vehicle- and FK506-treated HF 
groups, respectively) compared to their initial weight (15.5 ± 0.4g and 14.6 ± 
0.43g for vehicle- and FK506-treated HF groups, respectively). The daily 
food and water intake was lower than expected for this mouse strain, which 
was reported to be typically between 3-5 g/day/mouse and 3-7 
ml/day/mouse, respectively (Bachmanov et al., 2002). However, despite this, 
the food and water intake remained stable throughout the 10-week period 
with some minor fluctuations and significant differences between groups 
(Fig.4.1b,c). A slight decline in body weight and food intake was observed 
following the commencement of vehicle and FK506 administration 
(Fig.4.1a,b), with a sharp decrease in body weight in all treatment groups 
over the last 4-5 days of the experiment (Fig.4.1d). This was most likely a 
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stress response to the daily injections and later housing in metabolic cages 
at the final stages of the experiment rather than the vehicle/FK506 treatment 
itself. Despite this, the final body weights were significantly higher in the high-
fat diet-fed groups compared to the groups maintained on the standard diet 
(Fig.4.1e). 
 
Plasma and 24-hour urine biochemical analyses are shown in Table.4.1. 
Mean plasma creatinine values were higher than the expected range for mice 
using the Jaffe’s method (~10-44 µmol/L). This was most likely due to the 
reported complications in measuring plasma creatinine using this method, 
however, urinary creatinine concentrations have been found to be similar in 
mice when measured by the Jaffe’s method and the recommended HPLC 
(Dunn et al., 2004; Meyer et al., 1985; Palm and Lundblad, 2005), and so 
supports the urinary creatinine concentrations and the calculated electrolyte 
excretion ratios measured in this study. Regardless, plasma creatinine was 
significantly increased in the FK506-treated mice placed on the high-fat diet 
compared to its FK506-treated standard diet counterpart, while urinary 
creatinine levels were significantly decreased in all treatment groups relative 
to vehicle-treated mice (Table.4.1). These observations may be indicative of 
kidney dysfunction possibly as a result of the high-fat diet, particularly in 
combination with FK506 treatment, which may contribute to the detrimental 
consequences on graft function/survival in obese individuals. Therefore, it 
should be noted that any changes in urinary electrolyte levels observed in the 
FK506/HF group might be a reflection of altered GFR due to possible kidney 
dysfunction.  
 
No changes were found for plasma urate, magnesium and urinary calcium 
levels in all treatment groups. While there were no significant differences in 
plasma sodium between groups, mice fed on the high-fat diet treated with 
either vehicle or FK506 drastically excreted more sodium in their urine 
(Table.4.1). Plasma glucose was significantly increased in FK506-treated, 
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and both vehicle- and FK506-treated mice on the high-fat diet relative to 
vehicle-treated mice, with no changes in urinary glucose excretion 
(Table.4.1), indicative of altered glucose homeostasis in this model. In 
addition, plasma phosphate levels were significantly increased in both 
vehicle- and FK506-treated mice fed on the high-fat diet compared to treated 
mice on the standard diet (Table.4.1). This was similarly observed for urinary 
phosphate. Plasma bicarbonate was also lower in the high-fat group under 
both treatments. These observations may suggest impaired acid-base 
balance in the obese model. Interestingly, although no changes were 
observed for total plasma triglycerides, a significant increase in HDL-
cholesterol was found in mice fed on the high-fat diet, especially when 
followed with FK506 treatment (Table.4.1), which may be a compensatory 
response to possible increases in circulating total- and LDL- cholesterol 
levels. However, as these parameters were not measured in this study, this 
compensatory response cannot be confirmed. 
 
Overall, mice fed on a high-fat diet had greater weight gain and were heavier 
than those fed on a standard diet. Treatment with FK506 alone or the 
supplement of a high-fat diet with either vehicle or in combination with FK506 
treatment was associated with altered glucose, phosphate and acid-base 
balance. The plasma and urine biochemical analyses indicate partial features 
of metabolic syndrome in the group fed on the high-fat diet. However, 
because these results reflect the dietary intake of the preceding couple of 
days and does not consider day-to-day variability in intake, which may have 
also been influenced by adjustments to the metabolic cage, the absence of 
alterations in urate, magnesium and triglyceride levels cannot be ruled out. In 
addition, the changes observed with the combined high-fat diet with FK506 
treatment, as indicated by plasma and urinary creatinine levels, might be a 
consequence of altered GFR. 
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Figure 4.1. Body weight, food and water consumption during FK506 and/or high-fat diet treatment. A) Body weight change, B) food and, 
C) water intake of two groups of mice (n = 10 per group) fed on the high-fat (HF) diet. Mice were weighed twice weekly over the 10 weeks of the 
study. Vehicle and FK506 treatment commenced at week 8 (arrow) and was administered daily for the remaining 14 days of the study. D) Body 
weight change over the 14-day vehicle/FK506 treatment period in mice fed either the HF diet or the standard maintenance diet (n = 7 per 
group). From day 10, mice were housed in metabolic cages to allow for 24-hour urine collections. E) Comparisons of the final body weights on 
the final day of the treatment. All data are presented as the mean ± SEM. Body weight change is presented as the mean percentage (%) 
change in body weight normalised to the initial weight at day 1. Significance was determined by two or one-way ANOVA with Bonferroni post-
test. *P < 0.05, **P < 0.01, ***P < 0.001.   
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Table 4.1. Plasma and urine biochemistry. Effects of FK506 and/or a high-fat 
(HF) diet on plasma and urinary electrolytes. Values are presented as the mean ± 
SEM. Urine electrolytes are presented as the mean normalised to urinary creatinine. 
Significance was determined by one-way ANOVA with Bonferroni post-test.  
* P < 0.05, ** P < 0.01, *** P < 0.001; vs. Vehicle 
† P < 0.05, †† P < 0.01, ††† P < 0.001; vs. FK506 
‡ P < 0.05, ‡‡ P < 0.01, ‡‡‡ P < 0.001; vs. Vehicle/HF 
§ P < 0.05, §§ P < 0.01, §§§ P < 0.001; vs. FK506/HF 
Parameter Vehicle                       (N = 7) 
FK506                        
(N = 7) 
Vehicle/HF               
(N = 10) 
FK506/HF                  
(N = 10) 
Plasma  
Creatinine  
(μmol/L) 248.16 ± 42.17 
168.44 ± 8.57  
§§ 258.48 ± 33.15 
375.66 ± 50.54 
†† 
Na+  
(mmol/L) 133.61 ± 3.80 123.96 ± 5.64 119.19 ± 3.60 123.41 ± 3.28 
Glucose  
(mmol/L) 
5.70 ± 0.90  
†† ‡‡ § 
10.89 ± 1.00  
** 
10.30 ± 0.64  
** 
9.48 ± 0.84  
* 
Pi  
(mmol/L) 
2.19 ± 0.09  
‡‡ §§ 
2.27 ± 0.10  
‡ § 
2.75 ± 0.13  
** † 
 2.75 ± 0.08 
** † 
Triglycerides 
(mmol/L) 0.71 ± 0.12 0.87 ± 0.12 0.53 ± 0.06 0.72 ± 0.07 
HDLs  
(mmol/L) 
1.22 ± 0.16  
‡‡ §§§ 
1.71 ± 0.19  
§§§ 
1.88 ± 0.11  
** §§§ 
3.00 ± 0.10  
*** ††† ‡‡‡ 
Urate  
(μmol/L) 29.04 ± 17.13 11.66 ± 2.38 43.20 ± 13.49 25.84 ± 7.74 
Mg2+  
(mmol/L) 0.25 ± 0.02 0.21 ± 0.01 0.21 ± 0.01 0.22 ± 0.01 
HCO3- 
(mmol/L) 
15.95 ± 1.62  
‡ §§ 
16.82 ± 0.57  
‡‡ §§§ 
12.02 ± 0.60  
* †† 
11.53 ± 0.50  
** ††† 
Urine 
Creatinine  
(μmol/L) 
1041.35 ± 85.54  
† ‡ §§§ 
659.83 ± 80.79  
* 
711.55 ± 89.60  
* 
524.58 ± 39.39 
*** 
UNa/UCr  
(mmol/mmol) 
48.79 ± 6.77  
§§§ 
6.49 ± 4.34 
‡‡ §§§ 
116.18 ± 26.54  
†† 
181.32 ± 16.26 
*** ††† 
UGlucose/UCr 
(mmol/mmol) 2.28 ± 0.26  30.59 ± 20.98 0.87 ± 0.39 1.42 ± 0.47 
UPi/UCr  
(mmol/mmol) 
51.29 ± 9.44  
‡ § 104.65 ± 21.38 
239.75 ± 65.26  
* 
259.98 ± 25.55  
* 
UUrate/UCr 
(mmol/mmol) 1.23 ± 0.14 1.62 ± 0.26 2.08 ± 0.55 2.78 ± 0.36 
UMg/UCr  
(mmol/mmol) 43.85 ± 9.33 
65.16 ± 14.27  
‡ 
27.51 ± 7.09  
† 34.65 ± 3.03 
UCa/UCr  
(mmol/mmol) 3.01 ± 0.37 7.09 ± 2.54 4.21 ± 1.55 6.71 ± 0.89 
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4.3.2 Influences of FK506 and/or diet-induced obesity on renal 
transport proteins  
 
As previously mentioned, metabolic syndrome is commonly observed 
following renal transplantation and is comprised of a cluster of conditions 
including hypertension, obesity, insulin resistance, hyperlipidemia, 
hypophosphatemia, hypomagnesemia and hyperuricemia. Most of these 
individual conditions have been previously associated with CNI 
immunosuppression and have been linked to changes in a number of renal 
and intestinal transport proteins and function, suggesting that these transport 
proteins may also be altered in patients with metabolic syndrome in a similar 
manner. In the present study, these associated renal and intestinal transport 
proteins were analysed at both the transcriptional and translational levels to 
investigate whether these transport proteins are similarly altered in both CNI-
treated mice and a model of diet-induced obesity/metabolic syndrome. 
Analyses of mice under a combination of high-fat feeding and FK506 
administration were also performed to assess for an exaggerated response. 
The observations obtained from this study may enable the identification of 
transport proteins contributing to the pathogenesis of metabolic syndrome, 
and may also confirm the potential establishment of another mouse model of 
metabolic syndrome via treatment with CNIs. 
 
As implicated from the biochemistry data with regards to the marked 
reduction in plasma bicarbonate and increased plasma and urinary 
phosphate, mice fed on a high-fat diet treated with either vehicle or FK506 
appear to display altered acid-base balance. To evaluate these observations, 
analyses of mRNA and protein expression of the proximal tubular acid-base 
proteins, NHE3, NaPi-IIa and NaPi-IIc, were measured. Relative to vehicle-
treated mice, NHE3 mRNA expression was significantly increased in FK506-
treated mice fed either the standard or high-fat diet (Fig.4.2a). Western 
blotting showed a significant increase in NHE3 protein abundance in renal 
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BBMVs from vehicle- and FK506-treated mice on the high-fat diet, compared 
with the corresponding standard diet-fed mice (Fig.4.2b). However, mRNA 
expression of both NaPi-IIa and NaPi-IIc were only significantly increased in 
the FK506/HF group, with no changes following FK506 treatment or with 
high-fat feeding alone (Fig.4.3a,c), and no overall change in protein 
abundance (Fig.4.3b,d).  
 
An increase in plasma glucose was also found in the FK506-treated group 
and the high-fat diet-fed group with either treatment, suggestive of altered 
glucose homeostasis and the possible onset of insulin resistance/diabetes. 
To further explore this possibility, mRNA expression and protein abundances 
of the Na+/glucose cotransporters, SGLT2 and SGLT1, and the facilitative 
glucose transporter, GLUT2, were also measured. No significant changes in 
SGLT2 mRNA expression were found in FK506-treated and high-fat diet-fed 
control mice, whilst a combination resulted in a significant increase 
(Fig.4.4a). Only a slight but significant upregulation in SGLT1 mRNA 
expression was observed with control mice fed on the high-fat diet, while no 
overall change in SGLT1 protein was found (Fig.4.4c,d). Interestingly, 
SGLT2 protein expression was significantly decreased in the high-fat groups 
under both drug treatments (Fig.4.4b), which do not correlate with the 
marked elevations in plasma glucose. In addition, while GLUT2 mRNA 
expression was significantly upregulated in mice fed on the high-fat diet with 
FK506 treatment, protein levels remained unaffected in both BBMVs and 
homogenate samples from all treatment groups (Fig.4.5).   
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Figure 4.2. Analysis of the renal Na+/H+ exchanger, NHE3, after FK506 treatment and/or high-fat diet feeding. A) Relative mRNA 
expression of the Na+/H+ exchanger, NHE3, in whole kidney tissue from mice maintained on a standard or high-fat (HF) diet for 10 weeks and 
subjected to vehicle or FK506 treatment for 14 days. B) Representative western blots for NHE3 (arrow) in BBMVs prepared from whole kidney 
tissue. b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and normalised to b-actin. 
Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA with Bonferroni post-
test. *P < 0.05.  
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Figure 4.3. Analysis of the renal Na+/Pi cotransporters, NaPi-IIa and NaPi-IIc, 
after FK506 treatment and/or high-fat feeding. Relative mRNA expression and 
protein quantification of the Na+/Pi cotransporters, A, B) NaPi-IIa and, C, D) NaPi-
IIc, in whole kidney tissue and BBMVs prepared from mice maintained on a 
standard or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 
days. Representative western blots are shown for both proteins (arrow). E) b-actin 
(arrow) was run as a loading control. Densitometric analyses (right) were performed 
for each group and normalised to b-actin. Values are presented as the mean ± 
SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA 
with Bonferroni post-test. **P < 0.01, ***P < 0.001. 
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Figure 4.4. Analysis of the renal Na+/glucose cotransporters, SGLT2 and 
SGLT1, after FK506 treatment and/or high-fat feeding. Relative mRNA 
expression and protein quantification of the Na+/glucose cotransporters, A, B) 
SGLT2 and, C, D) SGLT1, in whole kidney tissue and BBMVs prepared from mice 
maintained on a standard or HF diet for 10 weeks and subjected to vehicle or FK506 
treatment for 14 days. Representative western blots are shown for both proteins 
(arrow). E) b-actin (arrow) was run as a loading control. Densitometric analyses 
(right) were performed for each group and normalised to b-actin. Values are 
presented as the mean ± SEM, relative to b-actin (n = 6). Significance was 
determined by one-way ANOVA with Bonferroni post-test. * P < 0.05, **P < 0.01, 
***P < 0.001.  
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Figure 4.5. Analysis of the renal glucose transporter, GLUT2, after FK506 
treatment and/or high-fat feeding. A) Relative mRNA expression of the glucose 
transporter, GLUT2, in whole kidney tissue from mice maintained on a standard or 
HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. 
Representative western blots and protein quantification for GLUT2 (arrow) are 
shown for both B) BBMVs and, C) homogenate fractions, prepared from whole 
kidney tissue. b-actin (arrow) was run as a loading control. Densitometric analyses 
(right) were performed for each group and normalised to b-actin. Values are 
presented as the mean ± SEM, relative to b-actin (n = 6). Significance was 
determined by one-way ANOVA with Bonferroni post-test. **P < 0.01, ***P < 0.001. 
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Under all treatment conditions, no significant differences were observed for 
the TAL Na+-K+-2Cl- cotransporter, NKCC2, at both transcriptional and 
translational levels (Fig.4.6). Unfortunately, due to a limited stock of a gifted 
antibody and commercially unavailable phospho-antibodies for NKCC2, 
changes in pNKCC2 abundance could not be measured. 
 
As previously explained, blood pressure could not be directly measured at 
the present time to confirm the hypertensive states in FK506-treated and 
diet-induced obese mice. Therefore, the establishment of increased sodium 
reabsorption, via the up-regulation and phosphorylation of the NCC 
cotransporter, was used as an indicator of increased sodium retention and an 
indirect measure for elevations in blood pressure. A significant increase in 
NCC mRNA expression was found in the FK506-treated group fed on the 
high-fat diet, while no significant differences in NCC expression were found 
in mice treated with FK506 or fed on the high-fat diet alone (Fig.4.7a). NCC 
protein levels were unaffected in all four groups (Fig.4.7b). However, pNCC 
was significantly increased in the FK506-treated and high-fat diet-fed control 
groups, relative to vehicle-treated mice, but was interestingly decreased in 
the FK506/HF group compared to the FK506 and vehicle/HF groups 
(Fig.4.7c). Overall, these findings confirm the establishment of a significant 
CNI- and diet-induced sodium retentive, and mostly likely, hypertensive state 
in these treatment groups. 
 
Expression of the distal epithelial Na+ channel, ENaC was found to be 
significantly higher in FK506-treated mice fed on either the standard or high-
fat diets compared to control mice on either diet (Fig.4.8a). However, the 
protein abundance for the a-ENaC subunit was significantly lower in the 
FK506-treated and vehicle/HF groups, and showed a slight, but not 
statistically significant, decrease in the FK506/HF group (Fig.4.8b).  
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Figure 4.6. Analysis of the renal Na+-K+-2Cl- cotransporter, NKCC2, after FK506 treatment and/or high-fat feeding. A) Relative mRNA 
expression of the Na+-K+-2Cl- cotransporter NKCC2 in whole kidney tissue from mice maintained on a standard or HF diet for 10 weeks and 
subjected to vehicle or FK506 treatment for 14 days. B) Representative western blots for NKCC2 (arrow) in homogenate fractions prepared 
from whole kidney tissue. b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA 
with Bonferroni post-test.   
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Figure 4.7 Analysis of the renal Na+/Cl- cotransporter, NCC, after FK506 
treatment and/or high-fat feeding. A) Relative mRNA expression of the Na+/Cl- 
cotransporter, NCC, in whole kidney tissue from mice maintained on a standard or 
HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. 
Representative western blots and protein quantification are shown for B) NCC 
(arrow) and, C) phosphorylated NCC (arrow), in homogenate fractions prepared 
from whole kidney tissue. D) b-actin (arrow) was run as a loading control. 
Densitometric analyses (right) were performed for each group and normalised to b-
actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). 
Significance was determined by one-way ANOVA with Bonferroni post-test. *P < 
0.05, **P < 0.01, ***P < 0.001. 
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Figure 4.8. Analysis of the renal epithelial Na+ channel, ENaC, after FK506 treatment and/or high-fat feeding. A) Relative mRNA 
expression of the epithelial Na+ channel ENaC in whole kidney tissue from mice maintained on a standard or HF diet for 10 weeks and 
subjected to vehicle or FK506 treatment for 14 days. B) Representative western blots for ENaC (arrow) in homogenate fractions prepared from 
whole kidney tissue. b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and normalised 
to b-actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA with 
Bonferroni post-test. *P < 0.05, **P < 0.01, ***P < 0.001.  
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4.3.3 Influences of FK506 and/or diet-induced obesity on proximal 
small intestinal transport proteins 
 
To further investigate the mechanisms behind the alterations in sodium 
retention, and glucose, phosphate and acid-base homeostasis in these 
models, intestinal-specific transport proteins were also assessed. For this, 
mRNA and BBMVs/homogenate samples were prepared from mucosa 
scrapes from the proximal (duodenum and jejunum) and distal (ileum) small 
intestine and large intestinal (colon) segments and analysed for changes in 
NHE3, NaPi-IIb, PiT1, SGLT1 and GLUT2 transporters. 
 
Under baseline and treated conditions, the NHE3 exchanger has relatively 
low expression levels in the proximal intestinal segment in comparison to the 
kidney and remained unchanged under all treatments (Fig.4.9a). Western 
blotting showed a significant decrease in protein abundance in the FK506/HF 
group relative to FK506-treated mice on the standard diet (Fig.4.9b). A slight, 
but not significant, decrease in NHE3 was also observed in the vehicle/HF 
group compared to the standard diet-fed control group. 
 
In keeping with previous reports, mRNA analysis of the NaPi-IIb 
cotransporter in small intestinal tissues from mice demonstrated lower 
expression levels in the proximal segment compared with the distal segment 
of the small intestines (Fig.4.10a,b and Fig.4.13a,b) (Marks et al., 2006; 
Radanovic et al., 2005; Sabbagh et al., 2009; Stauber et al., 2005). 
Treatment with FK506 resulted in a significant increase in NaPi-IIb mRNA 
expression while the supplement of the high-fat diet with either treatments 
led to a significant decrease (Fig.4.10a). In contrast, mice fed on the high-fat 
diet with either treatments displayed a significant increase in PiT1 mRNA 
expression which was inversely correlated with a decrease in protein 
expression, compared with standard diet-fed mice (Fig.4.10b,c). NaPi-IIb 
protein could not be detected by western blot in the proximal segment, which 
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is mostly likely attributed to its low mRNA expression. It should be noted 
however, that despite these observations, due to their relatively low mRNA 
expression and the uncertainties in both NaPi-IIb and PiT1 protein 
localisation in mice, as well as the functional role for PiT1, the changes seen 
for these transport proteins in this segment are unlikely to have a significant 
impact on phosphate balance. Attention was therefore focused towards the 
distal segment of the small intestine, which was reported as the main site of 
Na+-dependent phosphate absorption in mice (Marks et al., 2006; Radanovic 
et al., 2005; Sabbagh et al., 2009; Stauber et al., 2005). 
 
As expected, compared to its expression in the kidney, SGLT1 expression 
was higher in the small intestines, predominantly in the proximal intestinal 
segment, whilst GLUT2 expression was relatively low. In contrast to the 
renal-related findings, intestinal SGLT1 and GLUT2 mRNA expression 
remained unchanged under all treatment groups (Fig.4.11a,c). However, 
SGLT1 protein was significantly lower in the high-fat diet groups under both 
treatments compared with the standard diet-fed control group (Fig.4.11b). 
Similar to the renal observations, GLUT2 protein levels remained unchanged 
in all treatment conditions in BBMV samples (Fig.4.11d), but as previously 
mentioned, under the conditions used in this study, GLUT2 was not expected 
to be present at the BBM and unfortunately GLUT2 could not be detected in 
the homogenate fractions. 
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Figure 4.9. Analysis of the Na+/H+ exchanger, NHE3, in the proximal small intestine (PSI) after FK506 treatment and/or high-fat feeding. 
A) Relative mRNA expression of the Na+/H+ exchanger, NHE3, in PSI mucosa scrapes collected from mice maintained on a standard or HF diet 
for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. B) Representative western blots for NHE3 (arrow) in BBMVs prepared 
from PSI mucosa scrapes. b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA 
with Bonferroni post-test. *P < 0.05.  
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Figure 4.10. Analysis of the Na+/Pi cotransporters, NaPi-IIb and PiT1, in the PSI after FK506 treatment and/or high-fat feeding. Relative 
mRNA expression of the Na+/Pi cotransporters, A) NaPi-IIb and, B) PiT1, in PSI mucosa scrapes from mice maintained on a standard or HF 
diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. C) Representative western blots for PiT1 (arrow) in BBMVs prepared 
from PSI mucosa scrapes. b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA 
with Bonferroni post-test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 4.11. Analysis of the Na+/glucose cotransporter, SGLT1, and the 
glucose transporter, GLUT2, in the PSI after FK506 treatment and/or high-fat 
diet feeding. Relative mRNA expression and protein quantification of the 
Na+/glucose cotransporter, A, B) SGLT1, and the glucose transporter, C, D) GLUT2, 
in PSI mucosa scrapes and prepared BBMVs from mice maintained on a standard 
or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. 
Representative western blots are shown for both proteins (arrow). E) b-actin (arrow) 
was run as a loading control. Densitometric analyses (right) were performed for 
each group and normalised to b-actin. Values are presented as the mean ± SEM, 
relative to b-actin (n = 6). Significance was determined by one-way ANOVA with 
Bonferroni post-test. **P < 0.01, ***P < 0.001. 
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4.3.4 Influences of FK506 and/or diet-induced obesity on distal small 
intestinal transport proteins 
 
Due to the lower presence of villi, and therefore, the isolation of BBMVs in 
the distal segment of the small intestines, protein levels were measured in 
the homogenate fractions. 
 
In analyses for changes in acid-base proteins in the distal small intestines, 
NHE3 protein could not be detected with western blot applications, which 
was supported by the low relative mRNA expression in this segment and also 
showed no significant changes in all treatment groups (Fig.4.12). No 
changes were also found for NaPi-IIb mRNA expression (Fig.4.13a). 
Unfortunately, due to the poor protein quality of the homogenate fractions 
isolated from this segment, NaPi-IIb protein detection was not optimal and 
although protein quantifications showed a significant decrease in FK506-
treated mice and the high-fat diet-fed groups (Fig.4.13b), without further 
clarification no conclusions in terms of intestinal phosphate absorption can 
be drawn from these observations. A slight but statistically significant 
increase in PiT1 mRNA expression was found in the FK506/HF group 
(Fig.4.13c), with no changes in protein abundance in all treatment conditions 
(Fig.4.13d). However, again, due to the uncertainties with regards to the 
functional role for PiT1, the impact of these changes to this transporter is 
unlikely to be large. 
 
Similar to prior observations in the proximal small intestines, SGLT1 mRNA 
expression was unchanged in all treatment groups and was paralleled with 
no significant changes in protein abundance with very low-to-negligible 
protein detection (Fig.4.14a,b). GLUT2 mRNA also remained unchanged in 
all four groups and GLUT2 protein could not be detected in homogenate 
samples (Fig.4.14c). 
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Figure 4.12. Analysis of the Na+/H+ exchanger, NHE3, in the distal small 
intestine (DSI) after FK506 treatment and/or high-fat feeding. Relative mRNA 
expression of the Na+/H+ exchanger, NHE3, in DSI mucosa scrapes collected from 
mice maintained on a standard or HF diet for 10 weeks and subjected to vehicle or 
FK506 treatment for 14 days. Values are presented as the mean ± SEM, relative to 
b-actin (n = 6). Significance was determined by one-way ANOVA with Bonferroni 
post-test.  
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Figure 4.13. Analysis of the Na+/Pi cotransporters, NaPi-IIb and PiT1, in the DSI 
after FK506 treatment and/or high-fat feeding. Relative mRNA expression and 
protein quantification of the Na+/Pi cotransporters, A, B) NaPi-IIb and, C, D) PiT1, in 
DSI mucosa scrapes and homogenate fractions prepared from mice maintained on 
a standard or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 
14 days. Representative western blots are shown for both proteins (arrow). E) b-
actin (arrow) was run as a loading control. Densitometric analyses (right) were 
performed for each group and normalised to b-actin. Values are presented as the 
mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way 
ANOVA with Bonferroni post-test. *P < 0.05, ***P < 0.001. 
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Figure 4.14. Analysis of the Na+/glucose cotransporter, SGLT1, and the glucose transporter, GLUT2, in the DSI after FK506 treatment 
and/or high-fat feeding. Relative mRNA expression and protein quantification of the Na+/glucose cotransporter, A, B) SGLT1 and relative 
mRNA expression of the glucose transporter, C) GLUT2, in DSI mucosa scrapes and homogenate fractions prepared from mice maintained on 
a standard or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. Representative western blots are shown for 
SGLT1 protein (arrow). b-actin (arrow) was run as a loading control. Densitometric analyses (right) were performed for each group and 
normalised to b-actin. Values are presented as the mean ± SEM, relative to b-actin (n = 6). Significance was determined by one-way ANOVA 
with Bonferroni post-test.  
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4.3.5 Influences of FK506 and/or diet-induced obesity on large 
intestinal transport proteins 
 
As the large intestines are much smaller than the small intestinal segments, 
the collected mucosal scrapes were not sufficient for both mRNA and protein 
analyses, and so only protein analysis was performed on this segment. 
Additionally, because the large intestine does not have villi, protein 
abundances were measured in the homogenate fractions. 
 
As shown, NHE3 protein levels were significantly decreased in the high-fat 
groups with either vehicle or FK506-treatment, compared with FK506-
treatment alone (Fig.4.15). However, a-ENaC remained unchanged in all 
treatment groups (Fig.4.16). 
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Figure 4.15. Analysis of the Na+/H+ exchanger, NHE3, in the large intestines (LI) after FK506 treatment and/or high-fat feeding. 
Representative western blots of the Na+/H+ exchanger, NHE3 (arrow), in large intestinal homogenate fractions prepared from mice maintained 
on a standard or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. b-actin (arrow) was run as a loading control. 
Densitometric analyses (right) were performed for each group and normalised to b-actin. Values are presented as the mean ± SEM, relative to 
b-actin (n = 6). Significance was determined by one-way ANOVA with Bonferroni post-test. *P < 0.05, **P < 0.01. 
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Figure 4.16. Analysis of the epithelial Na+ channel, ENaC, in the LI after FK506 treatment and/or high-fat feeding. Representative 
western blots of the a-subunit of the epithelial Na+ channel, ENaC (arrow), in large intestinal homogenate fractions prepared from mice 
maintained on a standard or HF diet for 10 weeks and subjected to vehicle or FK506 treatment for 14 days. b-actin (arrow) was run as a loading 
control. Densitometric analyses (right) were performed for each group and normalised to b-actin. Values are presented as the mean ± SEM, 
relative to b-actin (n = 6). Significance was determined by one-way ANOVA with Bonferroni post-test.  
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4.4 Discussion 
 
Both cyclosporine (CsA) and tacrolimus (FK506) have been reported to 
influence the development of the individual conditions associated with 
metabolic syndrome in renal transplant patients (Boudreaux et al., 1987; 
Chapman et al., 1987; Grimm et al., 2006; Jevnikar et al., 1988; Kasiske et 
al., 2003; Ligtenberg et al., 2001; Margreiter, 2002; McCune et al., 1998; 
Pirsch et al., 1997; Roth et al., 1989; Schorn et al., 1991; Vincenti et al., 
2002; Woodward et al., 2003). CsA has shown to have a greater impact on 
lipid profiles and blood pressure, while FK506 has been associated with a 
higher incidence of PTDM, which is central to the development of metabolic 
syndrome (Grimm et al., 2006; Kamar et al., 2007; Kasiske et al., 2003; 
Ligtenberg et al., 2001; Margreiter, 2002; McCune et al., 1998; Pirsch et al., 
1997; Vincenti et al., 2002, 2007; Woodward et al., 2003). Due to these 
similarities, it was theorised that CNIs may influence the development of 
metabolic syndrome in renal transplant patients, however, this has not yet 
been investigated. Therefore, the present study sought to compare a model 
of CNI treatment with a model of diet-induced metabolic syndrome, which 
was followed by the examination of changes in transport proteins (at mRNA 
and protein levels) in the kidney and gastrointestinal tract to determine if 
specific cellular transport pathways may contribute to the development of the 
individual conditions associated with metabolic syndrome. 
 
4.4.1 Establishment of a diet-induced model of metabolic syndrome 
 
Metabolic syndrome is a commonly encountered complication following renal 
transplantation and is associated with CVD, graft loss and patient death 
(Pedrollo et al., 2016; Porrini et al., 2006; de Vries et al., 2004). Many animal 
studies using a high-fat feeding model investigated the pathogenic 
mechanisms that underlie its development. As previously mentioned, the 
C57BL/6J mouse strain is a particularly suitable model for studying metabolic 
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syndrome owing to its susceptibility to developing obesity, hyperinsulimeia, 
hyperglycemia and hypertension when placed on a high-fat diet (Black et al., 
1998; Deji et al., 2008; Gallou-Kabani et al., 2007; Surwit et al., 1988, 1995; 
West et al., 1992; Winzell and Ahren, 2004). Other studies using high-fat 
feeding in this strain have also reported compromised immune function and 
atherosclerosis development (Crevel et al., 1992; Paigen et al., 1985). The 
results presented in this chapter demonstrate that high-fat feeding in mice for 
a 10-week period induced systemic changes which were similar to human 
metabolic syndrome including obesity, altered glucose homeostasis and 
possible hypertension. 
 
The clinical diagnosis for metabolic syndrome includes hypertriglyceridemia 
and low plasma HDLs (National Cholesterol Education Program (NCEP), 
2012), however, this was not observed in the present study. Instead, 
hypertriglyceridemia was not observed in either treatment groups and a 
significant increase in plasma HDLs were detected in the high-fat diet-fed 
groups, which conflicts with expected lipid profiles. The reasons for this are 
not yet clear. However, studies in humans and mice fed on diets rich in fat 
and cholesterol also displayed elevated HDL levels and did not develop 
hypertriglyceridemia, which was suggested to be the result of increased HDL 
transport rates and reduced fractional catabolic rates (Brinton et al., 1990; 
Hayek et al., 1993; Schreyer et al., 1998). These investigators proposed that 
dietary fat-induced elevations in HDL levels may be an adaptive response to 
the metabolic load of the high-fat diet, which may support the observations 
seen in the present study.  
 
CNIs have also been associated with elevations in plasma LDLs, and have 
reported the involvement of a number of mechanisms including increased 
LDL oxidation, reduced LDL catabolism via reduced LDL receptor activity or 
a reduction in lipoprotein lipase activity and production, leading to impaired 
LDL clearance (Apanay et al., 1994; Bakar et al., 2009; Rayyes et al., 1996; 
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Tory et al., 2009). In the present study, CNI-treated mice did not exhibit any 
alterations in plasma triglyceride and HDL levels. It is possible that the 
absence of hypertriglyceridemia and hyperlipidemia in these CNI-treated 
mice may be a reflection of the lower incidence of lipid changes associated 
with FK506 over CsA, as confirmed in numerous clinical and animal studies 
(Artz et al., 2003; Baid-Agrawal et al., 2004; Ligtenberg et al., 2001; McCune 
et al., 1998; Pirsch et al., 1997). However, as total- and LDL-cholesterol 
levels were not measured in either models, diet- and CNI-induced 
hyperlipidemia cannot be ruled out. Further analyses are required to 
measure total- and LDL-cholesterol levels as well as LDL oxidation and 
lipoprotein lipase activity to explain for the hypertriglyceridemia observed in 
renal transplant patients treated with CNIs. 
 
Overall, biochemical analyses in mice fed on a high-fat diet displayed 
indications of altered glucose, acid-base and sodium homeostasis which are 
features associated with metabolic syndrome. FK506 treatment did not mimic 
these changes suggesting that CNI treatment alone might not be enough to 
induce the development of metabolic syndrome and that other factors may 
need to be present. In this regard, attention was drawn towards comparisons 
between FK506 treatment alone and in combination with high-fat feeding. 
The model of metabolic syndrome established was enough to permit 
investigations into the renal and intestinal transport proteins that may be 
involved in metabolic syndrome development and, therefore, became 
another main focus of this study. 
 
4.4.2 FK506 treatment and high-fat feeding on renal and intestinal acid-
base and phosphate transport proteins 
 
Patients with metabolic syndrome and type II diabetes mellitus commonly 
display decreased urinary pH and impaired NH4+ excretion, which are clinical 
and metabolic abnormalities associated with hyperuricemia and uric acid 
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nephrolithiasis, and can lead to kidney stone formation (Abate et al., 2004; 
Cameron et al., 2006; Daudon et al., 2006; Maalouf et al., 2007; Sakhaee et 
al., 2002). Studies using Zucker obese and high-fat diet-fed rats have 
suggested that renal lipotoxicity plays a part in the pathophysiology of these 
conditions through impaired NH4+ secretion and Na+/H+ exchange via a 
reduction in renal NHE3 protein and function (Bobulescu et al., 2008). This 
decrease in renal NHE3 protein was further supported in studies with Zucker 
obese rat models (Bickel et al., 2002; Riazi et al., 2006). However, the 
opposite was observed in the present study for the high-fat group and a 
number of possible reasons may explain this.  
 
The more likely reason could be an adaptation to the metabolic load from the 
high-fat diet. From the biochemical analyses, a significant reduction in 
plasma HCO3- , and increased plasma and urinary phosphate in the high-fat 
groups indicate signs of altered acid-base balance and potentially an acidotic 
effect. It is known that under acidotic conditions, the kidneys act to increase 
H+ and NH4+ excretion, reclaim HCO3- and reduce phosphate uptake via an 
upregulation of NHE3 and downregulation of NaPi-IIa transport proteins, 
respectively (Ambühl et al., 1998; Ambuhl et al., 1996; Amemiya et al., 1995; 
Laghmani et al., 1997; Soleimani et al., 1992; Wu et al., 1996). It is possible 
that the kidneys may be trying to adapt by increasing renal NHE3 protein 
expression, to compensate for potential NH4+ build up and the reduction of 
plasma HCO3-, and to provide H+ for luminal titrations. In addition, the 
reduction in NHE3 in the proximal small intestine and large intestine in the 
high-fat diet-fed groups, may be compensating for increased renal NHE3, 
mostly likely to prevent excessive H+ loss. Interestingly, previous proteomic 
studies in mice fed on a high-fat diet showed a downregulation of the 
intestinal basolateral Na+/HCO3- cotransporter, NBCe1 (Wiśniewski et al., 
2015), which could also explain for the reduction in plasma HCO3-. It should 
be noted that as urinary pH, NH4+ and plasma H+ were not examined in the 
			
197				
present study, confirmed impairment of NH4+ excretion and a possible 
acidotic (or hyperuricemic) effect of NH4+ build up cannot be assumed.  
 
Another possible reason for this increase in renal NHE3 in the high-fat diet-
fed groups could be due to the activation of the insulin-PI3K-SGK1 pathway, 
which is known to regulate NHE3 (Fuster et al., 2007; Klisic et al., 2002). 
Previous studies have revealed significant elevations in SGK1 protein 
abundance in SGK1+/+ mice after high-fat feeding as well as a marked 
increase in blood pressure, highlighting a potential contributing role for SGK1 
in hypertension development (Huang et al., 2006). This may suggest that the 
high-fat diet-induced stimulation of the insulin-PI3K-SGK1 pathway could 
account for the over-stimulation of renal NHE3 in this study. However, this 
may also not be the case in the present study, as contrasting studies in fatty 
acid-incubated opossum kidney cell culture models have shown abolished 
and unaffected effects of insulin and SGK1 on NHE3 activity, respectively 
(Bobulescu et al., 2008). Further assessment of the involvement and impact 
of this signalling pathway in this model and in the pathogenesis of post-
transplant hypertension and metabolic syndrome are needed. 
 
Hypophosphatemia is commonly observed with metabolic syndrome and CNI 
use, and has been shown in rodent studies to be related to the dysfunction of 
tubular phosphate reabsorption via a reduction in NaPi-IIa expression 
(Mohebbi et al., 2009; Moz et al., 2004). This downregulation of NaPi-IIa has 
been previously supported in diabetic Zucker obese rats (Bickel et al., 2002). 
In contrast, in the present study, the high-fat diet-fed group had significantly 
elevated plasma and urinary phosphate levels, indicative of 
hyperphosphatemia and phosphaturia, with no changes in the major Na+/Pi 
transport proteins. The consequences of hyperphosphatemia have been 
linked to disorders in bone remodelling with excessive bone resorption rates 
compared with bone formation rates. This results in calcium and phosphate 
release and an increased risk for vascular calcification and cardiovascular 
			
198				
disease, as demonstrated in previous studies of high-fat diet-fed LDL-
receptor-deficient mice, another obese mouse model for human metabolic 
syndrome and chronic kidney disease (Davies et al., 2003, 2005). Further 
studies of energy-rich, high-fat feeding in rats with normal renal function and 
uninephrectomised rats showed increased phosphate retention due to 
impaired renal phosphate excretion and promoted vascular calcification 
(Raya et al., 2016). Despite no accompanied increases in renal phosphate 
excretion, significant elevations of the plasma fibroblast growth factor-23 
(FGF23, a negative regulator of phosphate homeostasis) were also observed 
(Raya et al., 2016). These findings implicate resistance to the phosphaturic 
actions of FGF23 in these high-fat diet-fed animals, and was also proposed 
to be the result of reduced renal klotho expression, a regulatory hormone 
also known to affect phosphate metabolism (Raya et al., 2016). Others have 
also reported increased serum phosphate with no change in serum FGF23 
and parathyroid hormone (PTH) levels and attenuated responses of both 
these regulators following oral phosphate administration in patients with type 
II diabetes, leading to the progression of vascular calcification and 
atherosclerosis (Yoda et al., 2012). The mechanisms underlying the impaired 
phosphaturic responses to FGF23 and PTH under high-fat feeding and 
metabolic syndrome-affiliated conditions are not yet clear. The impact of 
these regulators on phosphate retention and excretion in the present study 
also remains to be clarified.  
The hyperphosphatemia and phosphaturia features observed in the high-fat 
groups may be attributed to a number of factors including the potential 
induction of renal dysfunction, as indicated by the creatinine values. This 
may have led to increased phosphate retention and deposition into the 
plasma from bone tissue. It is not clear why renal NaPi-IIa protein expression 
was unchanged with high-fat feeding considering the biochemical data 
obtained for plasma and urinary phosphate. However, a time-course study by 
Bielesz et al, showed that diurnal rises in renal phosphate excretion was not 
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accompanied by a change in NaPi-IIa protein (Bielesz et al., 2006). These 
authors also observed an increase in GFR, filtered load and tubular 
threshold, which were suggested as the main factors that determine overall 
renal phosphate excretion when faced with little or no changes in NaPi-IIa 
protein abundance and activity (Bielesz et al., 2006). However, in the present 
study, plasma and urinary creatinine levels indicate decreased GFR in the 
high-fat diet-fed mouse model and so contrasts with this conclusion. Another 
alterative explanation was that, in addition to regulation by BBM protein 
abundance, NaPi-IIa transporter activity may also be regulated.  
 
Interestingly, recent proteomic analyses in small intestinal mucosa samples 
from high-fat diet-fed mice have shown a downregulation of the intestinal 
NaPi-IIb cotransporter (Wiśniewski et al., 2015), which could explain for the 
relative decrease in NaPi-IIb protein expression in the high-fat group in the 
distal intestinal segment. However, this requires re-analysis as it is most 
likely that the decrease in NaPi-IIb in the distal small intestinal segment was 
related to the poor protein preparations used. Overall, further studies are 
required for the assessment of the influences of high-fat feeding on NaPi-IIa 
and NaPi-IIb cotransporter activity to confirm any impact of these transport 
proteins on phosphate retention and excretion, and the examination of 
phosphate loading from bone mass to account for the hyperphosphatmic 
effects observed.  
 
4.4.3 FK506 treatment and high-fat feeding on renal and intestinal 
sodium-glucose transport proteins 
 
Hyperinsulinemia and insulin resistance has been observed in rodents fed on 
a high-fat diet and is one of the main components of metabolic syndrome 
(Deji et al., 2008; Gallou-Kabani et al., 2007; Surwit et al., 1988, 1995; 
Winzell and Ahren, 2004; Woods et al., 2003). In this study, plasma glucose 
			
200				
levels were significantly elevated in the FK506-treated and the high-fat diet-
fed groups. This increase in plasma glucose in the FK506-treated group is in 
line with the known diabetogenic effects of FK506. Although these levels 
were not high enough to be considered clinically diabetic and plasma insulin 
levels were not measured to confirm hyperinsulinemia and insulin resistance 
in these mice, these observations are evidently indicative of altered glucose 
homeostasis and possible onset of insulin resistance.  
 
Studies in established SGLT2 and SGLT1 knockout mouse models have 
reported increased renal SGLT2 expression and SGLT activity as the 
determinant for hyperglycemia and a possible contributor for diabetes (Vallon 
et al., 2013). In the present study, renal SGLT2 protein expression was 
significantly decreased in the high-fat diet-fed groups. Intestinal SGLT1 
protein was also decreased in these groups and no changes were found for 
renal and intestinal GLUT2. The findings are in contrast to these studies in 
knockout mice, however, there are numerous reports that have shown 
variable impacts of diabetes on SGLT-mediated transport between different 
models. Studies in a number of streptozotocin-induced diabetic animal 
models have demonstrated both increased (Blank et al., 1985) and 
decreased (Harris et al., 1986; Yasuda et al., 1990) SGLT-mediated glucose 
transport. This variability was also found in mRNA and protein analyses of 
SGLT transporters which have also shown increased (Vestri et al., 2001), 
decreased (Harris et al., 1986; Yasuda et al., 1990) and unchanged 
(Dominguez et al., 1994) levels in these animal models. These 
inconsistencies were thought to be due to differences in the dose of 
streptozotocin used and the severity of induced diabetes between studies.  
 
Furthermore, a study comparing rat models of type I and type II diabetes, 
and rats with metabolic disruptions, via junk food (high in fat and sugar) or 
high-fat feeding, demonstrated differential responses of the renal glucose 
transporters (Chichger et al., 2016), suggesting that other factors may be 
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involved in transport protein regulation. While the type II diabetic rats and 
junk food-fed rats were accompanied by increased SGLT2, SGLT1 and 
GLUT2 expression, the type I rat model and rats fed on the high-fat diet 
demonstrated increased GLUT2 expression only (Chichger et al., 2016). This 
implies that differential changes in renal Na+/glucose cotransporters, and 
thus, the development of insulin resistance and type II diabetes appears to 
be influenced by the composition of the diet. Additional studies have been 
performed to investigate the effects of different compositions of diets on 
glucose transport in the small intestine and have shown variable effects. In 
one study, rats fed on a high-starch/low-fat diet displayed increased SGLT1 
and GLUT2 mRNA expression in the jejunum, compared to rats fed on a low-
starch/high-fat diet (Inoue et al., 2015). Another study reported significantly 
increased SGLT1 expression in the jejunum of rats fed a high-fat diet 
consisting of medium-chain fatty acids compared with a high-fat diet 
consisting of long-chain fatty acids (Yasutake et al., 1995). In addition, recent 
proteomic analyses in homogenised small intestinal mucosa samples from 
mice fed either a normal or high-fat diet (the same diet which was used in the 
present study), revealed a significant difference in 11% of intestinal proteins 
between these diets (Wiśniewski et al., 2015). This included a 
downregulation of the SGLT1 and GLUT2 transporters in the high-fat diet-fed 
group (Wiśniewski et al., 2015), which is in line with the SGLT1 data 
presented in this study.  
 
Taken together, these studies show that renal and intestinal glucose 
transporters are not regulated by the same factors in different diets and that 
the ratios of fat content and carbohydrate-to-fat can differentially influence 
glucose transporter expression and account for the variable results between 
studies. Therefore, the relative decrease seen for renal SGLT2 and intestinal 
SGLT1 transport proteins may be explained by the composition of the high-
fat diet. However, it is also likely that these reductions are compensatory 
responses to elevations in plasma glucose levels (induced by the 
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gastrointestinal-renal signalling axis), and/or possibly increased glucose 
transporter activity, which requires further clarification. Also, although GLUT2 
remained unchanged in this study, as transport activity was not measured its 
diabetogenic influence in the high-fat groups cannot be fully excluded. 
 
Another possible regulator and contributor in the pathogenesis of insulin 
resistance in patients with metabolic syndrome or diabetes is the AMP-
activated protein kinase, AMPK. This kinase has been previously shown as a 
positive regulator of SGLT1 and NKCC2 (Fraser et al., 2007; Richardson et 
al., 2011; Sopjani et al., 2010), and a negative regulator of NaPi-IIa 
(Dërmaku-Sopjani et al., 2013). In rodent studies with high-fat feeding and in 
models of insulin resistance, both AMPK mRNA, protein and activity has 
shown to be reduced, along with impaired insulin-stimulated glucose uptake 
and disrupted glucose homeostasis, all of which was improved following 
treatment with AMPK activators (Buhl et al., 2002; Cool et al., 2006; Halseth 
et al., 2002; Liu et al., 2006; Song et al., 2002). These findings were further 
supported in AMPK-deficient rodent studies with high-fat feeding (Fujii et al., 
2008). These studies demonstrate a possible link between AMPK and high-
fat diet-induced insulin resistance and, in the case of this study, suggests 
that the downregulation of AMPK with high-fat feeding may contribute 
towards the downregulation of SGLT1. However, this does not explain the 
unchanged levels of NaPi-IIa and NKCC2 transport proteins and requires 
further investigation. 
 
4.4.4 FK506 treatment and high-fat feeding on renal and intestinal 
sodium transporters and channels 
 
Hypertension is another condition associated with metabolic syndrome and, 
as already mentioned, is a significant risk factor for renal dysfunction 
following transplantation. As previously discussed in Chapters 1 and 3, the 
dysregulation of renal sodium transport proteins and sodium reabsorption is 
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fundamental to the development of elevated blood pressure. These renal 
sodium transport proteins include NKCC2, NCC and ENaC. 
 
There are a number of studies in Zucker obese rat models which have shown 
conflicting results regarding changes in NKCC2 transporter levels. In one 
study, no significant changes in NKCC2 protein abundance was observed 
(Bickel et al., 2001), which supports the findings from the present study. 
However, contrasting studies have found a decrease in whole kidney NKCC2 
and an increase in outer medullary fractions (Bickel et al., 2002; Riazi et al., 
2006). It is possible that the absence of changes in NKCC2 in the present 
study is related to decreased levels of known regulators of NKCC2. This 
includes vasopressin, which was found to be lower in Zucker obese rats 
(Bickel et al., 2001). However, it should be noted that these studies did not 
measure the phosphorylated active form of NKCC2 and, due to commercially 
unavailable antibodies and limited antibody stocks, this was also not 
assessed in the present study and so any sodium-retaining effects by this 
transporter cannot be ruled out. 
 
As already discussed in Chapter 3, the NCC cotransporter was identified as 
a regulator of blood pressure and plays an important role in hereditary forms 
of hypertension and following renal transplantation. NCC protein levels were 
unchanged in this study. This was similarly reported in previous analyses of 
renal sodium transporters in Zucker obese rats (Bickel et al., 2002). 
However, pNCC was significantly increased following FK506 treatment and 
in mice fed on the high-fat diet, indicative of sodium retention and, indirectly, 
possible elevations in blood pressure. Elevated blood pressure and 
increased phosphorylation/activation of NCC and the WNK-SPAK/OSR1 
pathway have been previously shown in diabetic db/db mice and Zucker 
obese rat models (Komers et al., 2012; Nishida et al., 2012; Sohara et al., 
2011). The conclusions drawn from these reports were suggested to be the 
result of elevations in plasma insulin levels and increased PI3K/Akt pathway 
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signalling, which are downstream substrates of insulin signalling (Komers et 
al., 2012; Nishida et al., 2012; Sohara et al., 2011). These elevations in blood 
pressure and NCC phosphorylation were found to be corrected in kinase-
dead SPAKT243A/+ and OSR1T185A/+ knock-in db/db mice (Nishida et al., 2012), 
further clarifying the involvement of WNK and SPAK/OSR1 kinases on NCC 
phosphorylation in models of metabolic syndrome. These studies suggest an 
important regulatory role for insulin signalling, via the PI3K/Akt pathway, as 
the driving force for the activation of WNK-SPAK/OSR1 signalling and NCC 
phosphorylation and function in patients with metabolic syndrome, and in the 
pathogenesis of salt-sensitive hypertension. Therefore, increased circulating 
insulin levels most likely explains for the increase in pNCC protein in the 
high-fat diet-fed group, but this requires confirmation. NCC phosphorylation 
is also known to be regulated by the SGK1 kinase and is also a known 
regulator of the WNK signalling cascade (Vallon et al., 2009). However, 
SGK1 phosphorylation was not seen in db/db mice fed low- or high-salt diets 
(Nishida et al., 2012), suggesting that SGK1 may not be involved in 
activating the WNK-SPAK/OSR1 cascade in some diabetic mouse models. 
 
The ENaC sodium channel is another major protein involved in regulating 
blood pressure. ENaC is regulated by a number of mediators, including 
aldosterone and SGK1. Increased plasma aldosterone levels have been 
observed in patients with metabolic syndrome and in obese animals (Bochud 
et al., 2006; Engeli et al., 2005; Kidambi et al., 2007; Nagase et al., 2006). In 
fact, weight loss studies demonstrate significant reductions in aldosterone, 
components of the renin-angiotensin II-aldosterone (RAA) system, and blood 
pressure (Engeli et al., 2005; Tuck et al., 1981), implicating the RAA system 
in the development of obesity-induced hypertension. The contribution of 
ENaC to the sodium-retaining effects in obesity-related conditions have 
differed between studies. In one study, Zucker obese rats aged 2 and 4 
months showed a significant increase in the b-ENaC subunit while the a- and 
g-ENaC subunits were unchanged (Bickel et al., 2001; Riazi et al., 2006). 
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Similarly, another study by the same group in 6-month Zucker obese rats 
also showed a significant increase in b-ENaC, but found a marked reduction 
in a-ENaC (Bickel et al., 2002). The conclusions drawn from these studies 
demonstrated differential regulation of the ENaC subunits. However, the 
physiological relevance of this differential regulation is not clear and the 
overall effect of increased b-ENaC abundance on sodium transport without 
the accompanying change in the other subunits could not be deduced. 
Furthermore, a study by May et al, showed that the synthesis and abundance 
of the a-ENaC subunit is the rate limiting factor for the assembly of the ENaC 
complex (May et al., 1997). Electrophysiological experiments in oocyte 
expression models have also established that the assembly of the subunits 
and functionality of the channel was dependent on a-ENaC abundance 
(Canessa et al., 1994). Therefore, the marked reduction in a-ENaC 
abundance may result in an overall downregulation of the ENaC sodium 
channel at the apical membrane. The reduction in a-ENaC in the FK506-
treated group observed in the present study support the previous findings 
and conclusions drawn in Chapter 3, and the findings from the high-fat diet-
fed group are in line with previous studies in 6-month Zucker obese rat 
models (Bickel et al., 2002). However, the reasons for this reduction are not 
known. As the a-ENaC subunit is known to be upregulated by aldosterone 
(Loffing et al., 2000; Masilamani et al., 1999; Pacha et al., 1993), an increase 
in protein abundance was expected in the high-fat diet fed group. It is 
possible that this reduction is related to compensatory/adaptive responses to 
increased sodium retention induced by renal NHE3 and pNCC transport 
proteins, to reduce renal sodium reabsorption and blood pressure. Another 
possibility is that this reduction may act as a counteracting response to 
increased ENaC activity. Functional studies are required to measure channel 
activity in these mice. 
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4.4.5 Limitations and conclusions 
 
To date, this is the first study to compare a model of CNI-administration with 
a diet-induced model of metabolic syndrome to determine whether CNIs may 
predispose renal transplant patients to metabolic syndrome and to analyse 
how the abundances of major electrolyte transport proteins may be affected 
during metabolic syndrome development. 
 
In this study, mice fed on a diet rich in fat had significant weight gain 
compared with lean normal diet-fed mice, despite no indications of 
hyperlipidemia and hypertriglyceridemia. Selective increases in renal NHE3 
and pNCC protein abundance were observed in the high-fat diet-fed group, 
which would most likely contribute towards the sodium-retaining effects, 
leading to hypertension. As previously described, blood pressure 
measurements were not available and so elevations in blood pressure could 
not be confirmed in this model. Therefore, for future clarification, 
measurements of blood pressure with the use of telemetry analysis would 
allow for confirmation of a hypertensive response to the high-fat diet and 
FK506 treatment. Alterations in plasma glucose are indicative of altered 
glucose homeostasis, however, further investigations are required to confirm 
potential insulin resistance and impaired insulin-stimulated glucose uptake. 
Although the plasma biochemistry results indicate hyperphosphatemia in the 
high-fat diet-fed groups, studies suggest that this could be linked to 
phosphate deposits from the bone into the plasma and for future studies, 
bone mass and phosphate content would be examined. 
 
The establishment of a model for metabolic syndrome is difficult, as it 
requires the exhibition of the exact pathological changes associated with 
metabolic syndrome, which is different for each patient. Currently used 
rodent models vary in terms of eitiologies and it remains unclear which of 
these models is the most appropriate to study human metabolic syndrome. 
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Some characteristics, such as hyperglycemia and hyperinsulinemia, are not 
consistently observed in some mouse models, and obesity is not as 
dependent on dietary factors, as the degree of metabolic dysfunction during 
high-fat feeding may also depend on the genetic background. The C57BL/6J 
mouse strain was used in this study due its high susceptibility to obesity 
development and insulin resistance/glucose intolerance when placed on a 
high-fat diet (Gallou-Kabani et al., 2007; Surwit et al., 1988, 1995; Winzell 
and Ahren, 2004), however, it is unclear whether these characteristics are 
related to a genetic factor and may also contribute to renal, lipid and 
metabolic abnormalities. Genetically engineered diabetic rodent models 
which are used to study hyperinsulinemia are also limited as the targeted 
gene for knockdown may be related to other important signalling pathways 
and so the inactivation or activation of investigated pathways may in fact be 
linked to these genetic modifications. Furthermore, significant compensatory 
mechanisms can occur in knockout and knock-in animal models which can 
also affect the outcome of the investigations.  
 
Overall, the diet-induced obese mouse model used in this study did not 
exhibit all the clinical features of metabolic syndrome and did not completely 
show comparable changes in renal and intestinal transport proteins to FK506 
treatment alone. The results from this study, extends the conclusions drawn 
from Chapter 3 that the presence of other stimuli, rather than CNI treatment, 
are the main contributing factors to alterations in glucose, sodium, and acid-
balance and in the development of hypertension and metabolic syndrome. 
Despite the limitations of establishing a model of metabolic syndrome, this 
model of high-fat feeding permitted the analyses and identification of the 
renal and intestinal transport proteins that may be involved in the 
development of the individual components that comprise metabolic 
syndrome.  
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Chapter V 
Urinary exosome isolation and analysis of (p)NCC levels in 
calcineurin inhibitor-administered and Gitelman syndrome 
patients 
5  
5.1 Introduction  
5.1.1 Urinary exosomes 
 
The use of rodent models for CNI-induced hypertension has provided 
significant insights into the transport proteins involved in sodium retention 
and the main contributors to elevations in blood pressure, namely via 
enhanced phosphorylation of the NCC cotransporter within the DCT. This 
has been further supported through immunohistochemical analyses in renal 
biopsy samples collected from renal transplant patients (Hoorn et al., 2011). 
However, protein abundance is difficult to measure in these patients due to 
the inability to obtain substantial amounts of renal tissue from live patients for 
protein analysis. Immunohistochemical analyses are also often limited owing 
to the common loss of structural integrity following collection and the under-
representative size of the sample obtained with regards to the whole kidney. 
Furthermore, renal biopsy procedures are uncomfortable and are often 
followed with complications such as bleeding and risks of internal damage to 
the targeted organ or neighbouring areas.  
 
Currently, efforts are being directed towards the development of a non-
invasive technique to identify novel biomarkers for the early detection and 
accurate diagnosis of renal disease, which would effectively improve the 
response to treatment and prevent increasing severities. In particular, the 
isolation and use of urinary exosomes has received substantial attention as a 
source of intracellular renal biomarkers for the diagnosis of renal diseases. 
Urine is an ideal biological sample alternative due to the ease and non-
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invasive nature of collection. In addition, unlike renal biopsy procedures, 
urinary exosomes provide a complete molecular representation of the entire 
urinary tract.    
 
Urinary exosomes are characterised as small membrane vesicles, ranging in 
diameter between 40 – 100 nm, with a ‘cytoplasmic-side inward’ orientation 
(Pisitkun et al., 2004). The formation and excretion of these vesicles has 
been described as a three-step process; 1) membrane protein ubiquitination 
and endocytosis, 2) fusion with the outer membrane of late endosomes 
called multivesicular bodies (MVBs) and then 3) fusion with the apical 
membrane of the renal epithelial cells which then releases exosomes into the 
urine. Urinary exosomes contain numerous proteins and nucleic acids, which 
may potentially reflect the physiological and pathological state of their cells of 
origin (Lv et al., 2013; Miranda et al., 2010; Pisitkun et al., 2004), and may 
therefore provide a non-invasive approach for determining the functional 
state of the kidney following renal transplantation and/or in renal- and 
systemic-related diseases. 
 
5.1.2 Urinary exosome biomarkers of renal disease 
 
In initial studies, membrane-bound proteins such as AQP2, NHE3, NKCC2 
and NCC were detected in low-density membrane vesicles isolated from 
human urine by ultracentrifugation and were suggested as markers for renal-
related disorders (du Cheyron et al., 2003; Kanno et al., 1995; McKee et al., 
2000). NHE3 was proposed as a novel candidate marker of renal tubule 
damage, whereby patients with acute tubular necrosis or prerenal azotemia 
presented significantly increased levels of urinary NHE3 compared with 
controls (du Cheyron et al., 2003). In addition, AQP2 was also exploited as a 
marker in clinical studies of patients with water-balance disorders, which was 
confirmed with immunoblotting, radioimmunoassay and immunoelectron 
microscopy applications in both urine samples and isolated urinary low-
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density membrane vesicles (Funayama et al., 2004; Kanno et al., 1995). 
These studies demonstrating the presence of membrane proteins in these 
small, low-density membrane vesicles led to its later characterisation as 
exosomes and facilitated closer analyses of the excretion processes of AQP2 
and other membrane proteins. 
 
Exosomes were first classified in urine by Pisitkun et al, in 2004, who 
demonstrated their potential use for biomarker discovery (Pisitkun et al., 
2004). In their study, proteomic analysis using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) identified numerous proteins directly 
involved in the endosomal pathway, exosome synthesis and the components 
responsible for MVB formation (Pisitkun et al., 2004). In addition, 295 
proteins originating from the renal tubule were identified, 21 of which were 
already known to be associated with specific renal diseases and blood 
pressure regulation (Pisitkun et al., 2004). The use of the highly sensitive LC-
MS/MS-based techniques allowed for the identification and qualitative and 
quantitative analysis of proteins from single samples and has been used in 
further large-scale proteomic profiling studies in urinary exosomes from 
normal human urinary samples (Gonzales et al., 2009). In their study, 
Gonzales et al identified 1,132 proteins, including 14 phosphoproteins 
(including pNCC and pNKCC2) and 117 proteins associated with diseases, 
34 of which were renal disease- and/or hypertension-related proteins 
(Gonzales et al., 2009). From both these investigations, the authors created 
an online urinary exosome protein database 
(https://hpcwebapps.cit.nih.gov/ESBL/Database/Exosome/), which provides a 
list of the identified 1160 proteins in urinary exosomes as well as potential 
disease-related biomarkers.  
  
Since these early proteomic analyses, many more studies have attempted to 
identify and evaluate biomarkers for renal, urogenital and systemic diseases 
using urinary exosomes as the starting material (Cheruvanky et al., 2007; 
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van der Lubbe et al., 2012; Pisitkun et al., 2012; Zhou et al., 2006a, 2006b, 
2008). To date, a variety of promising biomarkers have been identified. For 
example, investigations in urinary exosomes isolated from patients with acute 
kidney injury (AKI) have identified changes in proteins such as Fetuin-A 
(Sonoda et al., 2009; Zhou et al., 2006b), activating transcription factor-3 
(ATF3) (Zhou et al., 2008), and aquaporin-1 (AQP1) (Sonoda et al., 2009), 
as possible markers for the early detection of AKI. Wilms tumor-1 (WT-1) 
was also identified as a marker for glomerular disease and diabetic 
nephropathy (Jiang et al., 2009; Zhou et al., 2008), and several biomarkers 
have been suggested for genetic renal diseases, such as Gitelman 
syndrome, Bartter syndrome and Pseudohypoaldosteronism II (PHAII) 
(Gonzales et al., 2009; Isobe et al., 2013; Joo et al., 2007; van der Lubbe et 
al., 2012). In patients with Gitelman syndrome and Bartter syndrome type I, 
little to no-detection for NCC and NKCC2 proteins was observed in urinary 
exosomes, respectively (Corbetta et al., 2015; Gonzales et al., 2009; Isobe et 
al., 2013; Joo et al., 2007), while patients with PHAII display increased 
urinary excretion of NCC and pNCC (Adachi et al., 2010; Isobe et al., 2013; 
Mayan et al., 2008), which was also observed in rodent models of 
aldosteronism and patients with primary hyperaldosteronism (van der Lubbe 
et al., 2012). 
 
Urinary exosome-based approaches continue to emerge as important tools 
for the detection of biomarkers of renal- and systemic-related conditions. 
However, despite this promising outlook for utilising urinary exosome 
analysis in clinical settings, their use is hampered by the current lack of 
efficient and optimised methods for urine collection/storage, exosome 
isolation and protein normalisation/quantification, all of which will be 
discussed in the following sections.   
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5.1.3 Collection and storage of urine samples 
 
The first challenge encountered with the urinary exosome isolation process is 
the timing of urine collection, 24-hour vs spot urine. Ideally, exosome 
isolation from 24-hour urine samples would allow for the calculation of 
biomarker excretion rates over the 24-hour period, which would be highly 
representative of overall kidney function and would allow quantitative 
normalisation and comparisons of protein levels between patients. 
Unfortunately, this timed collection approach is often complicated by low 
patient compliance and would ultimately lead to unreliable results. Therefore, 
investigators have used and compared total protein levels from spot urine 
collections of first (overnight) and second (fresh) morning urine. Initial 
drawbacks for the use of first morning urine were related to concerns of 
bacterial contamination and possible protein degradation due to long 
residence in the bladder and, in this regard, second morning urine was 
suggested to be best suited for exosome isolation. However, comparisons of 
exosome proteins from first and second urine collections revealed similar 
amounts of total protein and exosome recovery with both collections (Zhou et 
al., 2006a), suggesting minimal protein degradation within the bladder/urinary 
tract and demonstrating that both first and second morning urine can be used 
for exosome isolation. 
 
Following urine collection, three important steps have been highlighted for 
consideration to ensure efficient preservation/storage of urine and exosome 
extraction; 1) the addition of protease inhibitors following collection, 2) short- 
and long-term storage and 3) extensive vortexing after thawing (Oosthuyzen 
et al., 2013; Zhou et al., 2006a). 
 
Once urine has been collected, optimal storage conditions are essential to 
prevent another common problem, proteolysis. It has been shown that 
urinary exosome degradation can occur within 2 hours of urine collection at 
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room temperature (Oosthuyzen et al., 2013). For the stability and 
preservation of urinary exosomes, it was recommended that protease 
inhibitors be immediately added to urine samples to prevent protein and 
exosome degradation (Oosthuyzen et al., 2013; Zhou et al., 2006a). The 
typical cocktail of protease inhibitors includes the serine and cysteine 
protease inhibitors PMSF and leupeptin, and a preservative such as sodium 
azide. Suitable storage conditions and extensive vortexing are also required 
for further preservation of exosomal proteins and high exosome recovery 
after thawing. Different storage temperatures (-80°C, -20°C and 4°C) and 
short- and long-term periods (1 week and 7 months, respectively), have been 
previously compared and have found, with confirmation by nanoparticle 
tracking analysis (NTA), that long-term storage at -80°C provides the most 
optimal and stable conditions compared with urine stored at -20°C and 4°C 
(Oosthuyzen et al., 2013; Zhou et al., 2006a). Storage at -20°C was 
particularly found to be the least favourable condition and was associated 
with a major loss in urinary exosome-related proteins (Oosthuyzen et al., 
2013; Zhou et al., 2006a). Extensive vortexing after thawing of samples 
stored at -80°C was also found to have the highest recovery of exosomes by 
up to 100% compared with urine stored at -20°C which recovered only 87% 
of exosomes after extensive vortexing (Zhou et al., 2006a). Overall, it is 
recommended that following collection, urine samples are supplemented with 
protease inhibitors, immediately stored at -80°C (for long-term) and, upon 
thawing/processing, are extensively vortexed for maximised exosome 
recovery. 
 
5.1.4 Urinary exosome isolation 
 
Several studies have been conducted to develop optimal methods for faster 
and more efficient isolation of urinary exosomes. Ultracentrifugation was the 
initial isolation method used which, following urine collection and protease 
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inhibitor addition, involves a two-step differential centrifugation protocol; a 
low-speed spin (17,000 x g) to remove cellular debris, followed with a high-
speed spin (200,000 x g) for 1-hour to pellet the exosomes. This protocol has 
shown to be the most effective and reproducible method for yielding intact 
exosomes, but is also problematic as it requires access to expensive 
instrumentation and is a very time-consuming process. Furthermore, the 
isolated exosome pellet is commonly contaminated by highly abundant 
proteins such as albumin and, in particular, uromodulin (also known as 
Tamm-Horsfall protein (THP)), which entraps a large proportion of exosomes 
in double-helical fibrils, preventing efficient exosome isolation and interfering 
with mass spectrometry and western blotting analyses (Fernández-Llama et 
al., 2010; Pisitkun et al., 2004). This polymeric THP network is often reduced 
by the addition of dithiothreitol (DTT) before the high-speed spin but this 
does not completely removal all THP and interfering abundant proteins 
(Fernández-Llama et al., 2010; Pisitkun et al., 2004). Alternatively, additional 
steps in the ultracentrifugation stage can be used to separate exosomes and 
the contaminating proteins based on 1) density, by a sucrose gradient or 
double-cushion ultracentrifugation (Raj et al., 2012), or by 2) molecular 
weight, by ultracentrifugation followed with size exclusion chromatography 
(UC-SEC) (Rood et al., 2010), but this makes it even more time-consuming 
and expensive. Current studies are attempting to refine faster and efficient 
exosome isolation methods that are more accessible to standard hospital 
laboratories through use of membrane filtration and precipitation protocols. 
However, these methods have yielded variable results. Ultrafiltration 
methods have included using commercially available nanomembrane 
concentrators to filter exosomes, followed by a low-speed centrifugation at 
3,000 x g for around 10 – 30 minutes (Cheruvanky et al., 2007). Although this 
technique was able to reduce the exosome isolation time to 0.5 – 2 hours, it 
also led to a low yield of urinary exosomes compared with the standard 
ultracentrifugation method and was complicated with protein accumulation on 
the filters, which could block further flow and complete protein collections. 
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Precipitation methods using a commercially available kit called ExoQuick-TC 
has also recently received significant attention, although this method is 
tailored more towards the isolation and analyses of exosomal nucleic acids. 
This kit omits the ultracentrifugation step and, in comparative studies, has 
shown significantly high qualitative and quantitative yields of exosomal 
miRNA and mRNA compared with the ultracentrifugation and 
nanomembrane filtration approaches, but only with using a modified version 
of the original protocol, which involved pellet resuspension in isolation 
solution/DTT and an additional low-speed spin step (similar to the standard 
ultracentrifugation method), prior to the addition of the ExoQuick-TC 
precipitation agent (Alvarez et al., 2012). Other studies have used a 
combination of exosome isolation methods such as ultrafiltration followed 
with exosomal RNA extraction kits (Channavajjhala et al., 2014). Overall, an 
optimal isolation method has still not yet been defined and from current 
investigations, different methods may be required depending on the research 
question. 
 
5.1.5 Normalisation 
 
Another challenge researchers face in the urinary exosome isolation process 
is defining a method of normalisation and quantification to accurately 
compare changes in biomarkers between patients and control exosome 
samples. Urine concentration is widely variable and without normalising 
methods, analyses of candidate urinary exosome biomarkers and 
comparisons between patients can lead to incorrect conclusions. Several 
methods have been investigated, including time-, urinary creatinine-, THP- 
and total protein-normalisation.  
 
Ideally, as already mentioned, isolation and normalisation of exosomes from 
timed 24-hour urine collections (timed-normalisation) would be the most 
accurate method based on measurements and comparisons of the excretion 
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rate of exosomal biomarkers. However, this approach is limited by low 
patient compliance and so creatinine and protein normalisations are 
alternatively used. Previous studies have reported equal exosome-
associated proteins within samples when normalised to urinary creatinine, 
suggesting this as the best option for clinical settings (Zhou et al., 2006a). 
Normalisation to urinary creatinine in spot urine essentially overcomes the 
complications of obtaining timed urine collections because urinary creatinine 
is assumed to be excreted at a constant rate. Unfortunately, this method is 
also limited, as it does not take into account conditions of renal diseases, 
such as acute kidney injury, where creatinine excretion rates are unstable. 
Protein normalisation methods to a particular protein in the urine have also 
been proposed. These proteins have included using THP or exosomal 
markers such as apoptosis-linked gene-2-interacting protein X (ALIX) and 
tumour susceptibility gene (TSG)-101 (Fernández-Llama et al., 2010; Zhou et 
al., 2006a). However, further studies are required to validate these as 
normalising proteins and to determine whether these proteins are constant 
under different pathophysiological conditions, which is currently unknown. 
More recent methods using the nanoparticle tracking analysis systems have 
also been utilised for exosome counting and analyses in whole urine based 
on their size (Oosthuyzen et al., 2013), which would be less time-consuming 
and would provide a more optimal normalising procedure but again requires 
access to expensive equipment.  
 
5.1.6 Aims of this study 
 
Urine is an ideal biological sample due its easy, immediate and non-invasive 
collection. The discovery of urinary exosomal biomarkers of disease has 
greatly inspired many investigations in attempts to exploit their use in 
diagnostic and therapeutic settings. However, this technique is yet to be fully 
established and some challenges remain at the urinary exosome isolation 
and normalisation stages. Despite this, many candidate biomarkers have 
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been identified including NCC and pNCC for which excretion of these 
proteins is significantly increased in patients with PHAII and decreased in 
patients with Gitelman syndrome (Adachi et al., 2010; Corbetta et al., 2015; 
Isobe et al., 2013; Joo et al., 2007; Mayan et al., 2008). In recent studies, 
western blot analyses of urinary exosomes of hypertensive CNI-treated renal 
transplant patients also revealed significantly increased urinary excretion of 
total NCC and phosphorylated NCC proteins compared with non-CNI treated 
controls, and was correlated with blood pressure responses to thiazides 
(Esteva-Font et al., 2014; Rojas-Vega et al., 2015; Tutakhel et al., 2017). 
This is consistent with previous observations and conclusions that NCC is 
the main contributor to CNI-induced hypertension (Hoorn et al., 2011; 
Melnikov et al., 2011). 
  
In the work described in this chapter, the standard ultracentrifugation protocol 
for urinary exosome isolation was used in urine samples from CNI-
administered renal transplant patients and Gitelman syndrome patients. 
These samples were normalised to both urinary creatinine and ALIX protein, 
and analysed with western blot applications. This study was conducted with 
the aim of aiding future developments for this non-invasive method to allow 
early detection/diagnosis and effective treatment for renal dysfunction 
following renal transplantation and in renal-related diseases. Further aims of 
this chapter were to also use this technique in mice to facilitate the analyses 
of other renal proteins in mouse models of hypertension and/or renal-related 
conditions. 
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5.2 Materials and methods 
5.2.1 Patients 
 
The protocols used received full ethical approval from the Royal Free 
Hampstead NHS Trust, NHS Research Ethics Committee and informed 
consent was received from all patients and controls. Further information on 
these patients are described in Section.2.6. 
 
5.2.2 Human plasma and urine biochemistry 
 
Routine plasma and urine samples were collected on the day of renal 
biopsies and clinical appointments. Biochemical analyses were performed as 
described in Section.2.6.2, by the Department of Clinical Biochemistry 
(Royal Free Hospital, London, UK). Urinary creatinine was measured as 
described in Section.2.1.6. 
 
5.2.3 Urinary exosome isolation 
 
Urinary exosomes were prepared as described in Section.2.6.3 or by 
Gonzales et al (Gonzales et al., 2010). The final exosome pellet was 
dissolved in 100µl of 2x laemmli sample buffer and stored in -80°C until 
further use.  
 
5.2.4 Silver nitrate staining 
 
Following SDS-PAGE, gels were subjected to staining with silver nitrate, as 
described in Section.2.5.7. 
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5.2.5 Western blot analysis 
 
Prior to loading on SDS-PAGE gels, samples were heated at 65°C for 15 
minutes. Sample loading amounts were normalised to the patient with the 
lowest urinary creatinine. Western blot protocols were carried out as 
described in Section.2.5.6. Following visualisation, membranes were striped 
and re-probed for either TSG101 or ALIX exosomal markers. Densitometry 
was measured and samples were normalised to either exosomal markers. 
 
5.2.6 Statistical analysis 
 
Data are presented as mean ± SEM, relative to ALIX or TSG101. N refers to 
the number of samples within each group. Significance was determined by 
unpaired T-test or one-way ANOVA. Significance was represented as: * P < 
0.05, ** P < 0.01, *** P < 0.001. 
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5.3 Results 
5.3.1 Urinary exosome isolation 
 
In order to optimise a method for urinary exosome isolation and to validate its 
efficiency by analyses of urinary NCC and pNCC protein excretion in CNI-
administered transplant and Gitelman syndrome patients, a protocol for 
urinary exosome isolation was first determined. Two modified versions of the 
standard ultracentrifugation protocol were initially examined (as outlined in 
Fig.5.1). Both these methods differ at the ultracentrifugation step. The first 
method was composed of the standard low-speed and high-speed spins, 
while the second appeared to be designed for increasing exosomal yield with 
larger starting urine volumes and multiple ultracentrifugation spins.  
 
Urinary exosomes were isolated from ~100 ml control urine using both these 
methods and analysed for detection of known renal transporter proteins. 
SGLT2, Na+/K+-ATPase a, and b-actin, were detected in isolated urinary 
exosomes using the protocol described by Tutakhel et al, (Tutakhel et al., 
2016), while no protein detection was observed for the second isolation 
protocol (Fig.5.2). In comparison to the mouse control sample, SGLT2 was 
detected as two bands (Fig.5.2a), with the strongest band present at the 
expected molecular weight and a faint lower-density band, which may be a 
cleaved product of the protein. Na+/K+-ATPase a was detected at a lower 
molecular weight compared with control sample (Fig.5.2b), but this may due 
to differences among species or a product of post-translational modifications 
such as glycosylation or cleaving. The signal detected for b-actin was weaker 
in urinary exosomes compared with control tissue and suggests that this 
protein is not suitable for normalisation in exosome protein analyses 
(Fig.5.3c). These findings suggest that the first isolation technique was best 
suited for this study and so further urinary exosome isolation experiments 
were performed using this method. Confirmation of protein extraction in 
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urinary samples was further determined with silver nitrate gel staining, which 
showed a significantly greater amount of proteins present in the final urinary 
exosome pellet (Fig.5.3a). However, this was also accompanied with the 
presence of the contaminating protein, THP. The urinary exosomal markers, 
TSG101 and ALIX were also present in these samples (Fig.5.3b,c), 
indicating successful urinary exosome isolation.  
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Figure 5.1. Urinary exosome isolation protocols. A schematic outline of two 
modified urinary exosome isolation protocols used in this study. Each of the 
protocols are modified versions of the original ultracentrifugation isolation method 
described by A) Tutakhel et al., (Tutakhel et al., 2016) and B) Gonzales et al., 
(Gonzales et al., 2010). 
 
 
 
 
 
 
A)
Urine collection
Protease inhibitor addition
Centrifuge
17,000 x g, 15 mins, 25°C
Centrifuge resuspended pellet
17,000 x g, 15 mins, 25°C
Keep supernatant (SN1)
Resuspend pellet in isolation solution/DTT
Ultracentrifuge supernatant
200,000 x g, 2 hours, 25°C
Keep supernatant (SN2)
Pool SN1 and SN2
Resuspend pellet
Contains exosomes
Prior to gel loading
Heat 15 mins at 65°C
Discard supernatant 
B)
Urine collection
Protease inhibitor addition
Centrifuge
17,000 x g, 10 mins, 25°C
Ultracentrifuge supernatant
200,000 x g, 1 hour, 25°C
Transfer supernatant to high speed tubes
To increase exosome yield
Add supernatant from 17,000 xg spin
Discard supernatant
Repeat ultracentrifugation
200,000 x g, 1 hour, 25°C
Vortex
Repeat ultracentrifugation
200,000 x g, 1 hour, 25°C
Resuspend pellet
Isolation solution/DTT
Vortex
Transfer suspension to high speed tubes
Fill with isolation solution
Resuspend final pellet
Contains exosomes
Prior to gel loading
Heat 10 mins at 60°C
Discard supernatant
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Figure 5.2. A comparison between two modified urinary exosome isolation 
protocols. Representative western blots for A) SGLT2 (arrow), B) Na+/K+-ATPase a 
(arrow) and C) b-actin (arrow) detection from urinary exosomes isolated from 100 
mL urine using two modified protocols. The first (1) protocol was adapted from 
Tutakhel et al., (Tutakhel et al., 2016) and the second (2) from Gonzales et al., 
(Gonzales et al., 2010). Samples were run alongside a control sample from mouse 
(M) renal tissue. In mouse, renal SGLT2 is detected ~75 kDa, Na+/K+-ATPase a is 
detected ~100 - 113 kDa (open arrow) and b-actin is detected ~42 kDa. 
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Figure 5.3. Confirmation of urinary exosome isolation. A) Silver nitrate stained gel of samples collected from each step of the urinary 
exosome isolation process from 100 mL urine. THP (box, detected ~95 kDa) was a common contamination observed following the isolation 
process. Representative western blots for exosomal markers B) TSG101 (arrow) and C) ALIX (arrow) as confirmation of successful urinary 
exosome isolation. TSG101 is detected ~43 - 47 kDa and ALIX is detected ~80 - 95 kDa.  
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The next experiments aimed to investigate whether these renal transport 
proteins could be detected in urinary exosomes isolated from lower volumes 
of starting urine, to allow for analyses in smaller urine volumes obtained from 
patients and mice. Urinary exosomes were prepared from 20 ml and 100 ml 
of control urine from two control subjects. At both volumes, all proteins could 
be detected, particularly in the first control sample (Fig.5.4). Again, a weaker 
signal was observed for b-actin (Fig.5.4e,f). Comparisons between the two 
control samples revealed lower protein detectability in the second exosomal 
sample which was consistent for all proteins measured (Fig.5.4). This was 
similarly observed for ALIX (Fig.5.5a,b) and TSG101 (Fig.5.5c,d) exosomal 
markers. 
 
These findings suggest that urinary exosome isolation using this method is 
highly variable, regardless of the starting urine volume. Therefore, for the 
remainder of the study, urinary exosomes were isolated from ~20 ml of urine. 
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Figure 5.4. Protein detection in urinary exosomes isolated from varying 
volumes of starting urine. Representative western blots for A,B) SGLT2 (arrow), 
C,D) Na+/K+-ATPase a (arrow; urinary exosome, open arrow; M control) and E,F) b-
actin (arrow) detection from urinary exosomes isolated from 20 and 100 mL of urine 
from two control samples. Samples were run alongside a control sample from 
mouse (M) renal tissue. 
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Figure 5.5. Detection of exosomal markers from varying volumes of starting 
urine. Representative western blots for exosomal markers A,B) ALIX (arrow) and 
C,D) TSG101 (arrow) from urinary exosomes isolated from 20 mL and 100 mL of 
urine from two control samples. 
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5.3.2 NCC/pNCC protein detection 
 
In order to compare changes in NCC/pNCC excretion in patients, the ability 
to detect NCC/pNCC in isolated urinary exosomes from control samples was 
first established. NCC was observed in urinary exosomes from four control 
subjects and at the expected molecular weight, as confirmed from using 
human and mouse control renal tissues (Fig.5.6a). This was similarly 
observed for pNCC but at a lower intensity, which is most likely a reflection of 
its baseline levels (Fig.5.6b).  
 
 
 
 
 
Figure 5.6. Detection of NCC and pNCC cotransporters in isolated urinary 
exosomes. Representative western blots for A) NCC (arrow) and B) pNCC (arrow) 
in isolated urinary exosomes from four control samples. Samples were run 
alongside control samples from human (H) and mouse (M) renal tissues. NCC is 
detected at ~130 – 160 kDa and pNCC is detected ~130 kDa. 
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5.3.3 Patient biochemistry  
 
The present findings show that our proteins of interest, NCC and its 
phosphorylated form, pNCC, can be detected using the current isolation 
method and at lower volumes of urine, and thereby allowed for protein 
analyses in CNI-administered renal transplant patients and Gitelman 
syndrome patients.  
 
Plasma samples were routinely collected on the day of urine collection from a 
total of 18 CNI-administered renal transplant patients (13 male and 5 female 
patients) and 4 Gitelman syndrome patients (1 male and 3 female patients). 
The Gitelman syndrome patients recruited for this study had been previously 
diagnosed on the basis of their genotype and were currently receiving 
treatment to manage the hypokalemia and hypomagnesemia phenotypes. 
Electrolyte analyses are shown in Table.5.1. It should be noted that no 
biochemical data was available for the age- and gender-matched control 
groups as only urine samples were collected. In both patient groups, normal 
plasma levels of sodium and calcium were observed, which were not 
significantly different between groups. Mean plasma creatinine was 
significantly higher in the CNI-treated transplant group, which is most likely a 
reflection of altered GFR from renal transplantation and CNI administration. 
CNI-administered renal transplant patients also displayed significantly higher 
levels of potassium which, although were not high enough for clinical 
diagnosis, were borderline hyperkalemic (potassium levels >5.5 mmol/L), 
which was expected for CNI-administered patients. In contrast, Gitelman 
syndrome patients showed lower potassium levels, which were slightly lower 
than the average range for potassium (3.6 – 5.2 mmol/L), and therefore, 
indicative of hypokalemia (<2.7 mmol/L). Bicarbonate plasma levels were 
also slightly but significantly lower (acidic) in CNI-administered transplant 
patients and higher (alkaline) in Gitelman syndrome patients compared with 
the average range for plasma bicarbonate (23 – 30 mmol/L). In both patient 
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groups, plasma phosphate was lower than the average range (0.8 – 1.5 
mmol/L). Although no significant differences were found between both patient 
groups, plasma phosphate levels were lower in CNI-administered renal 
transplant patients compared to the Gitelman syndrome group, which again, 
was expected for these patients. The Gitelman syndrome patients also 
displayed lower plasma magnesium levels (0.55 ± 0.06 mmol/L), indicative of 
hypomagnesemia (<0.7 mmol/L), which was expected for these patients. 
Unfortunately, urinary calcium measurements were not available for these 
patients to confirm the hypocalciuria phenotype. 
 
Overall, as expected, CNI-administered renal transplant patients displayed 
clinical symptoms indicative of hyperkalemia, metabolic acidosis and 
hypophosphatemia, while Gitelman syndrome patients showed 
opposing/mirroring symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
			
231				
Parameter 
CNI-administered 
Kidney Transplant 
Patients             
(N = 18) 
Gitelman Syndrome 
Patients                              
(N = 4) 
Creatinine (μmol/L) 210.50 ± 13.99 68.75 ± 8.34 *** 
Na+ (mmol/L) 138.61 ± 1.02 139.50 ± 1.04 
K+ (mmol/L) 4.92 ± 0.13 3.05 ± 0.29 *** 
HCO3- (mmol/L) 22.83 ± 0.52 29.25 ± 0.25 *** 
Corrected Ca2+ 
(mmol/L) 2.37 ± 0.03 2.43 ± 0.02  
PO4- (mmol/L) 0.32 ± 0.02 0.41 ± 0.01 
 
Table 5.1. Plasma Biochemistry. A summary of plasma electrolytes from CNI-
administered renal transplant and Gitelman syndrome patients measured on the day 
of urine collection. Values are presented as mean ± SEM. Significance was 
determined by unpaired T-test. ***P < 0.001; vs. CNI-administered kidney transplant 
patients. 
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5.3.4 Analysis of urinary NCC/pNCC excretion in renal transplant 
patients 
 
Urinary exosomes were isolated from 12 renal transplant patients who were 
receiving CNIs and 12 age- and gender-matched controls. Prior to gel 
loading, samples were normalised to the individual with the lowest urinary 
creatinine, to account for differences in exosome concentrations between 
individual samples, and densitometric analyses were initially normalised to 
the exosomal markers, TSG101 and ALIX. However, TSG101 detection was 
relatively weak compared with ALIX, which was clearly detected among 
isolated exosome samples, and so protein analyses were therefore 
normalised to ALIX only (Fig.5.7a,b). 
 
Relative densities were only measured for ALIX-positive control/patient pairs, 
which was shown for five out of twelve pairs. Compared to matched controls, 
a decreased trend was observed for urinary NCC excretion in CNI-
administered renal transplant patients (Fig.5.7c,d). However, no significant 
differences were observed for pNCC between controls and patients 
(Fig.5.7e,f). A band corresponding to THP was strongly detected ~95 – 100 
kDa as well as multiple low-molecular weight bands, which may represent 
entrapped proteins as well as cleaved products of the cotransporter. 
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Figure 5.7. Analysis of NCC and pNCC protein excretion in CNI-administered 
renal transplant patients. Representative western blots and densitometric 
analyses for exosomal markers A) TSG101 (arrow) and, B) ALIX (arrow), and C,D) 
NCC (arrow) and E,F) pNCC (arrow) in urinary exosomes isolated from CNI-
administered renal transplant patients. Samples were normalised to creatinine prior 
to gel loading. Patient samples were run alongside age- and gender-matched 
controls. Densitometric analyses were performed for each group and normalised to 
ALIX. Values are presented as the mean ± SEM, relative to ALIX (n = 5). 
Significance was determined using an unpaired T-test. 
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5.3.5 Analysis of urinary NCC/pNCC excretion in Gitelman syndrome 
patients 
 
In the next experiments, urinary exosomes were isolated from 4 patients with 
Gitelman syndrome and 4 age- and gender-matched controls. These 
exosomes were isolated from freshly collected and immediately processed 
and stored urine in attempts to reduce THP-mediated entrapment of 
NCC/pNCC proteins. Loading samples were normalised to urinary creatinine 
and densitometric analyses were normalised to a standard exosome sample, 
which was loaded alongside control and patient samples as an additional 
method for protein normalisation. ALIX normalised to this standard showed 
similar relative densities between control and patient groups (Fig.5.8a,b).  
 
Both NCC and pNCC proteins were detected in control and patient samples 
(Fig.5.8c,f). Densitometric analyses were normalised to either the standard 
sample or to standard-normalised ALIX. No significant differences were 
observed between the control and patient groups, however, a decreasing 
trend was observed in the patient group for both NCC (Fig.5.8d,e) and pNCC 
(Fig.5.8g,h) with either normalising methods. 
 
Additionally, THP, as well as multiple low molecular weight bands, were still 
strongly detected in these samples (Fig.5.8c,f), suggesting that protein 
degradation and THP-mediated protein entrapment may still take place 
potentially within the kidney and bladder preceding excretion. 
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Figure 5.8. Analysis of NCC and pNCC protein excretion in Gitelman 
syndrome patients. Representative western blots and densitometric analyses for 
A,B) ALIX (arrow), C-E) NCC (arrow) and, F-H) pNCC (arrow) in urinary exosomes 
isolated from Gitelman syndrome patients. Samples were normalised to creatinine 
prior to gel loading. Patient samples were run alongside age- and gender-matched 
controls. Densitometric analyses were performed for each group and normalised to 
either D,G) a standard sample (S) or, E,H) ALIX. Values are presented as the mean 
± SEM (n = 4). Significance was determined by an unpaired T-test. 
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Overall, there were no significant differences among CNI-administered renal 
transplant patients and those with Gitelman syndrome, compared with their 
corresponding matched controls. In addition, high levels of THP and low 
molecular weight products were observed which might have obscured 
precise protein quantification.  
 
Despite these findings, comparisons between CNI-treated patients and those 
with Gitelman syndrome revealed significantly decreased NCC protein 
excretion in Gitelman syndrome patients (Fig.5.9a). This was also observed 
for pNCC (Fig.5.9b). However, it should be noted that the relative densities 
for the control group matched to the Gitelman syndrome patients was lower 
compared with the control group matched to the CNI-treated patients. This 
was most likely related to differences in creatinine-normalised gel loading. 
Urinary creatinine was not statistically significant between matched control 
and patient groups, but was lower with Gitelman syndrome patients vs. their 
matched controls (5.44 ± 1.70 vs. 16.31 ± 5.19 mmol/L, respectively), 
compared to CNI-administered patients vs. their matched controls (14.31 ± 
2.15 vs. 14.01 ± 1.96 mmol/L, respectively). This reduction in urinary 
creatinine in the Gitelman syndrome group is a reflection of the inability of 
these patients to concentrate creatinine and so smaller volumes of control 
exosome samples were loaded compared to the patients, which may explain 
the relatively lower densities for the control group. 
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Figure 5.9. Comparisons of NCC and pNCC excretion in CNI-administered 
renal transplant patients and Gitelman syndrome patients. Densitometric 
analyses of A) NCC and B) pNCC cotransporters in age- and gender-matched 
controls (n = 9), CNI-administered renal transplant patients (CNI, n = 5) and 
Gitelman syndrome patients (GS, n = 4). Values are presented as the mean ± SEM, 
relative to ALIX. Significance was determined by one-way ANOVA with Dunn’s post-
test. *P < 0.05, **P < 0.01. 
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5.3.6 Further protein detection 
 
The following experiments were performed to validate whether the isolated 
urinary exosomes from this protocol could be used to analyse renal sodium-
dependent transporters from other segments of the nephron. These were 
analysed for the proximal tubule transporters, SGLT2 and NaPi-IIc, whose 
dysregulation/mutations result in diabetes and hereditary hypophosphatemic 
rickets with hypercalcuria (HHRH), respectively (Bergwitz et al., 2006; 
Lorenz-Depiereux et al., 2006; Rahmoune et al., 2005), and the distal tubule 
sodium channel, ENaC, which is known to cause Liddle’s syndrome 
(Shimkets et al., 1994), along with ALIX, which was detected in three out of 
the four control samples (Fig.5.10a). 
 
As already observed, SGLT2 was detected in all four samples, at the correct 
molecular weight, as confirmed from the human control sample (Fig.5.10b). 
However, NaPi-IIc and ENaC could not be detected in all samples 
(Fig.5.10c,d), implying the urinary exosome isolation protocol used in this 
study might not be suitable for protein excretion analyses of other renal 
transport proteins. 
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Figure 5.10. Protein detection of other renal transporters in isolated urinary 
exosomes. Representative western blots for A) ALIX (arrow), B) SGLT2 (arrow), C) 
NaPi-IIc and D) ENaC renal transport proteins from urinary exosomes isolated from 
four control samples. Samples were run alongside a control sample from human (H) 
renal tissues. ALIX is detected ~80 - 95 kDa (arrow), SGLT2 is detected ~75 kDa 
(arrow), NaPi-IIc is detected ~64 kDa (arrow) and ENaC is detected ~85 kDa 
(arrow). 
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5.4 Discussion 
 
Analyses of renal protein abundance in patients is hindered by the 
complications in obtaining renal tissues from live patients. The practical use 
of renal biopsies carries a great risk of internal damage and the collected 
sample can often lose structural integrity, making immunohistochemical 
analyses difficult. Extensive research is currently ongoing to exploit urinary 
exosomes as a source of biomarkers for renal disease and dysfunction. The 
results presented in this chapter focused on optimising a method for urinary 
exosome isolation to compare changes in urinary NCC and pNCC excretion 
in CNI-administered renal transplant patients and Gitelman syndrome 
patients to support previous findings and to determine whether this protocol 
could be used to analyse other excreted renal transport proteins. 
 
5.4.1 Urinary exosome isolation 
 
Urinary exosomes have been found to contain proteins, mRNAs and miRNAs 
secreted by epithelial cells from each segment of the nephron, which may 
provide an accurate representation of the physiological and 
pathophysiological state of the kidney and, as such, may be suitable for the 
identification of biomarkers for renal-related conditions (Lv et al., 2013; 
Miranda et al., 2010; Pisitkun et al., 2004; Valadi et al., 2007). Proteomic 
profiling in these urinary exosomes have already identified several disease-
related proteins, which may serve as potential biomarker candidates 
(Gonzales et al., 2009; Pisitkun et al., 2004). However, the use of the 
standard ultracentrifugation method for urinary exosome isolation in clinical 
settings is hampered by the low throughput, lengthy preparation and use of 
expensive instruments. Numerous investigations have been conducted to 
develop an alternative, faster and more efficient approach, but these have 
yielded variable results in exosomal yield and purity (Alvarez et al., 2012; 
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Channavajjhala et al., 2014; Cheruvanky et al., 2007; Merchant et al., 2010; 
Miranda et al., 2010; Raj et al., 2012; Rood et al., 2010).  
 
In this study, a number of adaptations to the standard ultracentrifugation 
method were tested to try to improve its reproducibility in yielding intact 
exosomes. Comparisons of two commonly used protocols revealed that the 
protocol described by Tutakhel et al was the best suited (Tutakhel et al., 
2016). This was confirmed by exosomal marker (ALIX and TSG101) and 
NCC/pNCC protein detection, which allowed for further investigations in 
patient urine. However, this exosomal isolation protocol was found be 
variable between samples and starting urine volume appeared to have no 
effect on protein detection. 
 
5.4.2 Urinary exosome analyses in patient urine 
 
Previous reports have observed very low or undetectable levels of urinary 
NCC protein excretion in patients with Gitelman syndrome and significantly 
increased urinary excretion of NCC in PHAII and CNI-administered renal 
transplant patients, which correlates with their relative abundances in the 
kidney under these conditions (Corbetta et al., 2015; Esteva-Font et al., 
2014; Isobe et al., 2013; Joo et al., 2007; Mayan et al., 2008; Rojas-Vega et 
al., 2015; Tutakhel et al., 2017). This is in line with the described role for 
NCC in sodium retention and blood pressure regulation. Gitelman syndrome 
is a hypotensive autosomal salt-wasting disorder and is the result of loss-of-
function mutations in NCC (Simon et al., 1996c), which accounts for the 
significant reduction in NCC excretion observed in these patients. As 
previously mentioned, clinical and rodent studies have demonstrated that 
CNI administration is associated with hypertension, via enhanced activation 
and phosphorylation of NCC, and exhibits clinical features that resemble 
PHAII, an autosomal dominant disease caused by gain-of-function mutations 
in regulators of NCC, resulting in upregulated renal sodium reabsorption and 
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elevated blood pressure (Boyden et al., 2012; Hoorn et al., 2011; Louis-Dit-
Picard et al., 2012; Melnikov et al., 2011; Wilson et al., 2001). These clinical 
phenotypes are ‘mirror-images’ of Gitelman syndrome, which was reflected in 
the plasma biochemical analyses in the patients used. In the present study, 
although no significant differences were observed for NCC and pNCC protein 
excretion between CNI-administered renal transplant patients and Gitelman 
syndrome patients with their matched controls, comparisons in Gitelman 
syndrome patients compared with CNI-administered renal transplant patients 
was significantly lower, as expected. 
 
5.4.3 Limitations 
 
Despite the attempts to optimise protein detection for urinary NCC/pNCC 
excretion in these patients for comparative studies, and confirmed urinary 
exosome isolation by the detection of the ALIX exosomal marker, some 
limitations of this study have been recognised. 
 
First, although the detection of exosomal markers, ALIX and TSG101, and a 
substantial amount of protein present in the final exosome pellet suggested 
successful isolation of exosomes from urine, no further methods were used 
for characterising the isolated exosomes such as electron microscopy or 
nanoparticle tracking analyses, to distinguish between exosomes and other 
larger microvesicles. However, as a modified version of the standard urinary 
exosome isolation technique was used in this study and revealed consistent 
ALIX detection, successful isolation of exosomes can be assumed.  
 
Another challenge faced with this method was protein normalisation and 
quantification. As mentioned, previous investigations have been performed to 
evaluate alternative methods of normalisation including urinary creatinine, 
THP and exosomal markers (Fernández-Llama et al., 2010; Zhou et al., 
2006a). In the present study, samples were normalised to urinary creatinine 
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prior to gel loading to account for differences in exosome concentrations 
between individual samples, and densitometric analyses were normalised to 
ALIX or a standard sample. The relative density of ALIX was found to be 
consistent among the samples, supporting that a similar number of 
exosomes were loaded on the gel. Normalising to THP has been previously 
proposed, however, this protein is also known to cause problems in exosome 
isolation. 
 
Contamination by THP was a major complication in the present study and 
currently remains a recurring problem in exosome isolation methods. THP is 
a glycoprotein that is synthesized in the TAL (Bachmann et al., 1985, 1990). 
This protein resides along the basolateral membrane, apical cytoplasmic 
vesicle compartments and in/near the luminal plasma membrane (Bachmann 
et al., 1985). Urinary exosomes are typically concealed by THP in a 
polymeric fibril network, which can hinder protein identification in applications 
such as mass spectrometry. The addition of DTT during the low-speed spins 
is used to dissolve this polymeric network, but this does not completely 
remove all THP (Fernández-Llama et al., 2010). In the present study, the 
addition of DTT had no effect on THP, even in freshly collected and 
processed urine. Additional steps have been investigated to separate 
exosomes and THP using sucrose gradients, double-cushion 
ultracentrifugation, size exclusion chromatography and NaCl-based 
precipitation (Kosanović and Janković, 2014; Raj et al., 2012; Rood et al., 
2010). Unfortunately, these methods still require the ultracentrifugation step, 
remaining both time-consuming and expensive, and although the removal of 
THP is required for exosome analysis, it is not clear whether the removal of 
THP in the urine samples with these methods may also result in the loss of 
potential biomarkers already entrapped by THP prior to processing, which 
may lead to inaccurate protein quantification.  
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Interestingly, it has also been suggested that THP itself may have a 
pathophysiological significance. THP is known to play a major role in the 
defence against urinary tract infections (Bates et al., 2004), however, 
previous studies have demonstrated that THP is involved in the pathogenesis 
of hyperuricemic nephropathy and chronic kidney disease (Dahan et al., 
2003; Hart et al., 2002; Rampoldi et al., 2003; Wolf et al., 2003). Patients 
with familial juvenile hyperuricemic nephropathy and autosomal-dominant 
medullary cystic kidney disease were found to possess mutations in the THP 
gene, which suggested a role for THP in renal urate handling (Dahan et al., 
2003; Hart et al., 2002; Rampoldi et al., 2003; Wolf et al., 2003). In these 
patients, THP was found to accumulate in the TAL as a result of the retention 
of mutated THP in the endoplasmic reticulum and delayed export to the 
plasma membrane (Rampoldi et al., 2003). In addition, alterations in THP 
synthesis or urinary excretion has been observed in patients with diabetic 
nephropathy, polycystic kidney disease, lupus nephritis and in a variant of 
Barttter’s syndrome (Rasch et al., 1995; Schroter et al., 1993; Tsai et al., 
2000), proposing THP itself as a renal disease biomarker (Zimmerhackl, 
1993). Furthermore, studies in THP knockout mice revealed a significant 
upregulation in mRNA and protein expression of major renal transport 
proteins including NHE3, NKCC2, ClC-K channels, barttin, ROMK, a-ENaC 
and NCC, suggesting that THP may also be important in regulating renal 
transporter functions (Bachmann et al., 2005). It is therefore unclear whether 
THP or other exosomal markers such as ALIX are affected under renal 
disease or dysfunction, which would also limit precise biomarker normalising 
and protein quantification. Further investigations are required to understand 
the shredding processes of these transport proteins, the impact of CNIs and 
THP on these processes, and the effects of CNIs on THP and ALIX.   
 
Another limitation of this study is that although the protein abundance for 
NCC and pNCC in the urinary exosomes analysed showed significant 
differences between CNI-administered and Gitelman syndrome patients, 
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other factors that may also regulate NCC expression and function were not 
considered. This includes salt loading or the use of alternative medications 
such as thiazides in CNI-administered renal transplant patients to treat 
elevated blood pressure. Previous studies in CNI-administered renal 
transplant patients taking thiazides and mineralocorticoids revealed a 
significant increase in urinary NCC excretion, indicating these thiazides might 
enhance NCC/pNCC shredding into the urine to account for increased 
phosphorylation and activation of NCC as a result of the CNI effects (Pathare 
et al., 2017; Tutakhel et al., 2017; Wolley et al., 2017). In addition, the data 
presented in this chapter are observational and do not directly establish the 
connection between CNIs, NCC upregulation and hypertension.  
 
No significant differences in NCC and pNCC abundance were observed 
between patients and their matched controls, but the overall relative densities 
of these proteins were much lower in Gitelman syndrome patients compared 
with the CNI-treated renal transplant group. The reasons for this absence in 
significance with the control groups are not yet clear. One reason may be 
that the control samples were collected from healthy subjects which contain 
lower levels of urinary proteins. Previous studies have reported significant 
increases in total and phosphorylated NCC abundance in CNI-treated renal 
transplant patients compared with CNI-free renal transplant patients but not 
in healthy controls, when normalised to CD9, another exosomal marker 
(Tutakhel et al., 2017). CNI-free renal transplant patients were not analysed 
in this study and future comparisons between these patients, CNI-treated 
patients and patients with Gitelman syndrome would potentially corroborate 
these findings. In addition, a small sample number of ALIX-positive pairs 
were analysed in the CNI-treated group and so may have masked any 
significant differences between the patients and their corresponding controls. 
This was mostly likely the same for the Gitelman syndrome group, although, 
the lower sample number in this case was due to the rarity of the disease. 
However, it should also be noted that the relative densities of the control 
			
246				
group for the Gitelman syndrome patients were also lower compared with the 
matched controls for the CNI-treated group which, as already mentioned, is 
mostly likely the result of differences in creatinine-normalised loading. 
 
Furthermore, as shown in further experiments, protein detection of other 
transport proteins was variable, suggesting that the protocol used in this 
study may not be suitable for analysis of renal transporters. In addition, it is 
not clear whether the abundance of protein per exosome vesicle varies and 
may be underrepresented in protein normalising and quantifying steps.  
 
5.4.4 Conclusions 
 
Overall, it is not yet established which method of exosome isolation and 
normalisation is the most suitable and whether exosomal markers such as 
ALIX, TSG101 and THP are affected under the pathogenic conditions 
investigated in this study. Though the modifications made to the current 
protocol improved exosome isolation, this was still not ideal for protein 
analyses and therefore requires further optimising. 
 
Although no differences in urinary NCC and pNCC excretion were observed 
between patients and their matched controls, the finding that urinary NCC 
and pNCC excretion was significantly higher in renal transplant patients and 
lower in Gitelman syndrome patients is consistent with observations from 
previous studies and the role for NCC in blood pressure regulation.  
 
However, as only a selection of renal transport proteins were identified in 
these isolated exosomes, it is likely the protocol used in this study was not 
fully optimal for the detection and analysis of transport proteins which are 
associated with renal-related conditions. It is clear that despite the 
substantial advances that have occurred in the aspects of urine storage and 
processing for urinary exosome isolation, a faster, efficient and reliable 
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method for routine exosome isolation has yet to be established. These 
improvements to the existing non-invasive methodology for urinary exosome 
isolation would drastically aid in the rapid and accurate diagnosis of a 
number of pathological conditions and the implementation of effective 
therapeutic treatments. 
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Chapter VI 
General Discussion 
6  
6.1 Aims of thesis 
 
Over the years, substantial advances have been made into understanding 
the cellular mechanisms involved in the development of hypertension, 
including following renal transplantation and in patients with 
Pseudohypoaldosteronism II (PHAII). A strong association between post-
transplant hypertension and an increased risk for cardiovascular events, and 
long-term graft and patient survival has been demonstrated in a number of 
follow-up studies (Kasiske et al., 2004; Opelz et al., 1998, 2005). These 
studies strongly highlight the need for the characterisation of the underlying 
pathogenic mechanisms involved in order to facilitate the development of 
more targeted treatments for managing blood pressure following renal 
transplantation and in patients with hypertensive diseases. Attention has 
been particularly directed towards the cellular effects of the calcineurin 
inhibitor (CNI) immunosuppressant therapy received following renal 
transplantation. Studies from clinical and experimental models of PHAII and 
CNI-induced hypertension have provided convincing evidence for the 
overactivation of the NCC cotransporter as the key factor, which acts through 
increased renal sodium retention and leads to elevated blood pressure 
(Boyden et al., 2012; Chiga et al., 2011; Hoorn et al., 2011; Lalioti et al., 
2006; Louis-Dit-Picard et al., 2012; Melnikov et al., 2011; Wilson et al., 2001; 
Yang et al., 2007, 2013). However, the sodium retaining effect on other 
sodium-dependent transporters present in the kidney and gastrointestinal 
tract, and their potential role in sodium retention and hypertension 
development under CNI or hypertensive conditions have not been studied. 
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It is well known that the kidneys play a major role in regulating sodium 
homeostasis. Sodium-coupled transport is the main mode of renal sodium 
reabsorption across the brush border membrane (BBM) and basolateral 
membrane (BLM) and includes; the Na+/H+ exchanger (NHE3), the 
Na+/glucose cotransporters (SGLT2 and SGLT1), the facilitative glucose 
transporter (GLUT2), the Na+/Pi cotransporters (NaPi-IIa and NaPi-IIc), the 
Na+/HCO3- cotransporter (NBCe1A), the Na+/K+/2Cl- cotransporter (NKCC2), 
the Na+/Cl- cotransporter (NCC), the Na+-dependent Cl-/HCO3- exchanger 
(NDCBE) and the epithelial Na+ channel (ENaC) (Fig.1.2). The expression of 
these transport proteins is tightly controlled by a number of factors including 
dietary salt and hormones such as vasopressin and aldosterone (Chiga et 
al., 2008; Hall and Varney, 1980; Hebert et al., 1981a, 1981b, 1981c; Loffing 
et al., 2000; Pacha et al., 1993). It is also known that dysregulation or 
mutations in some of these sodium transport proteins has a significant impact 
on blood pressure regulation and results in blood pressure-related diseases 
such as PHAII (gain-of-function NCC mutation), Gitelman syndrome (loss-of 
function NCC mutation) and Liddle syndrome (gain-of-function ENaC 
mutation) (Boyden et al., 2012; Firsov et al., 1996; Louis-Dit-Picard et al., 
2012; Shimkets et al., 1994; Simon et al., 1996c; Snyder et al., 1995; Wilson 
et al., 2001). A number of these transport proteins are also expressed in the 
gastrointestinal tract, including; NHE3, SGLT1, GLUT2, the Na+/Pi 
cotransporters (NaPi-IIb and PiT1), and ENaC (Fig.1.3).  
 
Earlier studies have provided evidence for a complex interplay between the 
kidneys and intestines, which was demonstrated for phosphate, potassium 
and sodium ions (Berndt et al., 2007; Carey, 1978; Lee et al., 2007; Lennane 
et al., 1975; Rabinowitz et al., 1988). During investigations in subjects 
following oral and intravenous sodium loading, a greater natriuretic response 
was observed after orally administered NaCl feeding compared with 
responses seen following intravenous NaCl infusion (Carey, 1978; Lennane 
et al., 1975). These authors concluded that the gastrointestinal tract is 
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involved in sensing and effector signalling responses to changes in sodium 
intake, which may signal the kidneys to either excrete or conserve sodium, 
accordingly. However, the ‘sensor’ for sodium in the gastrointestinal tract and 
the renal-signalling mechanisms are still not known. Furthermore, this 
interplay between both the kidneys and gastrointestinal tract under 
hypertensive physiological conditions has not been previously studied. 
 
The main aims of the experiments reported in this thesis were to investigate 
the effects of CNI-induced sodium retention on renal and intestinal sodium 
transporters and to test for the hypothesised cross-talk between the kidneys 
and intestines in adaptation to changes in sodium balance. In addition to 
these objectives, it has been demonstrated that a number of conditions, 
including post-transplant diabetes mellitus (PTDM) or metabolic syndrome, 
are also commonly encountered following renal transplantation with 
extensive evidence linking their development to CNI use (Boudreaux et al., 
1987; Chapman et al., 1987; Jevnikar et al., 1988; Ligtenberg et al., 2001; 
McCune et al., 1998; Pirsch et al., 1997; Roth et al., 1989; Schorn et al., 
1991; Vincenti et al., 2002; Woodward et al., 2003). However, this has not 
yet been investigated in detail. Therefore, in another set of experiments, 
animals were also maintained on a high-fat diet (as a model of metabolic 
syndrome) and assessed for changes in sodium transport proteins which 
were compared with those seen in FK506-treated animals. The initial aims of 
these experiments were to determine whether CNIs are the main influencers 
for the development of metabolic syndrome in treated transplant patients and 
to also identify which transporters (besides pNCC) contribute towards the 
development of hypertension and other post-transplant-affiliated conditions, 
such as PTDM and post-transplant metabolic syndrome. 
 
 
			
251				
6.2 Sodium and blood pressure 
 
One of the main functions of the kidneys is to maintain sodium and water 
balance, and thus blood pressure. Numerous volume expansion and renal 
transplant studies, as well as hereditary diseases of renal sodium transport, 
have all revealed that sodium retention and plasma volume expansion by the 
kidneys plays a critical role in chronic elevations of blood pressure (Boyden 
et al., 2012; Greene et al., 1990; Guidi et al., 1996; Guyton et al., 1972; 
Louis-Dit-Picard et al., 2012; Norman et al., 1975; Rettig et al., 1990b, 
1990a, 1989; Simon et al., 1996c; Wilson et al., 2001). Likewise, 
epidemiological studies have shown a positive correlation between dietary 
sodium intake and blood pressure across and within populations (Elliot et al., 
1996; Rose et al., 1988). This was further supported in controlled clinical 
trials showing that a reduction in salt intake lowers arterial pressure in both 
hypertensive and normotensive people (Sacks et al., 2001). However, the 
precise mechanisms of how excessive salt intake increases blood pressure 
are still not well understood. Several studies have postulated that dietary 
sodium-induced hypertension is the result of extracellular fluid volume 
expansion and cell swelling (Coleman and Guyton, 1969; Douglas et al., 
1964; Friedman, 1990a; Friedman et al., 1990b; Manning et al., 1979a, 
1979b; Villamil et al., 1982). Previous experiments in saline infused 
nephrectomised dogs demonstrated that volume expansion raises blood 
pressure by an ‘autoregulatory effect’ on the resistance vessels as a result of 
increased blood flow and cardiac output, causing vessel constriction and 
increased total peripheral resistance, which is then subsequently decreased 
to return to control levels (Coleman and Guyton, 1969; Manning et al., 
1979b). An increase in salt intake has also been associated with small rises 
in plasma sodium which increases extracellular fluid volume (Manning et al., 
1979a). Studies in clinical essential and experimental hypertension models 
have also shown that excessive salt intake correlates strongly with increased 
left ventricular mass and wall thickness (du Cailar et al., 1989; Fields et al., 
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1991; Frohlich et al., 1993; Leenen and Yuan, 1998; Yu et al., 1998). 
Spontaneously hypertensive rats (SHR) given a high-salt (4-8%) diet 
exhibited left ventricular hypertrophy and increased cardiac mass, while 
Wistar-Kyoto (WKY) rats fed on a high-salt diet showed increased cardiac 
mass without changes in arterial pressure (Frohlich et al., 1993; Leenen and 
Yuan, 1998), suggesting that dietary sodium may exacerbate a cardiac 
hypertrophic response to increased blood pressure. Furthermore, increased 
plasma sodium concentrations have been found to increase cell diameter, 
volume and protein content in rat myocardial myoblasts and vascular smooth 
muscle cells, as well as increased angiotensin type I receptor expression, 
angiotensin II activity and plasma renin (Gu et al., 1998; Nickenig et al., 
1998; Ruan et al., 1997; Simon and Illyes, 2001), implicating the activation 
and contribution of the renin-angiotensin-aldosterone system in 
vasoconstrictive and hypertensive responses to excessive salt intake. 
However, whether CNI-induced sodium retention affected cardiac output, 
extracellular fluid volume and activation of the renin-angiotensin-aldosterone 
system in the present study remains to be confirmed.  
 
In this thesis, the experiments performed in Chapter 3 aimed to assess for 
changes on sodium transport proteins in the kidney and gastrointestinal tract 
in a CNI-treated mouse model, to confirm their potential involvement in 
increased CNI-induced sodium retention. These sodium transport proteins 
were examined owing to their involvement in blood pressure regulation and 
as downstream targets of the WNK-SPAK/OSR1 signalling cascade. The 
experiments described for Chapter 4 aimed to compare these changes with a 
model of diet-induced metabolic syndrome, to determine whether CNIs may 
influence metabolic syndrome development following renal transplantation. In 
these studies, a clinically comparable dose of FK506 was administered, 
which was also twice the dose given in mice from a previous report (Hoorn et 
al., 2011). These studies utilised RT-PCR, western blotting and 
immunohistochemistry techniques in the kidneys and the three segments of 
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the gastrointestinal tract (proximal and distal small intestines, and the colon), 
alongside plasma and urine electrolyte analyses. 
 
Although blood pressure and sodium transport across the renal BBM was not 
measured, western blotting and immunohistochemistry demonstrated a 
significant upregulation of apical pNCC expression in the DCT which 
suggests increased sodium transport in this model and potentially elevated 
blood pressure. The most striking conclusion drawn from the experiments 
described in Chapters 3 and 4 was that the presence of other factors, 
particularly high dietary fat intake or an obese background, were the main 
mediators of alterations in renal and intestinal transporters, and thus, the 
development of metabolic complications encountered following 
transplantation (summarised in Fig.6.1). Interestingly, the findings from CNI 
treatment showed there may be homeostatic downregulation of sodium 
transporter expression in nephron segments outside of the DCT; renal NHE3 
and ENaC were downregulated by CNI treatment, which may be a 
compensatory mechanism to adapt to increases in sodium reabsorption at 
the DCT. Supporting this interpretion of the data, in the experiments 
described in Chapter 3, the supplement of a high-salt det led to a significant 
downregulation of renal NHE3. However, it is not fully clear what impact the 
downregulation of renal NHE3 and ENaC transport proteins has on blood 
pressure in this study, whether this downregulation is a compensatory 
response to upregulated transporter activity or to increased sodium transport 
via pNCC, or whether these are effects caused by CNIs or the WNK-
SPAK/OSR1 signalling pathway.  
 
The data obtained from Chapter 4 showed a significant increase for renal 
NHE3 and pNCC in mice fed on the high-fat diet, supporting an increase in 
sodium retention and blood pressure, which is line with conditions associated 
with high-fat feeding and metabolic syndrome. A significant decrease for the 
renal ENaC sodium channel was also observed in these mice, which was 
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suggested to be either a compensatory response to increased sodium 
reabsorption through NHE3 and pNCC or to increased ENaC activity, though 
this remains to be confirmed. This downregulation in renal ENaC contrasts 
with its expected effects in contribution to increased sodium retention and 
stimulation by known regulators in this model. 
 
Alongside NCC, both NHE3 and ENaC are known to play a role in blood 
pressure regulation. Genetic and acquired hypertensive diseases have been 
associated with increased NHE3 and ENaC protein and transporter activity 
(Kobayashi et al., 2004; Leong et al., 2006; Pinto et al., 2008; Pradervand et 
al., 1999b; Shimkets et al., 1994; Snyder et al., 1995). Previous studies in 
NHE3-deficient mice display lower blood pressure compared with wild type 
(Lorenz et al., 1999; Noonan et al., 2005; Schultheis et al., 1998a), while 
studies in hypertensive human and spontaneously hypertensive rat models 
showed increased NHE3 activity and proximal tubular sodium reabsorption 
(Burnier et al., 1993; LaPointe et al., 2002; Pinto et al., 2008; Weder, 1986). 
The conclusions drawn from these studies implicate that the dysregulation of 
proximal tubular reabsorption can have a significant impact on blood 
pressure and can contribute to the pathogenesis of hypertension. Both NHE3 
and ENaC are also implicated as downstream targets of the WNK-
SPAK/OSR1 signalling cascade (Ahmed et al., 2015; Pasham et al., 2012; 
Ring et al., 2007a; Yang et al., 2007). However, unlike ENaC, investigations 
on the regulation of NHE3 by the WNK-SPAK/OSR1 signalling cascade in 
relation to hypertensive conditions are lacking. It has been shown that ENaC 
activity is inhibited by WNK4 under basal conditions and is activated in 
PHAII-causing WNK4 mutations (Ring et al., 2007a; Yang et al., 2007). 
Studies in mutated WNK4 transgenic mice and in patients carrying the WNK4 
Q565E PHAII-causing mutation exhibit alleviated WNK4-mediated inhibition, 
higher responses to amiloride treatment and increased ENaC expression in 
the collecting duct and colon (Farfel et al., 2005; Ring et al., 2007a; Yang et 
al., 2007), which contributes to increased sodium reabsorption and blood 
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pressure. Taken together, these transport proteins are crucial in blood 
pressure regulation and contribute to the pathogenesis of hypertension 
through both genetic mutations and over-stimulation by known regulators. 
 
It is known that these major sodium transport proteins are regulated by a 
number of hormones. This includes angiotensin II (AngII). Activation of the 
renin-angiotensin system is associated with increased sodium transport in 
the renal proximal tubule and stimulated NHE3 protein expression and 
activity (Geibel et al., 1990; Gurley et al., 2011; Li and Zhuo, 2007; Riquier-
Brison et al., 2010; Xu et al., 2006), which contributes to increased blood 
pressure. This was demonstrated in mice where gene silencing of the 
angiotensin type IA receptor exhibited significantly reduced blood pressure 
and reabsorption at the proximal tubule compared with controls (Gurley et al., 
2011; Li and Zhuo, 2007). In addition, acute inhibition of the AngII type II 
receptor or the angiotensin-converting enzyme also showed decreased 
proximal tubular sodium transport and AngII-stimulated NHE3 activity, and 
protein and cell surface expression in animal and cell culture models (Leong 
et al., 2006b; Li and Zhuo, 2007). Another stimulatory hormone is insulin, 
which regulates both NHE3 and ENaC (Blazer-Yost et al., 1998; Fuster et al., 
2007; Gesek and Schoolwerth, 1991; Klisic et al., 2002). Previous studies 
have shown stimulated Na+/H+ exchange in the proximal tubular segments 
and in NHE3-expressing cultured cells by chronic treatment with insulin and 
have suggested this effect to be mediated by the PI3K-SGK1 pathway 
(Fuster et al., 2007; Klisic et al., 2002). Aldosterone is another important 
regulator. It is known to enhance sodium reabsorption at the distal segments 
of the nephron, but has also been demonstrated to stimulate NHE3 activity 
and increase cell surface expression at the renal proximal BBM (Drumm et 
al., 2006; Krug et al., 2003; Pinto et al., 2008). Aldosterone-induced sodium 
transport at the collecting duct occurs through ENaC activation (Blazer-Yost 
et al., 1998; Masilamani et al., 1999; Pacha et al., 1993). This is mediated 
through SGK1 signalling which reduces ENaC ubiquitination and degradation 
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through phosphorylating the ubiquitin ligase, Nedd4-2 (Chen et al., 1999; 
Debonneville et al., 2001; Snyder et al., 2002; Xu et al., 2005). This ubiquitin 
ligase has been shown to be important in regulating ENaC and blood 
pressure as Nedd4-2 knockout mice exhibit salt-sensitive hypertension and 
increased ENaC expression (Shi et al., 2008). Studies have also revealed 
that WNK1 activates SGK1 to regulate ENaC (Heise et al., 2010; Xu et al., 
2005). Numerous animal, oocyte and cell culture models have also 
demonstrated WNK-SPAK/OSR1-mediated phosphorylation of NCC by 
increased AngII, insulin, aldosterone and SGK1 signalling (Castaneda-Bueno 
et al., 2012; Chávez-Canales et al., 2013; Chiga et al., 2008; Rozansky et al., 
2009; San-Cristobal et al., 2009; Sohara et al., 2011; Talati et al., 2010; 
Vallon et al., 2009). 
 
Overall, mutations in these major renal sodium transporters or the 
upregulation of regulatory hormones and kinases can significantly alter 
sodium homeostasis can lead to rises in blood pressure. In the context of the 
present study, as the opposite was observed following CNI treatment, the 
downregulation of the major transport proteins points more towards a 
feedback response in order to adapt to increased sodium transport by pNCC. 
In addition, as previously mentioned, this may also be a reflection on the CNI 
model used in this study. Although regulators of sodium transport, such as 
AngII and aldosterone, were not assessed in the present studies, the 
upregulation observed for renal pNCC and NHE3 transport proteins with 
high-fat feeding provide evidence for increased blood pressure in this model 
and stimulation by these regulators, which are also known to be increased in 
obese patients and those with metabolic syndrome. In future studies, 
functional and kinetic analyses for the individual transport proteins with CNI 
treatment would confirm their contribution to sodium retention and the 
efficiency of the model used in this study. Furthermore, comparative 
analyses of these transport proteins and sodium transport across the renal 
and intestinal BBM in other models, such as PHAII or NCC-mediated 
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hypertension, to the data obtained from the model of metabolic syndrome 
may also warrant further investigations into the role of the WNK-SPAK/OSR1 
signalling cascade in the development of metabolic syndrome. Additionally, 
although substantial evidence from clinical and rodent models of 
hypertension implicates calcineurin, the target of CNIs, in the WNK-
SPAK/OSR1-NCC signalling cascade, its role in regulating renal sodium 
homeostasis and blood pressure, particularly in essential and hereditary 
hypertensive diseases, has yet to be established. Comparisons of blood 
pressure and changes in these sodium transport proteins and function across 
the renal and intestinal BBM in calcineurin knockout mice or oocyte 
expression models would also allow for further investigations to determine 
the role of calcineurin in sodium homeostasis. 
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Figure 6.1. Proposed model of the effects of CNI treatment, high-salt and high-fat feeding on renal and intestinal transporters. High-fat 
(HFD) or high-salt (HSD) feeding and CNI treatment (FK506) influences the down- and up-regulation of a number of renal and intestinal sodium 
transporters (arrows), some of which may be compensatory to increased sodium reabsorption via pNCC at the DCT. The data also suggests the 
adaptations to dietary fat intake may be regulated by activation of the SGK1 kinase in response to high-fat feeding, insulin and aldosterone. This 
kinase may also regulate NHE3 and pNCC. The relative effects of SGK1 on renal ENaC and intestinal SGLT1 and NHE3 are unknown.  
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6.3 Sodium and the immune system 
 
It is well established that the CNI-induced sodium retaining effects and 
increased dietary salt intake have a significant impact on blood pressure. 
However, alongside these hypertensive effects, it has also been revealed 
that dietary sodium intake can play a role in regulating the immune system. 
Previous mouse studies have shown that a high-salt diet can promote tissue 
inflammation and autoimmune disease development (Kleinewietfeld et al., 
2013; Wu et al., 2013), raising the possibility that sodium homeostasis is 
important in driving the increased incidence of autoimmune disease, as well 
as hypertension. Clinical and experimental studies have proposed the 
mechanisms involved in dietary salt-induced inflammation and autoimmune 
disease development are linked to an increase in the number of monocytes, 
production of proinflammatory cytokines and enhanced Th17 differentiation 
(Fig.6.2) (Binger et al., 2015; Kleinewietfeld et al., 2013; Wu et al., 2013; Yi 
et al., 2015). 
 
A clinical study by Yi et al, in healthy humans showed that subjects on a 
high-salt diet displayed a significantly higher number of monocytic cells 
compared with those on the low-salt diet and revealed a positive association 
between monocytes and dietary salt (Yi et al., 2015). Subjects maintained on 
a low-salt diet were accompanied by not only a lower number of monocytic 
cells, but also reduced production of proinflammatory cytokines and an 
enhanced production of anti-inflammatory cytokines (Yi et al., 2015), 
suggesting that high dietary salt intake is able to provoke an excessive 
immune response which can lead to the dysfunction of the immune system 
and thereby increase the risk of autoimmune disease. Furthermore, studies 
using flow cytometry, qRT-PCR and ELISA methods to investigate the effects 
of increasing NaCl concentrations on human Th17 cells showed dramatically 
increased induction of naïve CD4+ T cell expression of the proinflammatory 
cytokine, IL-17A (Kleinewietfeld et al., 2013). A strong Th17 phenotype under 
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high-salt conditions was also further confirmed in comparative microarray 
analyses of naïve CD4+ T cells differentiated with and without high-salt 
treatment (Kleinewietfeld et al., 2013). Additionally, high salt was shown to 
blunt the activation of non-inflammatory macrophages involved in 
suppressing effector T cell proliferation (Binger et al., 2015). These studies 
strongly implicate dietary sodium intake as a risk factor for autoimmune 
disease and chronic inflammation development, as well as hypertension.  
 
In the context of the present study, although the primary use of CNIs in 
transplant patients is to suppress the adaptive immune system, the sodium 
retaining effects in the kidneys may also provoke further imbalances in the 
immune system. This may predispose these patients to further risks of 
inflammatory-mediated conditions, alongside hypertension, and increased 
risks for cardiovascular events. However, further studies measuring anti- and 
pro-inflammatory cytokine expression with CNI-treatment and/or high fat- and 
salt conditions are required. 
 
6.4 Blood pressure regulation by the gastrointestinal tract 
 
Despite previous investigations with human and rodent models implicating an 
interplay between the gastrointestinal tract and kidneys in regulating sodium, 
no significant changes were observed for intestinal sodium transport proteins 
following CNI treatment and so any cross-talk between the kidneys and 
intestines was not evident in the present study. However, the data obtained 
from Chapter 4 may suggest otherwise. 
 
The experiments described in Chapter 4 showed that alterations in protein 
expression of renal and intestinal transporters following CNI treatment do not 
mimic those observed in mice fed on a high-fat diet, and revealed that CNI 
use alone does not lead to the development of metabolic syndrome. Mice 
became obese with high-fat feeding, and western blotting demonstrated a 
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significant increase in renal NHE3 and a decrease in renal SGLT2 and 
ENaC, while small intestinal SGLT1 and colonic NHE3 protein expression 
were also decreased (Fig.6.1). The downregulation of intestinal SGLT1 and 
renal SGLT2, along with elevated plasma glucose levels, are consistent with 
the proposed gastrointestinal-renal signalling axis and may implicate the 
activation of this interplay in the regulation of glucose, as well as sodium, 
under high dietary fat intake. This potential signalling axis between the two 
organs could also explain the significant increase and decrease observed for 
renal and colonic NHE3 expression, respectively. However, these findings 
suggest a feedback signalling mechanism between the kidneys and 
gastrointestinal tract, as opposed to the proposed feedforward signalling. 
 
As previously mentioned in Chapter 3, a study by Berndt et al, was one of the 
first to demonstrate and propose this feedforward mechanism between the 
gastrointestinal tract and kidney for the regulation of phosphate balance 
(Berndt et al., 2007). Infusion of phosphate into the duodenum of rats was 
shown to induce rapid urinary phosphate excretion, suggesting the presence 
of an intestinal phosphaturic factor that senses phosphate load and mediates 
renal excretion (Berndt et al., 2007). Likewise, rats chronically fed on a low 
phosphate diet and then acutely switched to a high phosphate diet caused a 
rapid increase in plasma phosphate, due to increased NaPi-IIb protein 
expression at the duodenum, which was accompanied by a decrease in renal 
BBM Na+/Pi transport activity and NaPi-IIa protein expression to compensate 
for the increased phosphate load (Giral et al., 2009). Furthermore, numerous 
studies in NaPi-IIb+/- and NaPi-IIb-/- knockout mice have also supported a role 
for this cotransporter in this feedforward signalling concept. Mice with a 
targeted deletion of the intestinal NaPi-IIb cotransporter display significantly 
reduced FGF23 levels and urinary phosphate excretion, which was 
correlated with increased renal NaPi-IIa and NaPi-IIc expression, in order to 
maintain normal phosphate balance (Ohi et al., 2011; Sabbagh et al., 2009; 
Schiavi et al., 2012). More recent investigations have observed similar 
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findings, whereby the loss of intestinal Na+/Pi cotransport was associated 
with reduced phosphaturia, as a result of increased renal NaPi-IIa expression 
and renal BBM Na+/Pi cotransport (Hernando et al., 2015). These findings 
demonstrate that the absence of the intestinal NaPi-IIb cotransporter is fully 
compensated for by the kidney to maintain phosphate levels. Taken together, 
these studies provide considerable evidence supporting this gastrointestinal-
renal sensing/signalling mechanism for phosphate regulation. In addition, 
although limited, there is also strong evidence of this feedforward mechanism 
for sodium regulation. Studies in humans and rats subjected to oral sodium 
loading exhibit profound natriuresis, compared to intravenous sodium 
loading, and have proposed that the intestinal sensing mechanism is 
mediated by the guanylin and uroguanylin intestinal peptides (Carey, 1978; 
Carrithers et al., 2002; Fukae et al., 2002; Lennane et al., 1975; Lorenz et al., 
2003; Mu et al., 1995).  
 
However, to date, there are no further published investigations on the 
mechanisms underlying this gastrointestinal-renal sensing/signalling axis for 
phosphate and sodium regulation, and the identity of the putative intestinal 
sensing factor for phosphate remains unknown. Additionally, the findings 
from these NaPi-IIb knockout studies for phosphate regulation may also 
suggest the presence of a sensing and signalling factor in the kidney, 
whereby the absence of intestinal NaPi-IIb and Na+/Pi transport, and the 
resulting hypophosphatemia is sensed by the kidneys and adapts by 
upregulating the renal Na+/Pi cotransporters and BBM transport. Although, 
this remains to be clarified. 
 
Contrastingly, previous studies have challenged the existence of this 
signalling axis and have observed opposing results. A recent study by Lee et 
al showed no changes in plasma phosphate, PTH concentration and urinary 
phosphate excretion in rats infused in the duodenum with phosphate at a 
physiological concentration (10mM), compared to the 1.3M phosphate 
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concentration used in the study by Berndt et al (Berndt et al., 2007; Lee et 
al., 2017). The expression of the renal NaPi-IIa and NaPi-IIc transport 
proteins were also unaffected following duodenal infusion at both 1.3M and 
10mM phosphate concentrations (Lee et al., 2017). In other studies, 5/6-
nephrectomised rat models of chronic renal failure exhibit increased plasma 
phosphate and decreased NaPi-IIa expression, whereas no change in 
phosphate absorption in the duodenum or jejunum, or in the expression of 
the intestinal NaPi-IIb transporter was observed, regardless of dietary 
phosphate intake (Marks et al., 2007). These findings may oppose any 
proposed sensing and signalling in the gastrointestinal tract as the 
conclusions drawn from this study demonstrate that the adaptive response to 
dietary phosphate in chronic renal failure was mediated by the kidney, while 
intestinal phosphate handling was not affected. However, as dietary 
phosphate intake did not affect intestinal phosphate absorption and NaPi-IIb 
protein abundance, these findings might also imply that chronic renal failure 
may have disrupted any signalling from the kidneys to the gastrointestinal 
tract and so is unable to adapt accordingly.  
 
In the present study, the upregulation observed for renal NHE3 and the 
associated downregulation for colonic NHE3 with high-fat feeding is 
consistent with the concept of a feedback mechanism. In addition, the 
downregulation of renal SGLT2 and ENaC transport proteins in this group 
are also indicative of intra-renal signalling within the nephron to adapt to 
increased sodium retention via renal NHE3 and pNCC. This inter- and intra-
organ signalling may be mediated by a number of regulators such as insulin, 
aldosterone and SGK1, which are known to be upregulated in this model and 
may partially explain for the changes seen for these transport proteins 
(Fig.6.1). Future studies analysing electrolyte transport and transporter 
expression/activity in conditional knockout models for specific epithelial 
transporters or FKBP12/calcineurin in either renal or intestinal tissues would 
clarify any possible signalling between the two organs in response to high-fat 
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feeding and CNI treatment, and would also allow for further investigations 
into the potential role of calcineurin in post-transplant metabolic 
complications. 
 
Alongside increased renal sodium retention and associated changes in 
intestinal transporter protein expression, high-fat feeding may also exert an 
effect through alterations in gut microbiota composition, which are known to 
have a significant impact on blood pressure and inflammation. Previous 
studies have demonstrated a symbiotic relationship between gut dysbiosis 
(microbial imbalance) and hypertension (Mell et al., 2015; Yang et al., 2015). 
Rat models of hypertension typically exhibit significant decreases in microbial 
richness and were associated with an increased Firmicutes/Bacteroidetes 
ratio, which are the dominant microorganisms in the intestines involved in 
maintaining intestinal immunity and homeostasis, and are widely considered 
as the signature of gut dysbiosis (Yang et al., 2015). These findings of gut 
dysbiosis were also observed in a small cohort of hypertensive patients 
(Yang et al., 2015), clearly implicating the impact of gut microbiota in the 
pathophysiology of animal and human hypertension. More recent studies in 
spontaneously hypertensive rat models have also demonstrated alterations 
in gut pathology, including increased intestinal permeability, inflammation 
and microbial dysbiosis, and have proposed this to be associated with 
dysfunctional central nervous system-intestinal communication, leading to 
hypertension development (Santisteban et al., 2017). 
 
Several lines of evidence have also shown that gut microbiota composition is 
altered in obese subjects and responds to changes in body weight and 
dietary fat, which may contribute to the dysregulation of the host’s metabolic 
functions (Hildebrandt et al., 2009; Turnbaugh et al., 2008). Studies in mice 
fed on a high-fat diet exhibited gut dysbiosis, characterised by reduced 
numbers of Bacteriodetes and increased numbers of Firmicutes (Hildebrandt 
et al., 2009; Turnbaugh et al., 2008). Additionally, the obesity trait was found 
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to be transmissible as transplantation of cecal microbiota from obese mice 
into germ-free recipients significantly increased adiposity compared to 
transplants of microbiota from lean donors (Turnbaugh et al., 2006, 2008). 
These alterations were thought to be the result of either the obese status 
altering gut microbiota or the direct effects of dietary fat. In supporting 
experiments, mice deficient for RELMβ, a protein involved in intestinal 
immune function and whose expression is induced by a high-fat diet, 
remained lean on the high-fat diet and showed similar changes in the 
microbial communities as wild-type mice, demonstrating that the composition 
of the gut microbiome was dependent on dietary factors and independent of 
the obese state (Hildebrandt et al., 2009). Although this strongly implicates a 
role for altered gut microbiota in promoting diet-induced obesity, the 
underlying mechanisms are still not well understood.  
 
Gut microbiota homeostasis has also been shown to be regulated by the 
innate immune system and plays a significant role in the pathogenesis of 
metabolic syndrome in both clinical and animal models. Mice deficient in toll-
like receptor 5 (TLR5), an activator of innate immunity, and fed on a high-fat 
diet were found to develop metabolic syndrome-related conditions such as 
obesity, insulin resistance and hyperlipidemia (Vijay-Kumar et al., 2010). 
Furthermore, colonisation of gut microbiota from TLR5-deficient mice into 
germ-free recipients conferred features of metabolic syndrome (Vijay-Kumar 
et al., 2010), showing that these phenotypes are transmissible and that the 
gut microbiota itself can mediate metabolic syndrome development. 
 
NHE3 has been particularly shown to be crucial for maintaining gut 
microbiota composition. NHE3 deficiency in mice was associated with 
alterations in ileum and colonic luminal and mucosal-associated microbiota 
composition, characterised by an increase in Bacteroidetes and a reduction 
in Firmicutes phyla (Engevik et al., 2013). Alongside, loss or inhibition of 
NHE3 was accompanied with increased sodium and pH in the stools, which 
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was shown to provide optimal conditions for bacterial growth and expansion 
in patients with Clostridium difficile infection (Engevik et al., 2013, 2015). 
Additionally, NHE3-/- mice develop colitis (colonic inflammation) which was 
correlated with increased mucosal T cell and neutrophil influx, as well as 
increased mucosal cytokine expression and permeability, all of which could 
be alleviated with broad-spectrum antibiotics (Larmonier et al., 2013; Laubitz 
et al., 2016). These findings show that NHE3 plays an important role in the 
regulation of the gut microbiota and that the absence of NHE3 may result in 
profound changes in colonic microbial ecology contributing to gut dysbiosis 
and intestinal inflammation.  
 
From the present study, although it is not known whether the downregulation 
observed for colonic NHE3 in the high-fat diet-fed group had a significant 
impact on gut microbiota composition, the conclusions drawn from previous 
studies in NHE3-/- mice highlight potential shifts in the relative abundance of 
bacterial phyla in the gut microbiota and intestinal permeability in this model. 
Furthermore, the lack of correlation between plasma electrolytes and the 
corresponding intestinal transporter expression could in fact be explained by 
the illustrated effects of high-fat feeding on intestinal permeability and gut 
microbiota composition. However, this remains to be established, as well as 
confirmation of intestinal inflammation. Comparisons to CNI-treated mouse 
intestinal segments would also be required to determine whether CNI use by 
transplant patients alters gut pathology and microbiome, and contributes to 
hypertension and metabolic syndrome development following transplantation. 
 
6.5 The impact of SGLT-mediated sodium transport on cell swelling 
and blood pressure 
 
As previously mentioned, PTDM and insulin resistance are a common 
occurrence following transplantation. These conditions are associated with 
CNI use and are hallmarks of metabolic syndrome. In diabetes, renal SGLT2 
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is upregulated, contributing to increased glucose reabsorption and 
hyperglycemia (Rahmoune et al., 2005). As described in earlier chapters, the 
SGLT2 and SGLT1 cotransporters are expressed in the proximal tubule, 
where SGLT2 reabsorbs approximately 97% of filtered glucose and SGLT1 
reabsorbs the remaining 3% (Turner and Moran, 1982; Vallon et al., 2011). 
Studies in knockout mouse models and mutation analyses in humans have 
reported SGLT2 as the main mediator of renal glucose reabsorption and 
contributor for hyperglycemia and diabetes (Santer et al., 2003; Vallon et al., 
2011, 2013). In a study by Rahmoune et al, analyses in patients with type II 
diabetes revealed a three-fold increase in renal glucose uptake compared 
with controls (Rahmoune et al., 2005). This study also reported a significant 
increase in SGLT2 and GLUT2 mRNA and protein expression in these 
diabetic patients (Rahmoune et al., 2005), consistent with the important role 
for SGLT2 in renal glucose reabsorption.  
 
SGLT2 inhibitors, such as dapagliflozin, canagliflozin and empagliflozin, are 
administered as treatment for type II diabetes, which act by aiding urinary 
glucose excretion. Numerous clinical trials in diabetic patients treated with 
SGLT2 inhibitors have demonstrated its benefits in increasing glycosuria and 
improvements in fasting plasma glucose levels (Bolinder et al., 2012; Chilton 
et al., 2015; Kawasoe et al., 2017; Stenlof et al., 2013; Vasilakou et al., 
2013). Clinical studies have also reported a blood pressure lowering effect 
with SGLT2 inhibitor treatment, along with a reduction in body weight. Meta-
analysis of a number of controlled studies in type II diabetic patients 
receiving SGLT2 inhibitors, compared with those receiving placebo or other 
anti-hyperglycemic agents, reported a mean reduction in SBP by 3.77-4.45 
mmHg and in body weight by around 1.74-1.80 kg (Vasilakou et al., 2013). In 
addition, a number of studies in patients with type II diabetes randomised to 
either a placebo or an SGLT2 inhibitor for a period of 12-76 weeks, showed 
that the groups treated with the SGLT2 inhibitor were associated with 
significant reductions in SBP, DBP, mean body weight, waist circumference 
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and fat mass compared to the placebo groups (Baker et al., 2014; Blonde et 
al., 2016; Bolinder et al., 2012; Chilton et al., 2015; Kohan et al., 2014; 
Roden et al., 2013; Stenlof et al., 2013). 
 
Taken together, these studies suggest that SGLT2 inhibitors may confer 
advantageous effects on blood pressure and body weight in patients with 
type II diabetes. However, the precise mechanisms underlying the blood 
pressure lowering effects remains under investigation. Studies have 
proposed that these effects are based on an osmotic or natriuretic effect 
(Baker et al., 2014; Kawasoe et al., 2017). In a study by Kawaksoe et al, 
treatment with SGLT2 inhibitors in obese patients with type II diabetes 
showed a significant decrease in SBP after two weeks, which was correlated 
with increased urinary glucose excretion but not urinary sodium excretion 
(Kawasoe et al., 2017). However, at 6 months after administration with 
SGLT2 inhibitors, the reverse was observed, the decrease in SBP was 
significantly correlated with urinary sodium excretion, suggesting that the 
long-term blood pressure-lowering effects of SGLT2 inhibitors may be 
explained by plasma volume reduction due to natriuresis (Kawasoe et al., 
2017).  
 
Overall, evidence from a number of studies in diabetic patients highlight the 
beneficial reductions in body weight and blood pressure with SGLT2 inhibitor 
treatment. Although these inhibitors would prove to be advantageous in 
plasma glucose control and lower the risk for hypertension particularly in 
PTDM patients, studies examining the effects of SGLT2 inhibition following 
transplantation are lacking. The data from these studies also imply that an 
increase in the accompanied sodium reabsorbed by the SGLT2 transporter 
can also contribute to increases in blood pressure in these diabetic patients. 
However, in the context of the present study, despite indications of 
hyperglycemia, significant reductions in renal SGLT2 and intestinal SGLT1 
proteins in mice fed on the high-fat diet was observed, regardless of CNI 
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treatment. Although the reasons for this are not clear, without confirmation of 
the effects of high-fat feeding on SGLT transporter activity, conclusions on 
the relative contribution of these transport proteins to rises in blood pressure 
in these mice cannot be drawn. 
 
6.6 Conclusions and future perspectives  
 
In conclusion, the experiments described in this thesis provides evidence that 
the CNI-mediated effects on blood pressure are likely to occur solely through 
the overactivation of NCC in the DCT and that, in the presence of increased 
sodium transport, the kidneys respond by downregulating major sodium 
transporters in the other nephron segments. In addition, data obtained from 
protein and biochemical analyses in a model of diet-induced metabolic 
syndrome demonstrates that, following renal transplantation, high dietary fat 
intake is the main risk factor for the development of metabolic syndrome-
associated conditions, not CNI administration alone. A significant reduction in 
renal SGLT2 and intestinal SGLT1 transport proteins in this model, most 
likely in response to elevated plasma glucose levels, are also consistent with 
previous proposals of a gastrointestinal-renal signalling axis for sodium. This 
feedback mechanism may also be the case for NHE3, however, this requires 
further investigations. 
 
As described, increased sodium uptake affects a number of systems as well 
as blood pressure homeostasis, including the composition of gut microbiota 
and the regulation of the immune system (summarised in Fig.6.2). The 
interplay of these systems was not investigated in the present studies, 
however, future investigations particularly into alterations in intestinal 
permeability and pathology may provide explanations for the plasma 
biochemistry data obtained in the model of metabolic syndrome used, 
especially for phosphate. Analyses for electrolyte transport and transporter 
activity following CNI-treatment and in diet-induced metabolic syndrome may 
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warrant additional kinetic and functional studies in renal and intestinal 
BBMVs to clarify the changes, or absence of changes, for the individual 
transporters observed at a translational level. Furthermore, confirmation for 
the involvement and impact of the insulin-PI3K-SGK1 and renin-angiotensin-
aldosterone signalling pathways in these models may also explain the data 
obtained. However, this would also require further investigations into the 
feedback/feedforward signalling pathways between the gastrointestinal tract 
and kidneys involved in the downregulation of renal ENaC, SGLT2, and 
intestinal SGLT1 proteins, which are in contrast to the regulatory effects by 
SGK1 and aldosterone. 
 
The conclusion drawn from these findings, along with supporting evidence 
from previous studies, suggests that the implementation of a treatment 
regimen which includes strict management of dietary fat intake following 
transplantation and in hypertensive individuals would be advantageous for 
blood pressure, glucose and lipid control, and would greatly reduce the risk 
of cardiovascular and renal disease. 
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Figure 6.2. Summary of the pathways regulated by dietary sodium and fat intake. Pathways influenced by increased dietary sodium and 
fat intake including the regulation of blood pressure, gut microbiota composition and the immune system.  
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Appendix I 
Country 
Year of 
Data 
Collection 
Age 
Range Gender 
Sample 
Size 
Prevalence 
(%) 
Awareness 
(%) 
Treatment 
(%) 
Control 
(%) Reference 
United 
States 
1989 - 
1990 35 - 64 
Male 450 30 56 17 44 (Antikainen et al., 
2006) Female 567 21 61 34 52 
2004 - 
2005 40 - 75> 
Male 220 57 85 80 38 (Dickson et al., 
2006) Female 472 59 77 75 39 
2007 - 
2010 20 - 79 
Male 5033 29.4 77.7 69.1 48.7 
(Joffres et al., 2013) 
Female 4970 28.8 84.6 79.1 57 
Canada 
1986 - 
1992 18 - 74 
Male 11,376 26 53 32 40.6 
(Joffres et al., 1997) 
Female 11,753 18 65 49 40.8 
1995 35 - 64 
Male 259 31 57 34 33 (Antikainen et al., 
2006) Female 268 26 69 34 40 
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2007 - 
2009 20 - 79 
Male 1649 19.7 80.4 76.5 66.8 
(Joffres et al., 2013) 
Female 1836 19.3 86.5 83.3 64.9 
Germany 
1991 - 
1992 35 - 64 
Male 394 40 49 28 16 (Antikainen et al., 
2006) Female 432 32 62 48 43 
1994 - 
1995 35 - 64 
Male 819 46 52 21 12 (Antikainen et al., 
2006) Female 872 34 59 31 32 
1997 - 
2001 
24 – 74 
(1 of 2) 
Male 1823 60.1 57.6 34.6 24.3 (Meisinger et al., 
2006) Female 1921 38.5 71.3 50.9 40.9 
1997 - 
2001 
24 – 74 
(2 of 2) 
Male 2073 41.4 55 28.2 36.2 (Meisinger et al., 
2006) Female 2151 28.6 73.6 51.3 48.1 
Italy 1993 - 1994 35 – 64 
Male 651 41 38 24 45 
(Antikainen et al., 
2006) Female 666 31 43 31 14 
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1994 35 - 64 
Male 685 54 45 13 13 (Antikainen et al., 
2006) Female 689 41 48 25 31 
1998 35 - 64 
Male 
8233 
44.8 46.4 26.7 22.5  
(Wolf-Maier et al., 
2003, 2004) 
 
Female 30.6 57.2 37.3 32.9 
Spain 
1994 - 
1996 35 - 64 
Male 1398 19 62 31 67 (Antikainen et al., 
2006) Female 1211 20 83 49 48 
2004 >18 
Male 1336 31.1 42.4 65.9 34.9 (Perez-Fernandez 
et al., 2007) Female 1548 20.7 61.3 77.6 37.5 
India 
1999 - 
2000 40 - 60 
Male 163 56.3 33.7 22.8 38.1 (Zachariah et al., 
2003) Female 151 52.3 44.3 35.4 25 
2001 - 
2002 >30 
Male 1441 33.2 22.8 22.4 15.9 (Hazarika et al., 
2004) Female 1739 33.4 20.7 20.5 20.2 
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2001 - 
2004 20 - 65> 
Male 1096 23.2 36.9 28 47 (Mohan et al., 2007; 
Pereira et al., 2009) Female 1254 17.2 26.2 16.8 44.2 
China 
1993 35 - 64 
Male 480 38 49 19 14 (Antikainen et al., 
2006) Female 643 36 63 31 21 
1992 - 
1994 35 - 59 
Male 8840 24.1 34.9 23.3 11.8 
(Wang et al., 2004) 
Female 9906 21.5 39.8 31.4 13.3 
1999 >35 
Male 4640 51.2 77 69 28 
(Li et al., 2003) 
Female 5063 42.2 78 70 38 
2000 - 
2001 35 - 74 
Male 7684 28.6 39.5 23.5 26.1 
(Gu et al., 2002) 
Female 8154 25.8 50.8 33.8 31 
 
Table A.1. Summary of the prevalence, awareness, treatment and control of hypertension in worldwide studies. Hypertension 
prevalence rates were recorded according to the international definition of hypertension. Control rates show the proportion of control among 
treated hypertensive patients.  
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